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ABSTRACT 
 
 
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease affecting up to one-
third of the adult population in western countries.  NAFLD is characterised by increased lipid 
accumulation (especially triglycerides) in liver cells. The disease has been described by 
various terms including fatty liver (NAFL, steatosis) and steatohepatitis (NASH), characterised 
by the presence of fat in the liver and inflammation with or without fibrosis.  NAFLD patients 
and especially those having NASH may progress to cirrhosis and rarely to hepatocellular 
cancer. NAFL increasingly affects children (paediatric prevalence is 4.2%-9.6%). Furthermore, 
a strong association exists between type 2 diabetes mellitus (T2DM), insulin resistance (IR), 
obesity, arterial hypertension and NAFLD. This PhD programme of work began with the 
investigation of the role of glyoxalase (GLO-1) enzyme system in NAFLD (Chapter 3). The 
initial hypothesis was that a down-regulation of GLO 1 would occur following fatty acid 
treatment. Following the inability to show a significant change in GLO 1 protein expression in 
fatty acid-treated cells which typify NAFLD, the research study investigated the role of vitamin 
D as a possible nutritional factor in the progression of NAFLD (Chapter 4). 
Using mechanistic approaches including cell culture and enzyme- linked immunosorbent 
assay (ELISA), the study investigated the effects of vitamin D supplementation on the 
induction of cytokine secretion as markers of inflammation in NAFLD (Chapter 5). In addition, 
public health approaches including a systematic review and meta-analysis were utilised to 
explore the relationship between vitamin D and NAFLD development / progression (Chapter 
6). Findings from both areas of research suggested that vitamin D may be an important marker 
in NAFLD patients although it may not be an actual treatment option for NAFLD: given the 
growing prevalence of NAFLD in different population groups, further research into the link 
between vitamin D and NAFLD is certainly justified.  
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1.1 Introduction 
1.1.1 Non-Alcoholic Fatty Liver Disease  
Non-Alcoholic Fatty Liver Disease (NAFLD) describes a wide range of hepatic 
pathological conditions beginning with macro vesicular accumulation of lipids (steatosis) 
especially triglycerides, in more than 5 % hepatocytes in the absence of significant alcohol 
intake and exclusion of secondary causes of hepatic fat such as viral hepatitis, medication – 
induced steatosis including tamoxifen and amiodarone (Angulo, 2007, Kleiner and Brunt, 
2012). Significant alcohol intake has been defined as consumption of more than 20 g alcohol 
per day in women and more than 30 g alcohol per day in men (Chalasani et al., 2012b).   Most 
NAFLD patients have simple steatosis which is the presence of fat without significant liver 
inflammation or hepatic injury hence regarded as relatively benign. This may however 
progress to Non- alcoholic steatohepatitis (NASH), typified by the presence of fatty liver in 
addition to inflammation and hepatocyte ballooning (Angulo, 2007). NASH is a more 
progressive form of the disease (Burt et al., 1998) and can lead to fibrosis, cirrhosis, liver 
failure, and hepatocellular carcinoma, (HCC) (Williams et al., 2011, Starley et al., 2010) 
(Figure 1.1). 
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Figure 1-1: Progression of non-alcoholic fatty liver disease (NAFLD) 
Schematic diagram illustrating NAFLD progression with liver histological sections showing 
normal, steatosis, steatohepatitis and fibrosis stages. Steatosis to inflammation stages are 
reversible while steatohepatitis to fibrosis stages are irreversible (Adapted from (Cohen et al., 
2011, Moore, 2010). 
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Studies on long- term outcome of NAFLD patients have revealed a high risk for 
developing HCC especially in patients with advanced fibrosis and cirrhosis (Ekstedt et al., 
2015), while elevated rate of liver- related mortality have been documented in patients with 
NASH (Ekstedt et al., 2006) (Söderberg et al., 2010). Overall, NAFLD patients, and more 
particularly, those with NASH, have a high risk of death from liver disease (13%), 
cardiovascular disease (25%) and cancer (28%) (Adams and Angulo, 2005).  
Alcohol consumption is associated with up to 69 % of liver disease hence remains the 
most important cause of liver disease especially cirrhosis (Zatonski et al., 2010), which 
eventually results to HCC. 
 Various terminologies used in describing NAFLD are detailed in table 1.1 below. 
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Table 1-1 Terminologies used in describing NAFLD 
(Puri and Sanyal, 2012, Dietrich and Hellerbrand, 2014). 
  
Term Description 
NAFL or Simple Steatosis Fatty infiltration of liver with minimal or no 
inflammation and without fibrosis 
NASH  Hepatic steatosis together with 
inflammation, hepatocyte ballooning with or 
without inflammation, may lead to cirrhosis, 
liver failure and possibly hepatocellular 
carcinoma. 
NAFLD An inclusive spectrum of fat accumulation 
without significant alcohol consumption. 
Defined as presence of fat in 5%–10% of the 
liver mass. 
Hepatic steatosis in more than 5% of the 
biopsy specimen. 
“Primary” NAFLD Associated with characteristics of Metabolic 
Syndrome without specific aetiology. Term 
occasionally used in literature without 
general acceptance. 
“Secondary” NAFLD NAFLD due to a definite cause 
Indicates absence of insulin resistance 
May describe a worsening of underlying 
“Primary” NAFLD. 
“Presumed” NAFLD  Used mainly in paediatric and 
epidemiological researches and definition 
premised on: 
 Abnormal serum liver enzyme levels 
including alanine aminotransferase, 
aspartate aminotransferase and 
gamma glutamyltransferase. 
 Negative results from viral studies 
indicating absence of viral infections 
 Exclusion of other common liver 
disease aetiologies 
 Echogenic or bright liver on imaging 
(often abdominal ultrasound) 
consistent with fatty infiltration. 
 
NAFL: Non-alcoholic fatty liver, NASH: Non-alcoholic steatohepatitis, NAFLD: Non-alcoholic 
fatty liver disease.  
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1.1.2 Epidemiology 
NAFLD is now regarded as a global epidemic disease with a prevalence of 20-33 % in 
the general European adult population (Angulo 2002). A prevalence of 12.5 % has been 
estimated for European general paediatric population including obese children by a review of 
epidemiological data (Blachier et al., 2013). NAFLD prevalence varies according to different 
countries or populations based on diagnostic criteria as well as availability of diagnostic tools 
(Lee et al., 2007, Vernon et al., 2011). Indeed, it has been argued that the current estimates 
of NAFLD prevalence are grossly underestimated based on the limitations of diagnostic 
methods (Lazo et al., 2013). For example, studies carried out using ultrasonography in Europe 
and the Middle East reported a NAFLD prevalence of 20 - 30 % (Bedogni et al., 2005, Zelber‐
Sagi et al., 2006)  while 15 % was reported in the Far East in a study carried out in China on 
3,175 subjects diagnosed by Ultrasound (Fan et al., 2005).   
Another study carried out on populations in Italy comprising of individuals without 
metabolic factors, and employing blood test for liver abnormalities and ultrasound as a 
diagnostic tool revealed a prevalence of NAFLD in 16 % of the population (Bellentani et al., 
2000) On the other hand, using magnetic resonance spectroscopy (Browning et al., 2004), 
reported a prevalence of 34 % among a large, multi-ethnic US adult population. A worrisome 
trend is the increasing prevalence of NAFLD in children and adolescents, as a NAFLD 
prevalence of 12.5% as detected by ultrasound was reported in European general paediatric 
population (Blachier et al., 2013). Furthermore, a meta-analytic assessment of prevalence, 
incidence and outcomes of NAFLD (Younossi et al., 2016)  estimated the global prevalence 
of NAFLD to be 25.24%, with the highest prevalence found to be in the middle East and South 
America and the lowest prevalence found in Africa (Figure 1.2 ) (Younossi et al., 2016). 
There is a strong linkage between NAFLD and obesity, type 2 diabetes (T2D), insulin 
resistance (IR), hypertriglyceridemia and arterial hypertension  (Lonardo et al., 2005, Loomba 
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et al., 2012). Hence, NAFLD is referred to as the hepatic manifestation of the metabolic 
syndrome (Lonardo et al., 2005, Neuschwander-Tetri, 2005).   Metabolic syndrome is defined 
as a cluster of risk factor which may increase the probability that an individual will develop 
atherosclerotic cardiovascular disease, type 2 diabetes  mellitus (T2D) and chronic kidney 
disease (Paschos and Paletas, 2009). The main underlying risk factors for metabolic 
syndrome has been documented to be abdominal obesity, dyslipidaemia, hypertension,, 
raised plasma glucose, a prothrombin state, and a proinflammatory state (Reynolds and He, 
2005). 
 In terms of identification, metabolic syndrome can be diagnosed by the presence of 3 
or more of the following in an individual: abdominal obesity (waist circumference > 88 cm in 
women, 102 cm in men), elevated triglycerides (> 150 mg/dl or on drug treatment for elevated 
triglycerides), reduced HDL-C level (< 50 mg/dl in women or< 40 mg/dl in men, hypertension 
and impaired fasting blood glucose.   Obesity is defined as body mass index (BMI) higher than 
30kg/m2 (National Heart and Institute, 1998), the severe form, morbid obesity is defined as 
BMI higher than 40kg/ m2 (Karmali, 2013). It is estimated that about 1.5 billion adults are 
overweight (BMI, 25-29.9 kg/m2) or obese worldwide while out of this, about 500 million 
individuals are obese (Finucane et al., 2011).  
The significant relationship between NAFLD and obesity has been shown by various 
studies. Boza et al., (2005), found that among obese patients undergoing bariatric surgery, a 
greater percentage of the patients had NAFLD (63 %) than NASH (26 %) (Boza et al., 2005).  
Also, Machado et al., (2006) reported a prevalence of 91 % NAFLD, 37 % NASH, and 1.7 % 
cirrhosis among obese patients undergoing gastric bypass (Machado et al., 2006). In addition, 
high prevalence of NAFLD (36-44 %) has been observed in children who are obese  (Blachier 
et al., 2013).  
However, NAFLD have also been documented in individuals having normal weight, 
indicating the role of genetics in the disease. A study based on data from the National Health 
Nutrition Examination Survey in the USA reported an estimated NAFLD prevalence of 7.4 % 
among lean individuals with BMI of 18.5 to 25 kg/m2 (Younossi et al., 2012). Among these 
 
 
8 
 
individuals, 1.4 % was diagnosed with NASH, in comparison with 27.8 %  NAFLD prevalence 
estimated for overweight / obese individuals, out of which 13.9 % had NASH (Younossi et al., 
2012). In addition, in a community - based study of 1911 non - obese  adult population in India, 
8.7% of NAFLD was reported, as diagnosed by ultrasound (Das et al., 2010).  Moreover, 
studies on Type 2 Diabetes patients in Europe have revealed NAFLD prevalence rates 
between 42.6 -69.5% (Targher et al., 2007, Williamson et al., 2011). 
1.2 NAFLD and Health-related quality of life 
 
 Apart from the clinical outcomes attributed to NAFLD, the disease is also associated 
with impaired health - related quality of life (HRQL), significant morbidity and also a high 
economic costs to the society (Younossi and Henry, 2016) . Patients’ HRQL mostly affected 
by NAFLD include mostly fatigue which also impairs normal daily functioning. A recent study 
by NHANES reported a smaller percentage of NAFLD patients (78 %) rating their health status 
as excellent compared to patients without NAFLD (90 %). 
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 Figure 1-2: Estimation of NAFLD prevalence in the general population as diagnosed by 
ultrasound or other radiological method. Reproduced from Younusi and Henry, (2016). 
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1.2.1 Diagnosis 
Generally, NAFLD is considered a silent disease as most patients show no clinical 
symptoms and if present, patients may experience dyspepsia, hepatosplenomegaly, a sense 
of fullness in the right upper abdomen, together with fatigue or malaise (Gao et al., 2013). 
Histological parameters observed in NAFLD may include steatosis, either alone or together 
with hepatocyte ballooning and fibrosis, mixed inflammatory cell infiltration as well as Mallory’s 
hyaline, which are aggregates of intermediate filaments in the cytoplasm, resulting from 
hepatocyte injury. (Angulo et al., 2007). Hepatic fibrosis has been considered the strongest 
predictor of disease progression and liver related complications; as revealed by the follow up 
study on NAFLD patients (Ekstedt et al., 2015). 
While it has been documented that increases in serum liver enzymes such as alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and/ or gamma glutamyl 
transpeptidase (GGT) is indicative of NAFLD (Vernon et al., 2011), it has also been argued 
that elevated liver enzymes alone may not give the true prevalence of NAFLD and may in fact 
underestimate it. This was confirmed by the Dallas Heart Study in the United States which 
determined the prevalence of hepatic steatosis and compared same with hepatic triglyceride 
content among 2,287 subjects from the three main ethnic groups in the United States including 
whites, blacks and Hispanics. Findings from the study showed that ALT level provided little 
diagnostic or prognostic value during assessment of people for NAFLD as most of the subjects 
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having hepatic steatosis (79 %) had normal ALT levels, defined as ALT ≤ 40 U/L for men and 
≤ 31 U/L for women (Browning et al., 2004). 
Therefore, in line with the guidelines of the American Association for the Study of Liver 
Diseases (AASLD), the diagnosis of NAFLD is acceptable when carried out by imaging or 
histology (Chalasani et al., 2012a), and only in individuals having no history of extensive 
alcohol intake (less than 30 g/day in males and less than 20 g/day in females), as discussed 
in section 1.1.1. In addition, secondary causes of hepatic fat accumulation must have been 
excluded in such individuals (Machado et al., 2006, Petta et al., 2009).  Such causes of 
secondary liver disease include: autoimmune or drug induced liver disease, hepatitis B and C 
viruses and metabolic diseases such as Wilson’s disease, hemochromatosis,  or α1- 
antitrypsin deficiency (Machado et al., 2006). 
In terms of diagnostic methods, while imaging techniques such as ultrasonography (US), 
magnetic resonance imaging (MRI), and computed tomography (CT) are sensitive and can 
detect steatosis, liver biopsy remains the gold standard for detecting NAFLD as it also reveals 
the grade of the disease (Angulo et al., 2007). It also excludes other possible causes of liver 
damage and provide an estimation of the degree of lobular inflammation, infiltration of fat into 
the hepatocyte, hepatocyte ballooning as well as fibrosis (Kleiner et al., 2005).  It is however 
limited as a tool for screening in general populations due to high cost and the invasive nature 
which could result to complications (Wieckowska et al., 2007). Moreover, it is subject to 
sampling error due to the heterogeneity of the liver (Shahin Merat et al., 2012). 
However, although MRI and proton magnetic resonance spectroscopy (H-MRS) are 
sensitive and can quantify steatosis, they are expensive and not readily available in clinical 
settings (Schwenzer et al., 2009). Ultrasound is limited as it can only detect steatosis from 
30% onwards and Computed tomography is limited as a diagnostic tool in NAFLD as the 
patients are exposed to radiation. Moreover, the accuracy of the methodology is reduced in 
the presence of underlying diffuse liver disease (Schwenzer et al., 2009) . Newer methods 
which are non- invasive and can assess the extent of fibrosis include transient elastography 
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and magnetic resonance elastography. These are however limited in availability (Cobbold et 
al., 2012). 
Furthermore, diagnostic algorithms including the Fatty Liver Index (FLI) and Enhanced 
Liver Fibrosis (ELF) tests are now being used as alternatives to liver biopsy (Lichtinghagen et 
al., 2013, Zelber-Sagi et al., 2013). These tests are useful for the purpose of making 
predictions on the status of steatosis or fibrosis by utilising patient parameters including age 
gender and serum biomarkers before triaging patients for liver biopsy. For instance, the ELF 
scores have been reported to be increased with age; in addition, men tends to have a higher 
score than women hence interpretation needs to be done cautiously (Lichtinghagen et al., 
2013). These tests therefore do not replace liver biopsy for which an evidence-based 
guidelines for use in clinical practise is already in existence (Rockey et al., 2009). 
 
1.2.2 Risk Factors for NAFLD Development and Progression 
The risk factors for NAFLD development and progression have been previously 
identified to include the following: 
1.2.2.1 Age distribution 
Older age (60 years and above) is a risk factor shown to be associated with NAFLD 
and its progression. The prospective study by (Kagansky et al., 2004) on 91 octogenarians 
revealed a NAFLD prevalence of 46%. In addition to this, (Frith et al., 2009)  carried out a 
study on 351 NAFLD patients of different age groups identified by liver biopsy and found that 
fibrosis and cirrhosis were more prevalent among the patients of ages 60 years and above. In 
addition, NAFLD risk factors including hypertension, diabetes, obesity and hyperlipidaemia 
were found to be more prevalent in the same group of patients compared to the patients who 
were less than 60 years old. 
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1.2.3 Gender 
  Recent study findings have revealed a higher prevalence of NAFLD and related fibrosis 
in men (Vernon et al., 2011). For example, the study by (Williams et al., 2011), investigated 
liver steatosis using ultrasound on four hundred adult population in the United States who 
were without a known liver disease. This was followed by liver biopsy in patients having 
positive ultrasound to determine NASH prevalence. Findings revealed that NAFLD and NASH 
prevalence were higher in males than females. Similar results were found in another study 
that investigated the relationship between metabolic syndrome in NAFLD and serum alanine 
aminotransferase (ALT) levels among 26, 527 Chinese subjects (Chen et al., 2008). This study 
employed ultrasound imaging to diagnose liver steatosis and showed that NAFLD was higher 
in men (30.94 %) than in women (15.65 %). The study also found that aminotransferase levels 
were higher in males than females.  
In addition, histological features of NASH, liver fibrosis as well as mortality in patients 
with NAFLD have been found to be linked with the male gender (Ong et al., 2005, 
Papatheodoridis et al., 2007). Hence, the male gender is likely to be more at risk for the 
development as well as progression of NAFLD and all these findings are in line with the current 
prevalence of NAFLD based on population study which is 15- 20 % in women and about 30-
40 % in men (Browning et al., 2004). Oestrogen in women may possess certain protective 
effects against NAFLD. In a cross-sectional study on 197 female subjects grouped according 
to menopausal status as either premenopausal, postmenopausal or Poly cystic ovarian 
syndrome, a higher prevalence of NAFLD of nearly 60 % was observed in postmenopausal 
women (Gutierrez-Grobe et al., 2010). In addition to this, a greater level of serum oestradiol 
was found in patients without NAFLD and mostly in the premenopausal females without 
NAFLD.  
 A possible explanation for this is the suggestion that certain changes occur 
physiologically in postmenopausal women due to the reduction in serum oestrogen level 
(Gutierrez-Grobe et al., 2010). One of such important alteration is redistribution of fat with a 
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consequence for dyslipidemia and glucose intolerance (Suzuki and Abdelmalek, 2009).  In 
line with this, a study in animals revealed an improvement in liver steatosis in aromatase - 
deficient mice which lack oestrogen producing ability after oestradiol replacement. The 
reduction in hepatic steatosis was shown to be accompanied with a restoration in 
mitochondrial and peroxisomal fatty β- oxidation (Nemoto et al., 2000). 
 
1.2.4 Ethnicity, genetics and environmental factors 
Study findings have identified ethnic origin is a risk factor for NAFLD development 
(Browning et al., 2004, Kallwitz et al., 2008). The study carried out by Browning et al., (2004) 
on a multi-ethnic US adult population, found the prevalence of NAFLD to be highest among 
Hispanic Americans (45 %) followed by Caucasians (33 %) while the lowest (24 %) was 
observed in those of African- American background. The high prevalence of NAFLD in 
Hispanics has been attributed in part to an increased prevalence of obesity and insulin 
resistance in this population. However, ethnic differences in BMI and IR, did not explain the 
reduced prevalence in subjects of African- American background. 
Variation in NAFLD prevalence across ethnicities suggests that genetic factors play a 
role in the development of the disease. The study among family members of overweight 
children with NAFLD (identified through biopsy) showed that it is a heritable disease 
(Schwimmer et al., 2009).  The patatin-like phospholipid 3 (PNPLA3) I148 polymorphism which 
is mostly found among Hispanics has been identified as a major player in this regard (Vernon 
et al., 2011, Tilg and Moschen, 2010). The I148M allele of this gene encodes adiponutrin 
(Kotronen et al., 2009) which has been shown to be a strongly associated with increased liver 
fat content in NAFLD (Romeo et al., 2008). The same study revealed a two-fold hepatic fat 
content in homozygous carriers of the I148M allele compared to non-carriers.  
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1.2.5 Metabolic conditions  
The finding that NAFLD is strongly associated with metabolic diseases including type 
2 diabetes has been confirmed by several studies. One study revealed a prevalence of 69% 
NAFLD cases identified by ultrasound among diabetic patients (Leite et al., 2009). In another 
study conducted on NAFLD patients with family history of diabetes in their first degree 
relatives, it was found that an association exists between family history of diabetes and 
presence of NASH and fibrosis and also between diabetes and NASH (Loomba et al., 2012).   
Apart from the reported high prevalence of NAFLD in type 2 diabetic (T2D) patients, it 
has also been shown that progressive liver disease occur in conjunction with T2D. In addition 
to this, Polycistic Ovarian Syndromme (PCOS) has been suggested to be the ovarian 
manifestation of metabolic syndrome as studies have shown that women with PCOS also have 
hepatic steatosis together with high Homeostasis model assessment of insulin resistance 
(HOMA-IR) scores (Loomba et al., 2012). 
1.3 Molecular Pathogenesis of Non- Alcoholic Fatty Liver Disease 
The liver performs several metabolic roles which are important for the normal functioning 
of the human body. These biochemical activities of the liver are facilitated through the rich 
blood supply of nutrients, substrates and hormones reaching the liver through the hepatic 
vascular network composed of the hepatic artery, delivering about 30 % of the blood reaching 
the liver and the portal vein, which supplies nearly 70 % of the blood reaching the liver (Sase 
et al., 2002). On getting to the liver, the FA in nutrients are metabolized by B - oxidation or 
they become esterified with glycerol to form Triacylglycerol (TAG), a means by which the liver 
is protected from the effect of unesterified FA (Fabbrini et al., 2010)  
A situation of lipid accumulation (steatosis) may then arise when there is an increase in 
FA uptake and consequently a higher rate of esterification of the FA to TAG compared to the 
rate of FA oxidation and secretion. Hence, the level of TG available in the hepatocytes 
represents the complex interaction existing among hepatic FA uptake, de novo lipogenesis, 
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FA oxidation and fatty acid export within  the very low density lipoprotein (VLDL) -TAG network 
(Fabbrini et al., 2010). 
The pathogenesis of NAFLD is poorly understood hence several mechanisms have 
been proposed for the progression of the disease from fatty liver through inflammation to 
fibrosis (Dowman et al., 2009). The first articulated theory for the pathogenesis of NAFLD was 
the “Two hit concept” proposed by Day and James in 1998. In this theory, the first hit was 
accumulation of fat in the liver (steatosis) which is required before hepatocyte injury can 
develop while the second hit represents agents of oxidative stress such as cytokines, 
adipokines, mitochondrial dysfunction and/ endoplasmic reticulum stress, bacterial endotoxin; 
these  initiate lipid peroxidation which results to necroinflammation and eventually NASH 
(Levene and Goldin, 2012). 
Hepatic inflammation resulting from steatosis is mediated by the activation of nuclear 
factor kappa B (NF-κB) signalling pathway (Cai et al., 2005). It was found that steatosis 
induced by high - fat diet in mice had higher NF-κB activity associated with increased hepatic 
expression of inflammatory cytokines such as interleukin-6 (IL- 6), tumour necrosis factor 
(TNFα), interleukin 1-beta ( IL- 1β) and activation of Kupffer cells (Cai et al., 2005). The same 
NF-κB pathway is directly activated by free fatty acid (FFA), identifying another mechanism by 
which central obesity with attendant increase in liver FFA supply contributes to inflammation 
(Cai et al., 2005). 
However, with the increasing knowledge of the role of FFA in promoting liver damage, 
the “two hit theory” has been modified. This modification explains the greater level of 
movement of FFA into the liver especially in conditions of insulin resistance and obesity. 
Sources of FFA in the liver include: diets, lipolysis and de novo lipogenesis (DNL) from amino 
acids or carbohydrates (Postic and Girard, 2008, Koutsari and Jensen, 2006). The study by 
Donnelly et al., (2005) using stable isotopes to determine total liver fat in NAFLD patients 
showed that 60 % of hepatic triglyceride are derived from FFA, 25 % from DNL and 15% from 
dietary sources (Donnelly et al., 2005). The authors also reported an increase in DNL from 5 
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% to 25 % in healthy subjects compared to NAFLD subjects.  It was also found that Hepatic 
triglyceride accumulates when FFA are esterified by glycerol in the hepatocytes (Dowman et 
al., 2009). 
As mentioned earlier, FFA are metabolised either by β-oxidation  to produce ATP 
(Asaoka et al., 2013), or by re-esterification reactions to triacylglycerol (TAG) which are then 
stored within the liver cells as lipid droplets, or  they may be packaged and afterwards released 
into the blood in form of very low density lipoprotein (VLDL) (Dowman et al., 2009). TAG 
production is regarded as a protective mechanism which converts lipids such as FFA, 
diacylglycerol (DAG) and ceramide to less pathologic forms (Samuel and Shulman, 2016) . 
The occurrence of liver fat accumulation may then arise from enhanced lipid synthesis, 
accelerated fat delivery, reduction in lipid export, as well as a reduction in fat oxidation (Postic 
and Girard, 2008), which further results to hyperglycemia, hypertriglyceremia and worsening 
of hepatic steatosis while the entire process becomes a vicious cycle, playing major role in 
whole body insulin resistance (Neuschwander‐Tetri, 2010). 
Increased FFA loading in the liver causes impairment of fatty acid β- oxidation in the 
liver mitochondria resulting in the generation of reactive oxygen species (Paradies et al., 
2014).  This leads to  further oxidative stress causing injury to the liver as well as inflammation, 
both initiating the progression of fibrosis (Boden et al., 2005).The study by Feldstein et al., 
(2004) provided a significant evidence that FFA activates inflammatory pathways and also 
increases oxidative stress and through these events cause direct toxicity to the liver (Feldstein 
et al., 2004). Studies on scavengers of ROS such as manganese superoxide dismutase 
(MnSOD) have yielded conflicting results. Some studies in steatotic livers of NAFLD / NASH 
patients have shown a reduction in the activity of hepatic superoxide dismutase  (Videla et al., 
2004, Valle et al., 2012) indicating a saturation of the enzyme by ROS production. However, 
an induction of MnSOD activity has also been reported (Perlemuter et al., 2005). 
The endoplasmic reticulum is a special organelle abundant in hepatocytes which 
functions to manage stressful conditions of the liver (Malhi and Kaufman, 2011). In stressful 
or pathologic conditions, increased ER stress occur leading to the induction of unfolded protein 
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response (UPR);  this directs the misfolded or unfolded proteins toward molecular chaperons 
to be refolded, or they may be directed to endoplasmic reticulum- associated protein 
degradation (ERAD) and  degraded (Malhotra and Kaufman, 2007). 
Following the accumulation of lipids in the hepatocytes, an increased expression of 
transcription factor Peroxisome proliferator-activated receptor gamma (PPARγ), which is 
majorly expressed in adipose tissue and lacking in healthy liver, has been documented in 
NAFLD patients (Pettinelli and Videla, 2011). This suggests an alteration of gene expression 
in fatty livers. Furthermore, insulin functions as a suppressor of adipose tissue lipolysis and 
this action is hindered in conditions of insulin resistance (which is often seen in NAFLD), 
enhancing the release of FFA from adipose tissue. The resultant hyperinsulinaemia produces 
two major associated effects, one of which is the up-regulation of sterol regulatory element 
binding protein-1c, a transcription factor which functions majorly in the regulation of genes 
involved in de-novo lipogenesis (DNL) (Stefan et al., 2008). The second effect is the inhibition 
of FFA β- oxidation which enhances more lipid accumulation in the liver (Postic and Girard, 
2008). 
In addition to the above theories, a proposed “third hit” was included which indicates the 
insufficient proliferation of the liver cells (Jou et al., 2008). According to this theory, cell death 
occurring in the liver of healthy individuals triggers the division of mature liver cells; replacing 
dead cells and restoring tissue function to normalcy. However, inhibition of such replication of 
mature liver cells is caused by oxidative stress which is usually found in NAFLD resulting to 
an increased population of hepatic progenitor cells (Jou et al., 2008). 
According to Roskams et al., (2003), hepatic progenitor (ova) cells can differentiate 
into hepatocyte –like cells following a “regenerative challenge”. This was shown by the group’s 
study on mouse models of fatty liver disease as well as in patients with either NAFLD or 
alcoholic fatty liver disease.  Findings from the study revealed a resultant increase in hepatic 
progenitor (ova cells) number due to liver damage from oxidative stress as well as inhibition 
of hepatocyte proliferation. The study also revealed a strong association between both 
intermediate hepatocyte – like cell number, ova cell number and stage of fibrosis suggesting 
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that risk for hepatocellular carcinoma may increase as a result of the activation of hepatic 
progenitor cells (Roskams et al., 2003). 
1.4 Toll- like receptors  
It has been suggested that toll-like receptors (TLRs), found on the gut epithelium and 
which can change in response to lipids from diets (FFA) may be involved in the pathogenesis 
of obesity-induced inflammation or insulin resistance (Medzhitov, 2001). Study findings on 
TLR4 has  shown that it induces pro-inflammatory cytokines in the epithelial cells and 
macrophages as a result of its response to fatty acid (Shi et al., 2006). Also, the study by 
(Tsukumo et al., 2007) found that mice lacking TLR4 do not exhibit inflammation and Insulin 
resistance due to high fat diet. 
However, another study findings showed that TLR dependent signalling may not be 
directly stimulated by saturated fatty acids thus questioning whether saturated FA are ligands 
for certain TLR (Erridge and Samani, 2009). The TLRs implicated in obesity –induced 
inflammation include TLR5 and TLR 9.  It has been shown that TLR 9 promotes steatohepatitis 
as mice deficient in the receptor do not exhibit liver inflammation (Miura et al., 2010). On the 
other hand, it was found that TLR 5 protects against steatosis and metabolic syndrome as 
mice lacking TLR 5 were shown to develop metabolic syndrome and steatosis (Vijay-Kumar 
et al., 2010). 
1.5 Extra –hepatic factors/tissues and their roles in NAFLD progression 
Apart from the liver, effects on the gut and adipose tissue are also involved in the 
pathogenesis of NAFLD. Indeed, studies have shown that factors altering the composition of 
the intestinal microbiota as well as barrier function lead to an enhanced bacteria endotoxin 
permeation and such effect is significant in the development and progression of NAFLD 
(Henao-Mejia et al., 2012). The human microbiota contains endotoxin lipopolysaccharide 
(LPS), a major constituent of several bacteria. The LPS triggers innate immune responses 
hence referred to as “second hit” in models of NASH study (Dowman et al., 2009).  
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Several activities involving the surface of the gut such as diets/ food intake may alter 
the ability of LPS to translocate thereby raising the level of plasma in circulation; such 
endotoxemia results to both inflammation as well as a worsening of obesity. The study by 
Miele et al., (2009) revealed elevated gut permeability among NAFLD patients compared with 
healthy volunteers and this was found to be associated with a high rate of small intestinal 
bacterial overgrowth (SIBO) in the same patients. In addition, the gut permeability and SIBO 
were found to be correlated with the extent of steatosis and not NASH (Miele et al., 2009).   
In addition, it is well known that thyroid hormones (TH) especially 3,3’,5-Triiodo-L- 
thyronine (T3) are involved in the regulation of several physiological processes including  
foetal development, protein, carbohydrate, mineral and lipid metabolism (Yen, 2001). The 
thyroid hormone (TH) following over activity of the thyroid gland or exogenous administration 
of TH has been found to exhibit several effects on lipid accumulation. Such effects include 
reduction in serum cholesterol levels, lipolysis, increased metabolic rate, weight loss and 
improved myocardial function (Motomura and Brent, 1998). The liver is one major target of the 
thyroid, indeed, it has been reported that changes in TH cellular signalling results in liver-
related diseases such as NAFLD and HCC (Chi et al., 2013). 
Furthermore, the TH metabolite 3, 5,- Diiodo-L- thyronine (T2) has also been shown to 
be important in the regulation of lipid accumulation in the liver. Findings from a study 
administering T2 to rats fed with high fat diet revealed  a reversal of lipid accumulation (Mollica 
et al., 2009), supporting the role of TH in NAFLD. However, the potential for the therapeutic 
use of TH is limited by severe thyrotoxicosis occurring with the use of TH receptor agonist 
(Kowalik et al., 2018).  
 
Figure 1.3 below illustrates the many factors and interactions involved in the 
development of liver steatosis and progression to NASH (Byrne and Targher, 2015). 
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Figure 1-3: The effects of adipose tissue inflammation, visceral ectopic fat 
accumulation, type 2 diabetes, diet and thyroid on the development and progression of 
NAFLD/ NASH 
Inflammation and type 2 diabetes are usually accompanied by viscera ectopic fat 
accumulation, and together these induces insulin resistance and hepatic necroinflammation 
(by activation of Kupffer cells) with hepatic stellate cells activation and progression of liver 
disease. Progression of liver disease over time leads to advanced hepatic fibrosis, cirrhosis 
and in some cases, hepatocellular carcinoma. High fat and high fructose diets together with 
genetic factors (for example PNPLA3 polymorphism) and thyroid increases liver fat 
accumulation thereby increasing hepatic fibrosis risk (DAG, di-acyl glycerol; DiPPA,di-
palmitoyl phosphatidic acid; HCC, hepatocellular carcinoma; LCFAs, long-chain fatty acids). 
Adapted from Byrne and Targher (2015). 
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1.6 Nutritional and Clinical Interventions for NAFLD 
Currently, no pharmacological treatment has been approved for NAFLD, hence 
management options include treatment of liver disease in patients with NASH due to the poor 
prognosis and treatment of diseases associated with NAFLD such as obesity, type 2 diabetes 
mellitus, insulin resistance and hyperlipidaemia in all patients (Chalasani et al., 2012a). In 
addition, a focus of interest available for NAFLD patients is geared towards lifestyle 
modification in terms of diet and exercise. These have been found to be beneficial in improving 
liver histology, with the amount (degree) of weight loss being directly proportional to the degree 
of hepatic histological improvement (Wong et al., 2013). Furthermore, embracing healthy 
lifestyle including weight loss and maintaining a healthy weight prevent further progression of 
NAFLD (Nobili et al., 2006).  
Several lifestyle intervention trials have shown improvements in weight loss and insulin 
resistance  (Nobili et al., 2008) , improvement in serum aminotransferase (AST) levels 
(Reinehr et al., 2009) reduction in NASH score(Nobili et al., 2008, Huang et al., 2005). The 
prospective study on dietary intervention in biopsy-proven NASH patients showed that a 10% 
loss in body weight was associated with improvement in liver histology (Vilar-Gomez et al., 
2015). Also, in another trial of 154 patients randomized to either a dietician- reinforced lifestyle 
intervention (comprising of advice for diet and required involvement in exercise of moderate 
intensity 3 times per week) or general recommendations to lose weight for 12 months, the 
findings revealed that NAFLD (assessed using magnetic resonance spectroscopy) was 
resolved in 64 % of the intervention group compared with 20 % of the control group (Wong et 
al., 2013).  
However, slower rate of weight loss of up to 0.5 kg/week in children and up to 1.6 
kg/week in adult has been recommended. This is because excessive fatty infiltration in the 
liver which may worsen portal fibrosis and inflammation has been attributed to rapid weight 
loss (Andersen et al., 1991). Some nutritional supplements have been tested in trials for 
possible use in NAFLD/ NASH treatment. These include Vitamin E (Lavine et al., 2011, 
Rinella, 2015),  
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Other possible therapeutic options for NASH patients include Pioglitazone, Pentoxyfillin 
and Obeticholic acid (Rinella, 2015). Pioglitazone and vitamin E were tested on 247 subjects 
in the Pioglitazone versus Vitamin E versus Placebo for the Treatment of Non-diabetic Patients 
with Non-alcoholic Steatohepatitis (PIVENS) trial (Sanyal et al., 2010). It was found that 
patients on Vitamin E had improved histological features of NASH while those on pioglitazone, 
though lacking improvement in hepatocyte ballooning, were found to have great improvement 
in insulin resistance, inflammation, steatosis and liver enzymes (Sanyal et al., 2010). 
Another possible treatment option, Pentoxifylline suggests histological benefit though 
studied in 2 small randomized clinical trials involving 85 subjects (Van Wagner et al., 2016). 
Bariatric surgery is now recommended for NAFLD patients in situation of unresponsiveness 
to pharmacological intervention or lifestyle changes, especially for those who are obese having 
a BMI of 40 or around 35-40 with comorbidities  (Sberna et al., 2018). 
1.7 Role of glyoxalase 1 enzyme in NAFLD 
Glyoxalase 1 (GLO 1), also referred to as lactoylglutathione lyase, methylglyoxalase or 
glx 1 is a member of the glyoxalase system found in the cytosol of every cell (Thornalley, 
2003b). The glyoxalase system is a glutathione – dependent cytosolic enzyme system 
discovered to be present at the beginning of embryo formation and development, persisting 
through maturation up to ageing (McLellan et al., 1994). It consists of Glyoxalase -1 and 
Glyoxalase II, the overall function of which is to detoxify reactive oxo- aldehyde or dicarbonyl 
such as methylglyoxal (MG) (Thornalley, 2003b, Birkenmeier et al., 2010);  
Generally, the system catalyses the conversion of reactive aldehydes such as MG and 
glyoxal, to the less reactive hydroxyacid (Thornalley, 2003b). GLO 1 catalyses the irreversible 
reaction forming S-D-lactoylglutathione from methylglyoxal- glutathione conjugate. Following 
this, Glyoxalase II then catalyses the conversion of S -2-hydroxyacylglutathione derivatives 
into D-lactate while re-forming glutathione which is consumed in the reaction step catalysed 
by GLO 1 (Himo and Siegbahn, 2001). The activity of GLO 1 prevents the accumulation of 
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such reactive aldehydes thereby avoiding glycation reaction mediated by reactive aldehydes 
(Shinohara et al., 1998). 
GLO 1 is ubiquitous in mammalian cells (Cameron et al., 1997) and is present in many 
organisms such as yeast (Martins et al., 2001) bacteria (Kim et al., 2010), protozoan parasites 
as well as plants   (Espartero et al., 1995). However, it is lacking in certain protozoans such 
as Entamoeba histolytical, Giardia lamblia and Trypanosoma brucei (Silva et al., 2013). 
Glyoxalase 1 activity has been found to be present in all human tissues with fetal tissues 
activities shown to be nearly 3 times higher than the corresponding adult tissues (Thornalley, 
2003b).  
Human GLO1 is a homodimer of 43/ 46 kDa, the active form containing Zn2+ ion which 
is responsible for its catalytic activity (Thornalley, 2003b). Also, GLO 1 was found to show 
activities with other divalent ions such as Co2+, Ni2+, Ca2+, Mg2+ and Mn2+ and each GLO-1 
monomer was found to contain 183 amino acids residues (Cameron et al., 1997, Himo and 
Siegbahn, 2001). 
1.7.1   Methylglyoxal (MG)  
Over a century ago, MG was discovered as a major intermediate in the metabolism of 
glucose in animals, plants and microorganism; hence present in all cells in both normal and 
diseased conditions (Silva et al., 2013). MG production occurs through different metabolic 
pathways including enzymatic or non- enzymatic forms. The enzymatic formation is through 
the activity of MG synthethase (Thornalley, 1990).The main source of MG in biological 
systems is its non-enzymatic formation from the breakdown of the triose phosphates, 
dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate (GA3P) during 
glycolysis (Phillips and Thornalley, 1993). MG is also obtained when glycated proteins are 
fragmented (Thornalley, 1993). 
MG is potentially toxic due to its highly reactive nature modifying DNA, lipids and 
proteins (mainly through arginine, lysine and cysteine residues),  forming advanced glycation 
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end products, AGEs (Murata-Kamiya and Kamiya, 2001, Falone et al., 2012). Carboxymethyl 
lysine (CML) and pentosidine are two examples of AGEs (Thornalley, 2003b). In humans, an 
estimated 3 mMol of MG is produced by an adult daily while only 0.3% of it is glycated 
(Rabbani and Thornalley, 2014). In addition, although MG is formed majorly within cells, some 
of it may leak out and this may result to glycation of both intracellular and extracellular proteins 
(Duran-Jimenez et al., 2009). 
AGEs have been implicated in the pathogenesis of diabetes, Alzheimer’s and 
Parkinson’s disease (Goldin et al., 2006), and its accumulation has been associated with 
ageing as well as retina and liver complications. In addition to being the main precursor of 
AGEs formation which leads to oxidative stress (Sena et al., 2012). MG also causes a direct 
elevation in free radical generation resulting to oxidative stress by increasing proinflammatory 
cytokines (Kalapos et al., 1993) and by lowering levels of antioxidants such as Glutathione, 
GSH (Amicarelli et al., 2003).  Moreover, it has been reported that MG causes impairment of 
mitochondria function (Seo et al., 2014) and all these effects have been attributed to 
stimulating the aging process .  
MG-derived AGEs mediate their effects through the activation of membrane receptor, 
RAGE, which recognises two main ligands including CML adducts and MG-derived 
imidazolones resulting to activation of NF-κB which in turn controls expression of  the receptor 
for advanced glycation end products (RAGE)  (Yao and Brownlee, 2009). Activation of NF- κB 
by RAGE is a redox- dependent reaction in which RAGE activates NADPH oxidase leading to 
generation of ROS, p21, protein kinase- C, Extracellular- regulated kinase (ERK) - 1/2, JNK 
and p38, all leading to the translocation of NFκB into the nucleus where it also activates the 
expression of cytokines such as IL-6, TNF-α, adhesion molecules, VEGF, and even RAGE 
(Goldin et al., 2006). 
Importantly, glycation by MG results in DNA damage and this has been shown by 
several studies. For example, using Chinese hamster ovary cells, (Goldin et al., 2006)  
Marinari et al., (1984), were the first to show that DNA crosslinks were formed when cultured 
mammalian cells were exposed to non- toxic concentration of MG. Using a chromatographic 
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assay, (Ahmed et al., 2002) identified protein AGE derived from MG to be the 
hydroimidazolone derivative of arginine (MG-H1), which has also been identified as a main 
AGE in proteins of body fluids and tissues, with elevated levels in diabetes and associated 
vascular complications, Alzheimer's disease, arthritis, Parkinson's disease, renal failure, 
cirrhosis, and aging (Rabbani and Thornalley, 2014). MG- induced DNA-AGEs have been 
implicated in age – related reduction of genomic function resulting to higher levels of markers 
of oxidative stress (Matafome et al., 2013). 
Furthermore, apart from increasing the circulating levels of modified proteins in the 
cell, it has been shown that MG also reduces the ability of cells to degrade the modified 
proteins (Matafome et al., 2012). A study revealed that MG modifies the 20S proteasomal 
subunit, thereby decreasing the activity of the proteasome (Queisser et al., 2009). In addition, 
another study showed that MG - induced proteasomal inhibition of 20S proteasome results in 
accumulation of protein- ubiquitin conjugates and a reduction in function of protein quality 
control pathway (Bento et al., 2010). These mechanisms may facilitate a reduction in cell 
viability and play a role in the progression of diabetic complications (Matafome et al., 2013).  
1.8 Methylglyoxal in Metabolic Disease 
Increased formation of MG occurs in conditions of hyperglycaemia. Indeed, studies 
have shown elevated plasma levels of MG in metabolic diseases including obesity and 
diabetes as well as in diet supplementation and fructose accumulation. For example, the 
clinical study by McLellan et al., (1994) on 43 patients with insulin - dependent (type 1) 
diabetes, 107 Non- insulin dependent (type 2) diabetic patients and 20 normal healthy control 
subjects found a higher plasma level of MG in the diabetic subjects compared to the control 
subjects (McLellan et al., 1994). In line with these findings, (Masterjohn et al., 2013) carried 
out a study on animals and found that rats fed with fructose diets showed an increased 
concentration of MG in their adipose tissues (Masterjohn et al., 2013). Also, (Li et al., 2005) 
found an increase in body weight of rats fed with a high fat diet for a period of 12 weeks. They 
also found MG-derived hydro imidazole (MG-H1) content of protein in the plasma, heart and 
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liver of the rats (Li et al., 2005). This may be a pointer to the relationship between obesity and 
MG.  
MG plays a major role in the development of diabetes and its complications. This is 
supported by recent studies one of which reported an impairment in glucose tolerance in rats 
on acute administration of MG (Dhar et al., 2010), while the other study found β-cell 
dysfunction and type 2 diabetes in rats chronically administered with MG (Dhar et al., 2011). 
. 
 
 
1.9  Glyoxalase 1 System in Metabolic Disease 
 
The Glyoxalase system functions to detoxify MG, thereby preventing accumulation of 
AGEs and formation of ROS. However, in disease condition such as diabetes, formation of 
reactive dicarbonyls is enhanced resulting in accumulation of MG with attendant glycation of 
proteins and lipids in the systemic circulation. Studies have shown that marked accumulation 
of MG occurred as a result of inhibition of GLO 1 in situ by cell- permeable inhibitors of GLO 
1 and also due to depletion of GSH (Thornalley, 1993, Abordo et al., 1999).  
On the other hand, (Shinohara et al., 1998)  reported a prevention of hyperglycemia-
induced AGE formation due to overexpression of GLO 1. The same overexpression prevented 
hyperglycemia - induced macromolecular endocytosis. Furthermore, one study reported an 
enhancement in MG detoxification as a result of overexpression of GLO 1 (Brouwers et al., 
2010).  This occurred in addition to a protection against endothelial dysfunction caused by 
streptozocin- induced diabetes in rats. Another study revealed that elevated levels of GLO 1 
protected diabetic mice against symptoms of diabetic neuropathy (Jack et al., 2012) . These 
studies provided evidences that GLO 1 elevation show protective roles in metabolic diseases, 
suggesting the possibility that development of GLO 1 inducers may be beneficial in conditions 
of elevated MG such as diabetes (Rabbani and Thornalley, 2014) and possibly associated 
diseases such as NAFLD. 
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The liver plays a major role in diseases as it regulates blood glucose through 
production and metabolism; however, metabolic diseases such as Type 2 diabetes and 
obesity are associated with liver dysfunction as a result of elevated levels of nutrients (nutrient 
flux) and metabolites (Rabbani and Thornalley, 2011). 
 
 
1.10  Fatty Acids and NAFLD 
 
Fatty acids are important components of biological cell membranes, playing vital roles 
in intracellular signalling. In addition, fatty acids serve as major energy stores. Evidence from 
studies both in animal models as well as in humans have shown that changes in dietary fats 
are important mechanisms in the development of NAFLD (Cortez-Pinto et al., 2006, Wang et 
al., 2006). The study by Muso et al., (2003) found that NASH patients consume diets richer in 
saturated fats and cholesterol (Musso et al., 2003). Furthermore, findings in obese patients 
with NAFLD suggests that the reduction in unsaturated to saturated fatty acid ratio in serum, 
fat and liver tissue might play a role in the pathogenesis of the disease (De Almeida et al., 
2002). 
Increased FFA levels have been associated with the development of IR, which plays 
a major role in the pathogenesis of NAFLD. Consumption of high fat diets have been 
associated with the development of T2D and obesity (Ricchi et al., 2009). While increase in 
concentration of circulating FFA occurs as a result of peripheral IR caused by the 
unchallenged antilipolytic action of insulin, there is an accompanying impairment of insulin 
signalling at the post receptor level (Samuel et al., 2004). This could further contribute to IR 
and further rise in FFA level. 
Palmitic acid (PA), also referred to as palmitate, and oleic acid (OA), also known as 
oleate are two major fatty acids reported to be abundant in western diets, in serum as well as 
in steatotic liver (Baylin et al., 2002, ARAYA et al., 2004). Paalmitic acid is a saturated (C 16: 
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0) long chain fatty acid while oleic acid is monounsaturated (C 18: 1). Study findings have 
shown that PA and OA induced steatosis in immortalized hepatocyte cell lines (Ricchi et al., 
2009) and in primary human hepatocytes (Joshi‐Barve et al., 2007). 
 
 
1.10.1 In Vitro Models for NAFLD 
Several evidences are in support for the use of in vitro models in the study of effect of 
lipid accumulation on liver health. The table below shows examples of immortalised cell lines 
and the methods previously utilised in the study of hepatic steatosis. Lipid accumulation 
measurements have been previously carried out using oil red O (ORO) staining. ORO is a 
lipid soluble diazo-dye. Other methods include Nile red which is a fluorescent lipid dye, 
triacylglycerol (TAG) assay using a kit which measures glycerol, and automated chemical 
analysers (auto-analyser) which measures glycerol. In this research study, the immortalized 
hepatocyte cell line, HepG2 was employed in most experiments.
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Table 1-2Cell lines utilised for investigating lipid accumulation 
Cell line Origin Fatty acids ratio Concentration 
used (mM) 
Treatment 
period (hr) 
Method References 
HepG2 Hepatoblastoma 
 
 
 
15 year old Caucasian male 
 
OA:PA (3 - 0.3) 
 
 
PA/SA 
OA/PA 
 
OA:PA (2:1) 
0.5 – 2 
 
 
0.2 
 
 
0.33 - 2 
24 
 
 
18 
 
 
24 
Nile Red 
 
 
Nile Red 
 
 
Nile Red 
(Gomez-Lechon 
et al., 2007) 
 
(Malhi et al., 
2007) 
 
(Ricchi et al., 
2009) 
Hep3B Hepatocellular carcinoma 
 
8 year old Black male 
PA 0.3 48 ORO Nath et al.2015 
HUH7 Hepatocellular carcinoma 
 
57 year old Japanese male 
OA:PA (2:1) 
 
OA:PA (2:1) 
0.6, 1.2 
 
1.2 
 
24 
 
24 - 96 
Nile Red 
 
Nile Red 
(Chavez-Tapia 
et al., 2012) 
 
(Giraudi et al., 
2015) 
HepaRg Tumour associated with 
HCV, progenitor-like 
 
female 
OA:PA (2:1) 0.1 – 0.5 48 TAG 
assay 
(Brown et al., 
2013) 
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1.11  Vitamin D 
Vitamin D is a secoisteroid hormone which exists in multiple forms, consisting mainly of 
vitamin D2 and vitamin D3, also known as ergocalciferol and cholecalciferol respectively. 
vitamin D2 is not constitutively produced by vertebrates but is produced by phytoplankton, 
yeast and invertebrate organisms following exposure to ultraviolet irradiation (Eliades and 
Spyrou, 2015).  On the other hand, vitamin D3 is produced in the skin of humans and most 
vertebrate animals following exposure of 7-dehydrocholesterol in the skin to solar ultraviolet 
B (UVB) radiation (Eliades and Spyrou, 2015). Humans can also obtain vitamin D from dietary 
sources such as beef, liver, egg yolk and milk products (Logan et al., 2013) as well as from 
dietary supplements containing vitamin D (Holick, 2006, DeLuca, 2004b).   
  Naturally, most foods do not contain vitamin D. Furthermore, fortification of foods with 
vitamin D is limited to few food items for example flour and cereal products. As a result, vitamin 
D2 has been manufactured from yeast by ultraviolet irradiation of ergosterol, and vitamin D3 
has been synthesized through the ultraviolet irradiation of 7- dehydrocholesterol from lanolin. 
Both are available commercially over-the-counter as vitamin D supplements (Holick, 2007a). 
Furthermore, results from research studies have confirmed that D3 is more effective than D2 
at raising serum 25 (OH) D levels (Tripkovic et al., 2015, Tripkovic et al., 2012). As a result, 
D3 has been used in all experimental work carried out this research study. 
1.11.1 Vitamin D synthesis 
Exposure of the skin to ultraviolet B radiation of up to 290-315 nm is necessary to bring 
about the conversion of 7-dehydrocholesterol to previtamin D3 which is thermodynamically 
unstable and is quickly changed to vitamin D3 (Holick, 2006).  The level of vitamin D3 
production depends on the amount of UVB radiation as well as the level of 7- DHC present in 
the skin epidermis.  Once vitamin D3 is produced, it is transferred into the circulation through 
the capillaries of the skin (dermis) by diffusion (Holick, 2007a). Once in the systemic 
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circulation, vitamin D3  binds to the vitamin D binding protein (DBP) and from here it is 
transported to the liver where it gets metabolised (Holick, 2007a). The synthesis and 
metabolism pathway of vitamin D is described in figure 1.4 below  (Rosen, 2011). 
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Figure 1-4: Vitamin D synthesis and metabolism. Reproduced from Rosen, (2011). 
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1.12 Factors affecting vitamin D production/status 
Several factors may affect the level of vitamin D3 production and these will affect the 
vitamin D levels in circulation. These are discussed below: 
1.12.1 Clothing and use of sunscreen:  
Production of vitamin D3 could be limited/inhibited due to clothing and use of 
sunscreen which prevents ultraviolet B rays from reaching 7- DHC in the skin, thereby limiting 
the amount of D3 that can be made (Tsiaras and Weinstock, 2011, Webb et al., 2010). 
1.12.2 Skin Pigmentation: 
  Production of D3 in the skin is decreased with greater skin pigmentation. This is 
because melanin in the skin which increases skin pigmentation, inhibits 7- DHC exposure to 
UVB (Holick, 2004). 
1.12.3 Proximity to the equator: 
  Variation in seasons and latitude causes changes in intensity of UVB radiation 
obtained from sunlight.  As a result, people living in closer proximity to the equator tends to 
get more sunshine and can rely on the exposure for D3 production. In UK populations, 
seasonal variations in serum 25OHD concentrations have been observed, with deficiency 
greatest in the winter months and lowest following the summer period (Webb et al., 2010, 
Darling et al., 2013). A study analysis of  serum 25 OH D from UK Caucasian male and female 
adults 40 years of age, found that seasonal  and geographical differences affect  25OH D 
concentrations as it found  that low vitamin D status was higher in Scotland compared with the 
Southern part of the UK (Hypponen and Power, 2007).  This is illustrated in figure 1.5 below 
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Figure 1-5: Effect of seasonal and geographical variation on the prevalence of low 25 
(OH) D concentrations (<40nm/L) in UK male and female populations. Reproduced with 
permission from Hyponen and Power 2007. 
 
1.12.4 Age 
As people age, the levels of 7- DHC in the epidermis gradually decreases. This, in 
addition to reduced exposure to sunlight can further increase the risk for hypovitaminosis 
(MacLaughlin and Holick, 1985).  A 70 year old is only able to synthesize about 25 % of the 
amount of vitamin D3 as a young adult due to a 75 % reduction in capacity for vitamin D 
synthesis (Need et al., 1993).  
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1.12.5  Adiposity 
Vitamin D is highly lipophilic in nature hence could be stored in adipose tissue thereby 
reducing the concentration of circulating 25 (OH) D (Wortsman et al., 2000).  Studies have 
demonstrated that an inverse relationship exist between adiposity and circulating 25 (OH) D. 
A study on obese and non- obese subjects revealed a lower 25OH D concentrations in the 
obese compared to the non-obese subjects (Hypponen and Power, 2007). Another study 
showed an increase in 25 (OH) D levels following moderate weight loss in obese individuals 
(Tzotzas et al., 2010). 
1.13 Regulation of vitamin D production 
The production of vitamin D is tightly modulated by certain hormones as well as the 
dietary and serum levels of calcium and phosphate (Zúñiga et al., 2011). Vitamin D modulates 
its own synthesis in two ways, one of which is by directly decreasing the activity of 1α 
hydroxylase (Henry, 1979), and another is through the inhibition of parathyroid hormone 
function (Brenza et al., 1998). 
1.13.1 Calcium 
The action of 1α hydroxylase has been shown to be indirectly associated with the levels 
of dietary and serum calcium of the organism. High serum levels of calcium has been shown 
to have a direct suppressant effect on the activity and expression of 1α – hydroxylase (Henry, 
2011). Furthermore, studies have shown that the regulation of 1α – hydroxylase by calcium 
is mediated by PTH, effecting directly on the kidney cells and involves the second 
messengers produced by protein kinases A and C (Henry and Luntao, 1989)  In addition to 
this, calcium modulates the expression of 1α – hydroxylase by decreasing PTH levels (Henry, 
2011). 
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1.13.2  Parathyroid Hormone / Calciotropic hormones 
Parathyroid hormone plays a major role in the regulation of 1α – hydroxylase activity. 
The study by Garabedian et al., (1972) demonstrated that animals with parathyroidectomy 
could not produce 1, 25-(OH)2 D3 whereas PTH administration restored the ability to 
synthesize 1, 25 (OH)2 D3  in the same animals (Garabedian et al., 1972). The modulation of 
1α – hydroxylase activity by PTH is mediated by cyclic AMP through Camp- responsive 
element (CRE) existing in the promoter region of the genes of interest (Garabedian et al., 
1974). 
 
1.14  Vitamin D Metabolism 
 
Absorption of vitamin D2 in diet occurs in the small intestine. Dietary vitamin D2 is 
incorporated into chylomicrons and from here transported to the liver which is also bound to 
vitamin D binding protein (Eliades and Spyrou, 2015, Holick, 2007b). Being a lipid soluble 
vitamin, the mechanism of absorption of dietary vitamin from the gastrointestinal tract is like 
that of other lipids. 
In the liver, vitamin D from both origins (skin and diet) is metabolised to 25- hydroxyl 
vitamin D (25 (OH) D by 25- hydroxylase (CYP 2R1) (Prosser and Jones, 2004). 25(OH) D is 
mostly used as an indicator of vitamin D stores as it is the main metabolite in circulation, with 
a long half-life (Prentice et al., 2008). This is further hydroxylated in the kidney by 25- hydroxyl 
vitamin D3-1α-hydroxylase (CYP 27B1) to the active form: 1, 25- dihydroxycholecalciferol also 
known as calcitriol (DeLuca, 2004a) (figure1.6).   
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 Figure 1-6:  Metabolic activation of vitamin D3 to its hormonal form (Taken from De Luca, 
(2004). 
 
 
 
1.15  Measurement of vitamin D status (Measuring circulating 25 (OH) D levels) 
 
Vitamin D status of an individual could be either sufficient, deficient, insufficient, or 
intoxicated. It has been agreed that the circulating 25 (OH) D levels is the best measure of 
vitamin D status. One reason for this is that 25 (OH) D levels represents the vitamin D obtained 
from both diet and exposure to sunlight. In addition, 25 (OH) D levels is the major form of 
vitamin D in circulation, having a half- life of approximately 2-3 weeks (Prentice et al., 2008). 
Although 1, 25 (OH)2 D is the biologically active form of vitamin D, it is not considered an ideal 
measurement for vitamin D level: one reason for this is the fact that it has a short half - life of 
between 4 - 6 hours (Prentice et al., 2008).  
  Several methods have been used in the measurement of 25 (OH) D levels. These 
include: protein binding assay, radioimmunoassay, enzyme - linked assays, high performance 
liquid chromatography (HPLC), Liquid chromatography – mass spectrometry (LC-MS) and gas 
chromatography – mass spectrometry (GC- MS) (Fraser and Milan, 2013). Initially, HPLC was 
considered the gold standard although a cumbersome assay, hence it was not routinely 
employed for clinical samples. LC-MS have been found to be very useful for the direct 
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measurement of 25 (OH) D levels in human serum, measuring both 25 (OH) D2 and 25 (OH) 
D3 quantitatively (Holick, 2009).  
1.16  Vitamin D function 
The major physiological function of vitamin D is bone mineralisation. In addition to this, 
vitamin D is essential for the absorption of dietary calcium and phosphate. The importance of 
vitamin D in maintaining a balance of calcium and phosphate has been highlighted (Lips and 
Van Schoor, 2011, Christakos et al., 2011). Bone mineralisation failure therefore results in 
rickets in children and osteomalacia in adults (Underwood and DeLuca, 1984). In addition, 
vitamin D hormone causes an elevation in serum calcium levels in 3 separate ways including 
the induction of proteins, mediation of active intestinal calcium absorption and stimulation of 
active absorption of phosphate in the intestine.  
Furthermore, in conditions of poor or no intestinal calcium absorption, vitamin D 
hormone plays a major role in the mobilization of calcium from bone in the absence of dietary 
supply.  Two mechanisms are involved in increasing blood calcium concentrations, especially 
in the absence of intestinal calcium absorption. Osteoblasts are stimulated by Vitamin D 
hormone, leading to the production NFKB ligand, also referred to as RANKL (Suda et al., 
2003). RANKL then brings about an activation of resting osteoclasts; stimulating 
osteoclastogenesis. Thus, the vitamin D hormone has an important function in enabling 
calcium mobilization from bone when not present in diet (Suda et al., 2003). This function is 
mediated by vitamin D and PTH in vivo (Garabedian et al., 1972). 
1.17  Mechanism of vitamin D action 
Vitamin D exhibits it biological activity by binding to and activating the vitamin D receptor 
(VDR), a member of the superfamily of nuclear receptor which functions as ligand- activated 
transcription factor (Nagy et al., 2012).  The cellular properties of 1, 25 (OH)2 D3 are mediated 
by the VDR and in the absence of 1,25 (OH)2D3, whilst VDR is majorly distributed to the cell 
cytoplasm (Nag-pal et al., 2005). Interaction of 1,25(OH)2D3  with VDR induces formation of 
two independent protein interaction surfaces on the VDR, one that facilitates association with 
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the retinoid X receptor (RXR) necessary for DNA binding, and one that is required for 
recruitment of co-regulators necessary for gene modulation (Pike et al., 2012). 
 Following interaction with 1, 25(OH)2 D3, VDR dimerizes with RXR and translocate to 
the nucleus where it binds to vitamin D response elements (VDRE) in vitamin D responsive 
genes. Depending on the target gene either co-activators or co-repressors are attracted to the 
VDR/RXR complexes to induce or repress gene transcription (Nagpal et al., 2005, Pike et al., 
2012) 
1.18  Vitamin D deficiency 
Vitamin D deficiency is an important public health problem which may occur due to 
inadequate diet, poor exposure to sunlight, vitamin D malabsorption, kidney or liver disease 
and genetic disorder (Zhai et al., 2016). Such deficiency has been attributed to bad bone 
mineralisation resulting progressively to diseases such as bone softening, Osteomalacia, 
rickets and osteoporosis. The reducing trend in serum 25 (OH) D levels has been associated 
with decreasing rate of milk consumption, avoidance of sunlight exposure and increasing rate 
of body mass index (Yetley, 2008). 
Many experts have now defined vitamin D deficiency as serum 25 (OH) D concentrations 
below 20 nanogramme (ng) per millilitre (mL), an equivalent of 50 nanomole (nmol) per Litre 
(L) (Holick, 2007a, Bischoff-Ferrari et al., 2006). Vitamin D insufficiency is considered to be 
between serum 25 (OH) D levels between 20 and 30 ng/ mL (50-75 nmol/L) (Heaney et al., 
2003) while vitamin D sufficiency is taken as serum 25 (OH) D levels above 30 ng/mL (75 
nmol/L) (Dawson-Hughes et al., 2005, Rosen, 2011).  
1.19  Vitamin D and NAFLD: Evidence from scientific studies  
Although vitamin D is majorly involved in the regulation of bone metabolism 
(Kucukazman et al., 2014) and mineralisation (Zhai et al., 2016), recent studies have shown 
significant association between vitamin D levels and other diseases including diabetes, 
hyperlipidemia, hypertension, peripheral vascular disease (Anderson et al., 2010), obesity, 
inflammation and insulin resistance (Chagas et al., 2012). Accumulating evidence from 
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previous studies showed an inverse relationship between serum 25(OH) D levels and IR, 
diabetes risk and metabolic syndrome (Reis et al., 2007). Hence, a possible role for vitamin D 
in the pathogenesis of NAFLD have been suggested (Targher et al., 2007).  The study by 
Targher et al., (2007) showed an independent association between low serum levels of 25 
(OH) D and severity of hepatic steatosis, necrosis and fibrosis in NAFLD patients. More 
recently, vitamin D deficiency has been reported as an important risk factor for Non Alcoholic 
fatty liver disease, NAFLD (Mohamed, 2015).  
Several cross-sectional studies have investigated the relationship between vitamin D 
deficiency and NAFLD. A cross-sectional study in 6567 healthy men in Korea showed a 
significant reduction in NAFLD risk among the group with higher serum 25- hydroxyl vitamin 
D3 compared with the lower group (Rhee et al., 2013). In the same study, 43.6 % of the 
participants were diagnosed with NAFLD and 21.1 % with metabolic syndrome. In addition, 
the mean 25 (OH) D3 level was significantly lower in participants with NAFLD compared with 
those without NAFLD. Another cross-sectional study in East China consisting of 5066 
subjects and NAFLD prevalence of 43.3 % revealed a lower vitamin D level among NAFLD 
subjects compared with subjects without NAFLD (Zhai et al., 2016). Authors confirmed an 
independent association between NAFLD and vitamin D deficiency (OR 1.54; 95 % C.I 1.26, 
1.76).  Other cross-sectional studies showing similar findings include Hao et al., (2014), and 
Chung et al., (2016). (Hao et al., 2014, Chung et al., 2016).   
Experimental studies using animal models have also shown similar results. The study 
by Kong et al., (2014) proposed that vitamin D deficiency probably up-regulate synthesis of 
endogenous fatty acid in NASH through the impairment of enterohepatic circulation (Kong et 
al., 2014).  Findings from the same study revealed that the administration of 1, 25- dihydroxy 
vitamin D3 suppresses hepatic lipogenesis and inflammation which altogether resulted in 
correction of NASH phenotypes (Kong et al., 2014).  Another study by Nakano et al., (2011) 
studied the effect of sunlight therapy and vitamin D supplementation on NAFLD progression 
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in rats. Authors found that both treatments additionally decreased IR and hepatic steatosis 
(Nakano et al., 2011). 
Few randomised controlled trials have investigated the relationship between vitamin D 
and NAFLD. Sharifi et al., (2014), studied the effect of vitamin D supplementation on serum 
aminotransferase, IR, oxidative stress, and inflammatory biomarkers in 53 adult patients 
diagnosed with NAFLD. The study was a randomized, double blind, parallel designed 
placebo-controlled trial in which participants either received one tablet consisting of high dose 
(50,000 IU) vitamin D3 every 14 days for 4 months or a placebo for the same period of time 
(Sharifi et al., 2014). Findings from the study showed that supplementation with vitamin D 
significantly increased serum 25 (OH) D3 levels greater than two fold in the intervention group 
compared to placebo. 
 In addition, vitamin D supplementation significantly reduced serum malondialdehyde 
(MDA); a marker of lipid peroxidation which has been shown to be increased in NAFLD 
patients (Malaguarnera et al., 2005). Such reduction in MDA suggests another mechanism 
through which vitamin D may improve NAFLD (Sharifi et al., 2014). Furthermore, the study 
found a near significant reduction in high sensitive C-reactive protein (hs-CRP) levels in the 
treated group compared to the placebo. Serum hs- CRP levels correlates with histopathologic 
features of NAFLD hence a reduction indicates a slowing down of NAFLD progression and 
decrease cardiovascular risk (Targher et al., 2007).  
Another randomized double blind placebo – controlled trial investigated the effect of 
calcitriol supplementation on NAFLD progression risk (Amiri et al., 2017), based on liver lipid 
accumulation, serum lipid profile and insulin resistance in 73 NAFLD patients. Subjects were 
randomized to receiving low dose (1000 IU) vitamin D supplement as 25 µg/d calcitriol in 
addition to weight reduction diet for 12 weeks. Findings showed a reduction in triglycerides 
(TAG), high density lipoprotein (HDL), insulin and HOMA levels in the calcitriol than placebo 
group. Also, study findings showed an improvement in the grade of fatty liver which was 
confirmed by sonographic echogenicity in the calcitriol group compared to the placebo group. 
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1.20 Overall aim of the thesis 
 
The overall aim of the thesis was to investigate the effect of vitamin D3 supplementation 
on the progression of NAFLD as measured by the induction of pro-inflammatory cytokines (IL-
8 and IL-6) in fatty acid treated HepG2 cells and in a cohort population of healthy South Asian 
and Caucasian women. 
1.20.1 Specific chapter hypothesis and aims  
Chapter 3 Hypothesis: Fatty acid treatment will induce lipid accumulation in hepatocyte 
cell line (HepG2 cells) and this will reduce the protein expression of glyoxalase 1 enzyme 
in the hepatocytes. 
Aim 1:   To investigate the effects of fatty acids (palmitic and oleic acid) on the induction 
of lipid accumulation in hepatocyte cell line (HepG2 cells).  
Aim 2: To investigate the effect of lipid accumulation on the expression of glyoxalase 1 
(GLO 1) enzyme protein in the hepatocytes. 
Chapter 4 Hypothesis: treatment of HepG2 cells with fatty acids (PA and OA) will induce 
an increase in the levels of proinflammatory cytokines (IL-8 and IL-6) while vitamin D 
supplementation will reduce the induction of the pro-inflammatory cytokines. 
Aim 1: To investigate the effect of fatty acid-treatment of HepG2 cells on the induction 
pro-inflammatory cytokines (IL-8 and IL-6) using cell culture and Enzyme-Linked 
Immunosorbent Assay (ELISA). 
Aim 2:  To determine whether supplementation of cells with vitamin D3 will alter the 
induction of cytokines production, using cell culture and ELISA.  
Chapter 5 Hypothesis: vitamin D supplementation will cause a reduction in the level of 
markers of immune function (IL-6).  
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Aim 1: To investigate the effect of vitamin D supplementation on markers of immune 
function (IL-6). 
Aim 2: To determine the role of ethnicity on effect of vitamin D supplementation on 
markers of immune function (IL-6). 
Chapter 6: Hypothesis: vitamin D will influence risk of NAFLD development  
Aim 1: To carry out an extensive systematic review and meta-analysis to examine the 
effect of vitamin D on NAFLD risk in different population groups. 
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2 CHAPTER 2- GENERAL METHODOLOGY 
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2.1 Introduction 
The methodologies used in the conduct of experiments and analysis throughout this 
research project will be outlined and described in this chapter. Reference to background 
literature will be made where applicable.  
2.2 Background on cell line (HepG2) used in thesis 
 
HepG2 (ATCC, Middlesex, UK), a pure immortalised cell line of hepatocellular 
carcinoma which was obtained from the liver tissue of a 15 year old Caucasian American male 
with a well differentiated hepatocellular carcinoma, was utilised in this research study. These 
cells are of epithelial morphology (Costantini et al., 2013) and were chosen for this study 
because they are devoid of viral infections and have been shown to express metabolic 
functions specific to the liver such as triglyceride and cholesterol metabolism, hence their wide 
usage for metabolic studies (Javitt, 1990). 
2.3  Tissue culture methods 
 Cells were routinely grown and maintained on T 80 flasks at 37 o C in a humidified 
atmosphere supplied with 5% carbon dioxide. Cells were grown in T 80 flasks, T 25 flasks, 6- 
well plates and 96 well plates depending on the type of experiment being conducted. The 
culture media used were Dulbecco Modified Eagle’s Medium (DMEM) containing low (5.5 mM) 
glucose or high (25 mM) glucose supplemented with 10% foetal bovine serum (FBS), 2 mM 
L-glutamine, 1% non-essential amino acids (NEEA) and 100 U/mL penicillin and 100 U/mL 
streptomycin. These are also described in table 2.1. The cells were utilised between passage 
numbers 7-25. 
Cells were routinely passaged at 80% confluency. For the passage of confluent 
adherent cells, the existing medium was removed, cells were then washed with phosphate 
buffered saline (PBS) to remove inhibitory calcium and covered in Trypsin - EDTA for three to 
five minutes to aid cell detachment. Culture medium was added to neutralise the effect of 
trypsin, cells were collected and formed into single cell suspension using syringe and needle. 
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Cells were then counted then plated at the required density for seeding and stored in 
incubator.  
For the purpose of cryopreservation, harvested cells in single cell suspension were 
pelleted by centrifuging at 300g for 5 minutes, re-suspended in FBS containing 10% DMSO, 
cooled to -80 ºC at 1-3 ºC /min in a cell freezing container and stored in liquid nitrogen (-196 o 
C) for long term storage and -80 o C for short term storage.  
 Table 2-1: Tissue culture media and supplements 
Item Source 
Dulbecco Modified Eagle’s Medium (DMEM) 
with low glucose (1g/L) 
Lonza, Basel, Switzerland 
Dulbecco Modified Eagle’s Medium (DMEM) 
with high glucose (4.5g/L) 
Lonza, Basel, Switzerland 
Dimethyl sulphoxide (DMSO) Sigma Aldrich (Dorset, UK), 
Phosphate buffered saline (PBS) Oxoid (BE17-516Q)  
Foetal Bovine Serum, heat inactivated Lonza, Basel, Switzerland 
Penicillin/ Streptomycin Lonza, Basel, Switzerland 
L-Glutamine Lonza, Basel, Switzerland 
Trypsin - EDTA (0.25%), phenol red Lonza, Basel, Switzerland 
Non- essential amino acids (NEAA) Lonza, Basel, Switzerland 
  
 
2.4  Fatty Acid Treatment 
2.4.1  Treatment of HepG2 with Palmitic and Oleic acid 
The monounsaturated fatty acid, Oleic acid (OA) and the saturated fatty acid, palmitic 
acid (PA) were utilised as treatments to load lipid into the cells.  Briefly, 25 mM OA or 25 mM 
PA prepared in DMSO were complexed with 5.56% fatty acid free (FAF) bovine serum albumin 
(BSA) in deionised water (ddH20), fatty acid: FAF-BSA, 1:9,v/v) at a molar ratio of 3.3: 1 for 1 
hour at 37ºC ( all reagents from sigma-Aldrich, Poole UK). This methodology was developed 
in-house in the MOORE group, although the use of DMSO as a vehicle for FFA has been 
documented previously (Chavez-Tapia et al., 2012, Madec et al., 2011). During complexing, 
the stock solutions were placed in a water bath maintained at 37ºC and mixed by vortexing 
after every 10 minutes for a total period of one hour.  Each solution was then sterile filtered 
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before the preparation of final treatment mixture which includes adding each fatty acid - BSA 
complex to serum free media before treating the cells. Cells were treated with OA or PA 
concentrations ranging from 100 to 500µM in serum –free DMEM with the DMSO having a 
final concentration of 2%. Treatment was applied for 24 hours after which the desired 
experimental endpoints were measured. 
2.4.2 Cell Viability 
Cell viability was assessed using Trypan blue stain. HepG2 cells were treated with 
fatty acids for 24 hours and immediately after this, cells were harvested using trypsin. 
Following this, 10µl of trypan blue dye was added to an equal volume of cell in suspension 
with thorough mixing. 10µl of the mixture was then pipetted into an automated cell counter 
which reads the total number of cells in volume as well as the number of live cells.  
2.4.3 Intracellular Lipid Accumulation Quantification by Nile Red Assay  
 Nile red, a fluorescent and lipophilic dye was used to quantitatively assess the 
intracellular lipid accumulation in HepG2 cells following treatment with fatty acids.  Nile red 
assay methodology was adapted from a previous study (McMillian et al., 2001). Prior to the 
procedures, 1 µM Nile red solution was prepared from 1mM Nile red (stock solution) by diluting 
5µM of 1mM Nile red stock solution with phosphate-buffered saline, PBS, pre-warmed at 37  
o C.  After 24 hours of fatty acid treatment, cells were harvested using trypsin and counted by 
an automated cell counter (T20, Biorad UK). The volume of cell suspension corresponding to 
500,000 live cells was then aliquoted for Nile Red staining.  
The aliquoted cell suspension was centrifuged at 800 x g for 10 minutes at room 
temperature after which the supernatant was removed. 500 µL of 1µM Nile Red was then 
added to cell pellets, followed by vortex mixing and incubation at 37 o C in the dark for 10 
minutes. The incubation was carried out in the dark as the fluorescence properties of Nile red 
is very sensitive to the environment. Cells were centrifuged again at 800 x g for 10 minutes at 
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room temperature and supernatant was removed. Cells were re-suspended in 500 µL pre-
warmed PBS, and formed into single-cell suspension using 19 gauge needle and syringe. 100 
µL of cell suspension were then pipetted in three technical replicates into a 96 well half area 
black plates.  
The plates were then incubated for 2 minutes at 37ºC and shaken for 30 seconds 
before fluorescence measurement at excitation 485-12nm and filter emission 520 nm with the 
gain set at 1575. Fluorescence expressed as relative fluorescence unit (RFU) was measured 
using an automated microplate reader (BMG LABTECH FLUOstar Omega, Ortenber, 
Germany). The Nile red fluorescence value was obtained by the formula below: 
Nile red =
 𝑇𝑟𝑒𝑎𝑡𝑒𝑑𝑅𝐹𝑈
𝑉𝑒ℎ𝑖𝑐𝑙𝑒𝑅𝐹𝑈
  
2.4.4 Nile red staining of HepG2 cells: imaging using fluorescent microscope 
HepG2 cells were seeded in 6 well plates until 70% confluent and afterwards were 
either untreated or treated with vehicle (DMSO) or fatty acids (palmitate or oleate). After 24 
hours, cells were washed once with PBS and on removal, 1UM Nile red solution was added 
to each plate, plate was incubated in the dark at 37 C. After 10 min, Nile red stain was 
removed, cells were washed twice with PBS. Finally, a fresh volume of PBS was added to 
ensure total coverage of cells and following this, cells were imaged by Nikon Fluorescent 
microscope as shown in figure 2.1 below. 
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  Figure 2-1 Photomicrograph of HepG2 cells stained with Nile red. 
HepG2 cells grown in DMEM (low glucose) until 70% confluency were either untreated or 
treated with vehicle (DMSO), 400uM Palmitic acid (PA) or 500uM Oleic acid (OA) for 24 hrs. 
Cells were then stained with Nile red and imaged by fluorescent microscopy (100X 
magnification). a) Untreated, b) Vehicle, c) PA, d) OA. 
 
Table 2-2: Materials used in fatty acid treatment and lipid accumulation 
 
Materials Source 
Oleic acid Sigma Aldrich (Dorset, UK) 
Palmitic acid Sigma Aldrich (Dorset, UK) 
FAF- BSA Sigma Aldrich (Dorset, UK) 
DMSO Sigma Aldrich (Dorset, UK) 
Filter Millex (Millipore, UK) 
DMEM Lonza, (Basel, Switzerland) 
Nile red  Invitrogen Life Technologies (Paisley, UK) 
PBS Oxoid (Basingstoke, UK) 
Automated cell counter T20, Biorad, UK 
Trypan blue Sigma Aldrich (Dorset, UK) 
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2.5  SDS PAGE and Western blotting 
 
Western blotting is an immunoassay that uses specific antibodies to identify proteins 
that have been separated based on size and charge by gel electrophoresis. 
2.5.1 Preparation of cell lysate  
Cells already in cell culture plates were washed once with ice cold PBS, lysed and 
collected in an appropriate volume of  ice cold IP lysis buffer (comprising of  1% NP-40, 25mM 
Tris HCL, 150mM Nacl, 1Mm EDTA and 5% Glycerol) or radio immunoprecipitation assay 
buffer (RIPA). Halt TM Protease inhibitor cocktail was added to the lysis buffer at a dilution of 
1: 100. Lysed cells were incubated on ice for 5-10 minutes with slight agitation, then lysates 
were scraped and collected from wells. Lysates were centrifuged at 10,000g (rpm) at 4ºC for 
10 minutes to remove cell debris. The supernatant which contains the protein was then 
transferred into a fresh Eppendorf tube and stored at -80 o C until subsequent use. 
2.5.2 Isolation and preparation of primary human hepatocytes. 
Primary hepatocytes samples were kindly provided by Dr Bernadette Moore, obtained 
from King’s college, London with prior ethical approval. Hepatocytes were isolated in the 
King’s Cell Isolation Unit, King’s College Hospital, London, under sterile conditions. Cells were 
isolated by a collagenase perfusion technique adapted from (Dhawan et al., 2006) and (Mitry 
et al., 2003) hereby described. Liver segments were received on ice after which the cut surface 
of the liver tissue was cannulated using an intravenous cannula (Size G16 or G18). The 
cannula was secured in place by suturing and this also stopped leakage from other small 
vessels. Liver tissues were perfused with perfusion buffer solutions made up of Hank’s 
balanced salt solution (Biowhittaker UK, Berkshire, UK) containing 0.5mM EGTA, followed by 
Hank’s balanced salt solution, then Eagle’s modified essential medium (EMEM) (Biowhittaker, 
UK) containing collagenase P at 500mg/L, at 30mL/min. The perfusion solutions and liver 
tissues were kept at 37º C during perfusion. Following this, the digested tissue was minced in 
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ice –cold EMEM containing 2% human serum albumin (HSA) and filtered through sterile 
gauze. 
 Isolated hepatocytes were kept in liquid nitrogen on receipt. Samples were prepared 
by first thawing briefly in water bath at 37 ºC and afterwards, about 1.7mL of each sample was 
transferred into a 2 mL Eppendorf tube, samples were then centrifuged at 200g for 5 minutes 
at 4ºC (to pellet the cells). The supernatant was removed and cells were lysed to release 
protein by the addition of 500 - 700 µL IP lysis buffer containing protease inhibitor, while 
vortexing on ice for 5 minutes. Cell lysates were then aliquoted into 500 µL Eppendorf tubes 
and stored at -80 ºC for later determination of protein concentration and western blotting 
analysis. 
 
2.5.3 Determination of protein concentration 
Protein concentrations were determined using the Thermo Scientific Pierce 
Biccinchoninic (BCA) Protein Assay kit according to the manufacturer’s instructions. Briefly, 
bovine serum albumin standards of known concentration were made up in distilled water. The 
working reagent (WR) was prepared by mixing 50 parts BCA reagent A with 1 part BCA 
Reagent B (50:1, Reagent A: B). 10µL of each standard and lysed protein samples were added 
to the 96-well microplate in duplicate. A 200µL volume of the WR was added to each well and 
mixed thoroughly on a plate shaker for 30 seconds. The plate was then incubated at 37 o C for 
30 minutes and the absorbance was measured at 520nm, in an automated plate reader 
(FLUOstar Omega, Ortenberg, Germany). The interpolated concentration of total protein was 
obtained from the standard curve. 
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2.5.4 Immunoblotting (Western Blotting) 
Immunoblotting was performed using whole cell lysates. First, protein samples were 
prepared by adding appropriate sample buffers [5X Laemmli, 5X non- reducing (to which DDT 
was added prior to use), or 4X Licor (to which β- Mercaptoethanol was added). The sample in 
buffer solution was further denatured by heating at 95 oC for 5 minutes. 20 μg of HepG2 total 
protein, 50ng of pure Recombinant human GLO1 protein or 40µg of primary hepatocytes total 
protein were subjected to 15% sodium dodecyl sulphate-polyacrylamide (SDS PAGE) gels at 
room temperature. Protein extracts were separated on the gel based on their molecular weight 
at 1000 voltages using 1X Tris-Glycine-SDS running buffer. Separated proteins were then 
transferred from the gels on to PVDF membranes (activated in methanol for 5 minutes prior to 
use) in a wet transfer procedure at 300 mA of current, for 2 hours using 1X transfer buffer 
consisting of Tris hydrochloride, glycine and methanol. After the transfer, membranes were 
blocked for 1 hour in 5% non- fat dry milk in 1x Tris-buffered saline with 0.1% tween-20 (TBS-
T) at room temperature.  
Blocking was followed by membrane probing using primary antibodies in a multiplexed 
manner. Overnight incubation was carried out on a roller at 4 ºC using rabbit anti-COX IV 
(1:5000) E311 (cell signalling) plus rat anti- glo1 (1:4000) anti-GLO1 (SAB4200193; Sigma 
UK) at 1:4000.  After incubation, membranes were washed four times with 1x TBS-T for 5 mins 
and this was followed by simultaneous incubation with secondary antibodies labelled with 
appropriate fluorescent dye for 1 hour at room temperature. Secondary antibodies used 
included donkey anti-rabbit, and goat anti- rat antibodies (1:10000) dilution. Primary antibodies 
were diluted in 5% BSA in 1X TBS-T while secondary antibodies were diluted  in 5% non- fat 
dry milk in 1x Tris-buffered saline with 0.1% tween-20 (TBS-T) at room temperature.  
The primary antibodies selected were from different types of host animal and the 
secondary antibodies chosen were labelled with different IR (Infrared) dye fluorophores. Blots 
were imaged using the Odyssey Infrared Imaging System (LI-COR Biosciences, Cambridge) 
in both 700 and 800nm channels in a single scan at 169µm automatic resolution. COX IV was 
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used as a loading control. Protein expressions of GLO 1 and the loading control, COX IV were 
quantified using image studio lite software.  This was done by drawing rectangular marks 
around each band lane and the software quantifies the intensity of each band which is then 
giving in numbers. Individual GLO 1 protein expressions were normalized to the expressions 
of loading control COX IV to obtain relative GLO 1 expressions. 
 
2.5.5 Detection of Antigen/Antibody Binding 
Membrane- bound proteins were detected using Odyssey CLX imaging system (LI-
COR Biosciences, Cambridge), a sensitive far red/ near infra-red (NIR) two colour 
fluorescence scanner previously described (Schutz-Geschwender et al., 2004). The 
mechanism is based on an indirect method of detecting antibody binding involving the use of 
secondary antibody conjugated to a NIR dye (fluorophore). Light source from the imager 
produces an excitation in the fluorophore, the emitted fluorescent signal is then captured by 
the camera to give the final image (Schutz-Geschwender et al., 2004). 
In addition, the secondary antibody is raised against the host species of the primary 
antibody. Two colour (multiplex) detection system was employed in this study as the method 
can identify two different antigenic targets while exhibiting high sensitivity for both channel. It 
thereby saves time and prevent sample wastage. In addition, the method allows for easier and 
more precise normalization against internal loading control. 
2.5.6 GLO 1 expression unchanged in normal and fatty human primary hepatocyte 
sample  
Western blotting of normal and fatty human primary hepatocyte samples revealed GLO 
1 protein bands around the 24 kDa and 46 kDa regions Also, the loading control, COX IV was 
detected around the 17kDa region. The 24 kDa band is close to the 21 kDa molecular weight 
band specified for GLO 1 monomer by the manufacturer and the 46 kDa band has been 
specified for the active human GLO 1 dimer (Thornalley, 2003).  Statistical analysis showed 
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no significance difference between GLO 1 expression in normal and fatty hepatocytes. 
However, there seemed to be a variation in COX IV expression between normal and fatty 
samples, raising questions as to its suitability.  This was later shown to be due to the graph 
not starting at zero point. Also, a look at the Coomassie stained gel showed differences in 
protein band pattern, indicating possible individual variations. Quantification of Coomassie 
also showed different band intensities, showing that the samples had different Coomassie 
profile. 
 
 Table 2-3: Composition of the gels and buffers used in immunoblotting 
 
Component Composition 
Resolving gel 30% Bisacrylamide, 0.5M Tris pH : 6.8, 10% 
SDS 
Stacking gel 150mM Tris pH: 6.8, 0.1% APS, 0.1% 
TEMED, 3.75% acrylamide 
IP Lysis buffer 1% NP-40, 25mM Tris HCL, 150mM NaCl, 
1Mm EDTA and 5% Glycerol 
RIPA buffer  
1X Gel Sample Buffer 10% glycerol, 60mM TrispH6.8, 2% SDS, 
0.01% bromophenol blue, 1.25% beta-
mercaptoethanol 
1X Running buffer 25mM Tris base, 195 mM glycine, 0.1% 
(w/v) SDS. 
1X Transfer buffer 25mMTris base, 192mM glycine, 20% (v/v) 
methanol 
Tris buffered Saline (TBS) 50Mm Tris, pH7.5, 150mM NaC in water 
TBS-Tween (TBS-T) 0.05%v/v Tween-20 in TBS 
 
Table 2-4: Antibodies used in Western Blotting analysis 
Primary antibodies (concentration) Supplier 
Rabbit anti-COX IV (1:5000)  Cell signalling  (E311) 
Rat anti-GLO1  (1:4000) Sigma UK (SAB4200193) 
Secondary antibodies  
Donkey anti-rabbit (1:1000) Licor Biosciences, UK 
goat anti- rat (1:10000) Licor Biosciences, UK 
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2.6 Enzyme-linked immunosorbent assay (ELISA) 
2.6.1 Principle 
Enzyme-linked immunosorbent assay is a technique that utilises paired antibodies to 
quantify an antigen using a standard curve. First, the capture antibody is coated unto a 96-
well micro-titre plate in order to immobilize the antigen. Following the plating of samples, a 
biotinylated detection antibody which recognises a different epitope is added to the 
immobilized antigen, the biotin tag allows a tight binding to streptavidin which is conjugated to 
the enzyme horseradish peroxidase (HRP). HRP conjugated detection antibodies may also 
be used as an alternative. This subsequently catalyse the oxidation of 3, 3, 5, 5 - Tetramethyl 
benzidine (TMB) into a blue product. The reaction is then terminated by the addition of dilute 
H2S04 generally referred to as stop solution which causes a generation of a more intense 
yellow colour. The product absorbs light at a wavelength of 450nm and the optical density 
(OD) can be measured on an ELISA plate reader. 
2.6.2 Protocol for the measurement of IL-8 and IL-6 cytokines from fatty acid- treated 
HepG2 cells 
Interleukins 8 (IL-8) and IL-6 were detected by ELISA using a commercial kit obtained 
from Thermo Fisher Scientific and used according to manufacturer’s recommendation. Briefly, 
96-well plate was coated with 100 µL capture antibody and the plate incubated overnight at 
4ºC. The next day the capture antibody was discarded, plates were washed three times with 
the wash buffer (containing PBS+ tween ) and wells were blocked in 200µL of ELISA diluent 
(2% BSA) for 1 hour at room temperature. After blocking, 100µL of samples and/or standards 
ranging from 1000 pg/mL – 15 pg/mL for IL-8 detection and 200 pg/mL- 2pg/ML for IL-6 
detection were added to the wells and the plate was incubated overnight at 4 o C for maximal 
sensitivity. 
 The next day, samples and standards were aspirated and the plate washed three times 
with the wash buffer, then 100 µL of detection antibody added to wells and incubated for 1 
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hour at room temperature. After 1 hour, the plate was washed as above and 100 µL avidin - 
horseradish peroxidase (HRP) conjugated antibody specific for IL-8 or IL-6 was added to wells 
and incubated for 30 minutes at room temperature. The plate was washed three times again 
with the wash buffer and the colorimetric reaction was initiated by adding 100 µL of 
tetramethylbenzidine (TMB) solution. The plate was incubated at room temperature for about 
5 to 7 minutes until the blue colour develops. Then the reaction was stopped with an equal 
amount of 2N H2S04 and the optical density measured at 450nm using the FLUOstar Omega 
microplate reader (Ortenberg, Germany). 
2.7 Cell Culture for vitamin D supplementation studies 
HepG2, an immortalised cell line was cultured in Dulbecco Modified Eagle’s Medium 
(DMEM) containing low (5.5 mM) glucose supplemented with 10% Foetal Bovine Serum 
(FBS), 2 mM L-glutamine, 1% NEEA and penicillin/streptomycin (100 IU/mL each). Cells were 
routinely maintained at 37 o C in a humidified atmosphere with 95% oxygen and 5% carbon 
dioxide. Cells were seeded in T-80 flasks for routine maintenance and in 6- well plates for 
vitamin D3 pre-treatment preceding fatty acid treatment. For routine maintenance, cells were 
seeded  in T80 flasks and passaged every 72 hours while for vitamin D3 pre-treatment/ fatty 
acid treatment, the cells were seeded at 700,000 cells per well with or without vitamin D3 for 
48 hours. After this, cells were treated with either vehicle, fatty acids (PA or OA) or TNFα 
(TNFα 20 ng/mL), which serves as a positive control, for 24 hours. A set of untreated cells 
serves as a negative control.   
 Vehicle treatment consist of BSA in 10% v/v dimethylsulphoxide (DMSO). Fatty acid 
treatment with PA and OA were applied to cells at a final concentration of 400 µM and 500 µM 
respectively. For the fatty acid treatment, 25mM OA or 25mM PA was added to 5.56% w/w 
BSA to allow the formation of a fatty acid- BSA complex which will enhance the transport of 
fatty acid into the cells. Each solution is placed in water bath maintained at 37 o C for 1 hour, 
in which the solution is vortexed every 10 minutes. Afterwards, each solution was then sterile 
filtered before the preparation of treatment which includes adding each fatty acid- BSA 
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complex to complete media before treating the cells. Cells were then treated with physiological 
serum of fatty acids (palmitic acid, 400 µM or oleic acid, 500 µM) for 24 hours. Absorbance 
and fluorescence measurements were taken by FLUOstar Omega microplate reader 
(Ortenber, Germany). 
2.8  Fatty Acid Treatment in vitamin D supplementation studies 
Three different steps or modifications were employed in the investigation of effect of 
vitamin D supplementation on the induction of IL-8 secretion in the fatty acid- treated HepG2 
cells. Firstly, HepG2 cells were grown to about 70% confluency then treated with fatty acids 
complexed with FAF BSA and co-incubated with 100 nM vitamin D3 for 24 hours. Treatments 
were applied in serum –free media. In the second method, HepG2 cells were supplemented 
with 50 or 100 nM  vit D3 for 48 hours, followed by treatments with fatty acids complexed with 
fatty acid- free or standard BSA. Treatments were applied in complete media.  In the third 
method, HepG2 cells were supplemented with 50 or 100 nM vit D3 for 48 hours, followed by 
treatments with fatty acids complexed with FAF or standard BSA plus vitamin D3 continuous 
for 24 hours. Treatments were applied in complete media. These are described in table 2.4 
below.  
Table 2-5: Different methods employed for vitamin D treatment of cells. 
 Time and method of 
vitamin D supplementation 
Fatty acids complexed 
with § 
Media state #  
Method 1 24 hours (co- incubation*) Fatty acid free BSA 
 
Serum-free 
Method 2a 48hours (supplementation**) FAF or standard BSA Serum- free  
Method 2b 48hours (supplementation**) FAF or standard BSA Complete 
Method 3 48 hours supplementation 
+24 hours continuous*** 
FAF or standard BSA Complete 
* Co-incubation: Vitamin D3 and Fatty acids were added together for 24hrs. 
 ** Supplementation: Vitamin D3 was added 48hrs before fatty acids. During the fatty acid 
treatment, no vitamin D3 was present. 
 *** Continuous: Vitamin D3 was added 48hrs before fatty acids and was also included in the 
fatty acid treatment.  
§:  BSA is used as a carrier for the fatty acids, and different preparations were tested. FAF 
BSA (Sigma A7030)): Prepared using heat shock fractionation but free from fatty acid, 
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essentially globulin free. Standard BSA (Sigma A3059): Prepared using heat shock 
fractionation. FAF and standard BSA were compared in the same experiments. Serum- free 
media (prepared without FBS) or complete media (prepared with FBS) were used.  Method 2 
developed as complete media was tried. 
 
 
Table 2-6: Materials used in vitamin D supplementation and IL-8 measurement 
Materials Supplier 
1α, 25- Dihydroxyvitamin D3 Enzo life sciences (BML- DM200) 
Coating buffer : 10X Phosphate Buffered 
Saline 
Thermofisher (1856919) 
Capture antibody: Anti-Human IL-8 Purified Thermofisher (4344026) 
human IL-8 lyophilized standard Thermofisher (4297535) 
Detection antibody: anti – human IL-8 Biotin Thermofisher (4344025) 
Avidin-Horse Radish Peroxidase Thermofisher (4337570) 
ELISA diluent (5X) Thermofisher (1857191) 
Substrate (1X TMB solution), Thermofisher (E108514) 
Phosphate Buffered Saline Oxoid, Basingstoke (BE17-516Q) 
Stop solution: 2N H2S04 Thermofisher  
96-well plate, NUN C maxisorp Thermofisher 
Tween -20 Sigma (P139) 
 
 
Table 2-7: Materials used in vitamin D supplementation and IL-6 measurement 
 
Materials Source 
1α, 25- Dihydroxyvitamin D3 Enzo life sciences (BML- DM200) 
Coating buffer : 10X Phosphate Buffered 
Saline 
Thermofisher (4322366) 
Capture antibody: Anti-Human IL-8 Purified, 
Anti-Human IL-6 Purified 
Thermofisher (4323905) 
human IL-8 lyophilized standard, human IL-
6 lyophilized standard, 
Thermofisher (4316792) 
Detection antibody: anti – human IL-8 Biotin, 
anti – human IL-6 Biotin, 
Thermofisher (4323901) 
Avidin-Horse Radish Peroxidase Thermofisher (4337572) 
ELISA diluent (5X) Thermofisher (4314846) 
Substrate (1X TMB solution), Thermofisher (E108514) 
Phosphate Buffered Saline Oxoid, Basingstoke (BE17-516Q) 
96-well plate, NU maxisorp Thermofisher 
Tween -20 Sigma (P1379) 
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2.9 RNA extraction 
 
RNA was extracted from HepG2 cells by the use of a QIAamp RNA Blood Mini Kit 
(Qiagen) according to the recommendation of the manufacturer. Cells were lysed in RLT buffer 
containing β – mercaptoethanol (Sigma) which functions to inactivate RNases. The lysate was 
then homogenised using a QIAshreder spin column after which the flow through was collected. 
An equal volume of 70% ethanol (sigma) was added to the homogenised lysate to adjust 
binding conditions. The QIamp spin column was centrifuged at 14,000g for 30 seconds, 
binding RNA to the silica membrane of the QIamp. Then, the column was washed with buffers 
RW 1 and RPE to elute contaminants and washed RNA was eluted from the column with 
RNase- free water. After the extraction, RNA was quantified using a Nanodrop (TM 2000) 
spectrophotometer (Thermo Scientific). 
 
Table 2-8: Materials used in RNA extraction  
Materials Source 
RLT buffer Qiagen, Netherlands 
QIAshreder spin column Qiagen, Netherlands 
Ethanol Qiagen, Netherlands 
β – mercaptoethanol Qiagen, Netherlands 
RPE Qiagen, Netherlands 
RW Qiagen, Netherlands 
 
 
2.10 The D2-D3 Study 
2.10.1 Study Design 
The D2-D3 study was a randomised, double-blind, placebo-controlled food fortification 
trial carried out at the University of Surrey. A total of 335 participants were included in the 
study consisting of healthy South Asian or Caucasian women, aged 20-65 years with a BMI 
of 18-30kg/m2. Participants were randomised to receive either placebo or vitamin D 
intervention product (an orange juice and a biscuit), daily, alongside their normal diet, thereby 
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receiving 15µg/day of vitamin D2, 15ug/day vitamin D3 or placebo for 12 weeks across two 
consecutive winter periods.  
There were five intervention products including: placebo, vitamin D2 juice, vitamin D2 
biscuit, vitamin D3 juice and vitamin D3 biscuit. Subjects received an orange juice and a biscuit 
to consume daily, only one of these would be fortified while the other would be a placebo. 
However, both products were placebo in the placebo group. Participants made three visits 
over the 12- week study period: at visit 1, baseline (V1), week 6 (V2) and week 12 (V3). 
2.11 Measurement of Vitamin D and its metabolites 
  
Total 25-hydroxyvitamin D (25 (OH) D) measurements were carried out by Dr Jacqueline 
Berry of the University of Manchester and Manchester Royal Infirmary, UK). The laboratory is 
accredited by the Clinical Pathology Accreditation (CPA) UK (CPA number 0865) and also 
certified as proficient by the vitamin D Quality Assurance Scheme (DEQAS). With the methods 
used, it was possible to distinguish between 25- hydroxyvitamin D2 (25OHD2) and 25- 
hydroxyvitamin D3 (25 (OH) D3) components of total 25 (OH) D levels. This also allowed for 
the independent quantification of the metabolites. Serum 25 (OH) D concentrations were 
determined by liquid chromatography tandem mass spectrophotometry (LC-MS/MS). An 
ABSciex 5500 tandem mass spectrophotometer (AB Sciex UK Ltd, Warrington, UK) and a 
MassChrom ® 25 (OH) D3/D2 kit for LC-MS/MS (Chromsystems instruments and Chemicals 
GmbH, Grafelfing, Germany) following the manufacturer’s instructions. The intra - and inter –
assay variations were 3.7 % and 4.8 % respectively.  
2.12 Protocol for IL-6 measurement by high sensitive ELISA   
 
Interleukins 6 (IL-6) were detected in participant plasma samples by high sensitive 
human IL-6 Quantikine ELISA kit purchased from R and D systems (Minneapolis, USA) and 
used according to the manufacturer’s instructions. Briefly, 100 µL assay diluent was added to 
each well, followed by the addition of 100 µL standard or sample per well, the plate was 
covered with adhesive strip and incubated for 2 hours at room temperature on a horizontal 
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orbital microplate shaker set at 500 ± 50 rpm. Next, the plate was washed six times by an 
automated plate washer, filling each well with about 400 µl wash buffer and aspirating after 
each wash. A 30 seconds soak time was included between each addition of wash buffer and 
aspiration.  After each wash, plate was inverted on a clean paper towel and rapped at least 
10 times to remove excess wash buffer. 
 Next, 200 µL of human IL-6 HS conjugate was added to each well and the plate 
incubated for 2 hours at room temperature on the shaker. After 2 hours, the plate was washed 
six times again as described above, then 50 µL substrate solution was added and plate 
incubated for 1 hour at room temperature on the benchtop. After this and without washing, 50 
µL amplifier solution was added to each well, plate was incubated for 30 mins at room 
temperature on the benchtop, this initiates the colour development then 50 µl stop solution 
was added to each well to end the reaction. The optical density for each standard and sample 
was measured at 490nm and 650nm using the FLUOstar Omega microplate reader having a 
minimum detection level of 0.70pg/mL.  
Wavelength correction was carried out by subtracting the optical density readings at 
650nm from the readings at 490nm. A standard curve was generated using the MARS data 
analysis software of the Omega Plate reader (BMG LABTECH). The same software wizard 
was used to calculate the concentration of each sample and standard which were run in 
duplicates. A new standard curve was generated for each plate measurements. The intra-
assay coefficient of variation (CV) was calculated for each ELISA plate.  
Table 2-9: Materials used in high sensitive ELISA 
Materials Supplier 
Human IL-6  HS microplate R & D Systems, USA (892291) 
Human IL-6  HS standard R & D Systems, USA (892293) 
Human IL-6  HS conjugate R & D Systems, USA (892292) 
Assay diluent RD1-75 R & D Systems, USA (895811) 
Calibrator diluent concentrate R & D Systems, USA (895489) 
Wash buffer Concentrate R & D Systems, USA (895188) 
Stop solution R & D Systems, USA (895032) 
Substrate R & D Systems, USA (895884) 
Substrate diluent R & D Systems, USA (895885) 
Amplifier solution R & D Systems, USA (895886) 
Amplifier diluent R & D Systems, USA( 895887) 
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2.13 Statistical Methods 
Assessing the supernatant or lysate from a single sample in duplicate or triplicate 
indicate technical replicates while biological replicates were carried out by exposing cells to 
the same experimental conditions on different days. At least 3 biological replicates were 
carried out for all experiments. 
Data are expressed as mean ± Standard error of mean (SEM) unless otherwise 
specified. Statistical analysis was carried out using either two-tailed Student’s t test for 
unpaired data or one-way analysis of variance (ANOVA) with Dunnett's test post hoc (for 
intracellular lipid accumulation and cell viability determinations), or Turkey’s test post hoc (for 
GLO 1  expressions) as appropriate.  Significance was defined by a P value of <0.05. 
Statistical analyses were performed by Graph Pad Prism 6 or Statistical Package for the Social 
Sciences (SPSS) (IBM SPSS statistics 24). Graph generation was carried out by Graph Pad 
Prism 6. 
2.14 Further Methods 
 
Further methods for the systematic review and meta-analysis are discussed in chapter 6.  
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3 CHAPTER 3 
 
Role of Glyoxalase GLO 1 enzymes in NAFLD 
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3.1 Introduction 
 
  NAFLD is characterised by increased lipid accumulation in hepatocytes (Kleiner and 
Brunt, 2012). Furthermore, it is known that the disease is strongly associated with features of 
metabolic syndrome including insulin resistance, obesity, diabetes, hypertension and 
dyslipidaemia (Loomba et al., 2012). Elevated levels of MG has been reported in conditions 
of hyperglycaemia. For example, a study on diabetic patients revealed a 5-6-fold increase in 
plasma MG compared to non-diabetic patients (McLellan et al., 1994). The same study 
reported that α- oxoaldehyde metabolites, MGH1, is increased in conditions of diabetes due 
to a raised plasma and tissue concentration of MG. As a result, MG metabolism by the 
glyoxalase system has been linked with diabetic complications (Thornalley et al., 1989) . 
 In addition, it has been suggested that MG may play a role in insulin resistance and 
damage to beta cell, while insulin resistance is a hallmark in NAFLD development and 
progression (McLellan et al., 1994) . Furthermore, the GLO 1 gene has been shown to play a 
role in indices of body mass index (obesity). The Meta-analysis in search of obesity 
susceptibility loci in mice showed GLO 1 genes as one of the significant genes associated with 
body weight in mice (Wuschke et al., 2007). 
Recent study findings showed a reduction in GLO 1 activity and mRNA levels of white 
/ viscera adipose tissue (VAT) of mice fed with high fat diet compared to control (Maessen, 
2015). The study also found that overexpression of GLO 1 in high fat fed mice resulted in a 
significant suppression in gain in body weight compared to control animals. Moreover, a 
proteomics study using high performance lipid chromatography mass spectrometer (HPLC-
MS) analysis in a mouse model for NAFLD by Spanos and Moore (2018), showed that GLO1 
protein expression was decreased in the animal model of NAFLD. The same study showed 
similar downregulation of  GLO 1  protein from biopsies of paediatric NAFLD patients using 
immunochemistry staining techniques (Spanos and Moore, 2018). However, the study did not 
confirm a causal relationship between lipid accumulation in the liver and reduction in GLO 1 
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expression. Hence, the aim of the study was to investigate the effect of lipid loading on GLO 
1 expression in vitro.  
3.1.1 Hypothesis, Aims and Objectives  
It was hypothesised that hepatic lipid loading and nutrient perturbation would cause a 
reduction in GLO 1 levels. The aim of this study was to characterize GLO 1 response to hepatic 
lipid loading and nutrient perturbation and also to determine the impact of GLO 1. 
The specific objectives were to  
1. measure the effects of nutrients (i.e. fatty acids) on lipid accumulation in HepG2 cells  
using low and  high glucose concentration. 
2. Measure the effect on GLO1 protein expression in the HepG2 cells. 
3.2 Methods 
 
The full details of methods are described in section 2.4.  In brief, HepG2 cells were 
treated with fatty acids including 400 µM palmitic acid and 500 µM oleic acid. The 
concentration of fatty acid used in this chapter were determined in house in the Dr Bernadette 
Moore group from a previous experiment  based on the dose-response of saturated and 
unsaturated fatty acids on HepG2 and HUH-7 cells using MTT assay (Maldonado and Moore, 
in preparation). 
The experiments were repeated to confirm the findings obtained and in order to get more 
understanding on GLO 1 molecular mass and dimeric nature in SDS- PAGE / western blotting, 
the pure E. coli -derived recombinant human GLO 1 protein was obtained (R&D Systems, 
500ng/µL). To determine the appropriate amount of the pure protein to load in western blotting, 
different concentrations (250ng, 125ng, 62.5ng or 31.25ng) of the pure protein were loaded 
on SDS- PAGE gel and taken through western blotting procedures. Image scanning revealed 
concentration around 50 ng to be appropriate for loading (see appendix A). 
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3.3  Results :  Effects of Oleic acid and palmitic acid treatment on lipid accumulation, 
cell  viability and GLO 1 protein expression in HepG2 cells (low glucose) 
 HepG2 cells cultured in low (5.5 mM) glucose containing DMEM  were treated with 
either DMSO (vehicle) as a control, 400 µM palmitic acid (PA) or 500 µM oleic acid (OA) for 
24 hours.  Cells were then assessed for viability and intracellular lipid accumulation using 
Trypan blue and Nile red staining respectively. In addition, photomicrographs of cells were 
taken after Nile red staining using fluorescence microscope. In the repeat experiments, cells 
were treated with with either DMSO (vehicle), 400 µM palmitic acid (PA), 500 µM oleic acid 
(OA) or 1 µL/ mL cycloheximide (CHX) for 24 hours.  A set of untreated cells were included as 
a negative control. Photomicrographs of cells were taken after Nile red staining to assess 
intracellular lipid accumulation.  
3.3.1 Palmitic acid and oleic acid induce significant lipid accumulation in HepG2 
cells (low glucose). 
5.5mM (Low) glucose is a model for physiological glucose.  HepG2 cells cultured in 
5.5mM glucose (n= 5 independent experiments) revealed a significantly higher intracellular 
lipid accumulation after treatment with 400 µM PA (P = 0.0002) and 500 µM OA (P < 0.0001) 
compared to vehicle. 500 µM OA treatment had a higher fold change in lipid accumulation 
than 400 µM PA treatment (Figure 3.3.1A). Photomicrographs of HepG2 cells cultured in low 
glucose, taken after treatment with fatty acids (400 µM PA and 500 µM OA) for 24 hours 
followed by Nile red staining showed a greater magnitude of intracellular lipid accumulation 
after PA and OA treatment compared to vehicle  and negative control (Figure 3.3.1B).  
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Figure 3-1: Palmitic acid and oleic acid induces significant lipid accumulation in HepG2 cells 
(low glucose) 
HepG2 cells cultured in low (5.5mM) glucose containing DMEM were treated with either 
DMSO (vehicle) as control, 400µM PA or 500 µM OA for 24 hours. Intracellular lipid 
accumulation  was quantified by Nile red staining. Values are expressed relative to vehicle as 
mean ± SD, (A): n = 5 independent experiments, PA (P = 0.0002), OA (P < 0.0001), Statistical 
Analysis was carried out using one-way ANOVA with Dunnett's test post hoc. *P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001. 
 
 
3.3.2 Effects of PA and OA on HepG2 cell viability  
Viability of HepG2 cells cultured in 5.5mM (low) glucose (n=5 independent 
experiments) and assessed by Trypan blue staining, was prominently reduced after treatment 
with 400µM PA. On the other hand, OA treatment did not significantly affect cell viability 
(Figure 3.2). Cell viability was reduced by 32.2% with 400µM PA treatment (P = 0.0003) while 
14.4% reduction was induced by 500 µM OA (P = 0.1453).  
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Figure 3-2: Effects of PA and OA on HepG2 cell viability 
HepG2 cells cultured in (a) low glucose containing DMEM were treated with either DMSO 
(vehicle), 400 µM PA or 500 µM OA for 24 hours. Cell viability was determined by Trypan blue 
staining. Values are expressed relative to vehicle as mean ± SD,  n = 5 independent 
experiments, PA (P = 0.0003), OA (P = 0.1823). Statistical Analysis was carried out using one-
way ANOVA with Dunnett’s test post hoc. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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3.3.3  GLO 1 expression in HepG2 unchanged after PA and OA treatment (low 
glucose) 
20 µg protein of HepG2 cells maintained in low glucose and treated with either DMSO 
(vehicle), 400 µM palmitic acid (PA), 500 µM oleic acid (OA) or 1 µL/ mL cycloheximide ( CHX), 
for 24 hours, or  untreated cells (negative control). 50ng protein of the recombinant human 
GLO 1 (Rh GLO 1) was also loaded on the same gel (n = 3 independent experiments). Protein 
samples were subjected to western blotting using reducing gel. Findings showed GLO 1 
monomer protein bands around the 24 kDa region and GLO 1 dimer bands around the 46 kDa 
region for both HepG2 and Rh GLO 1 (Figure 3.3a). The 24 kDa band is close to the 21 kDa 
molecular weight band specified for GLO 1 monomer by the manufacturers, and 25 kDa band 
specified for recombinant GLO 1 by the manufacturer. Total GLO 1 was computed as 
described in section 2.44. 
Statistical analysis revealed no significant difference in GLO 1 protein expression in 
HepG2 cells treated with either fatty acid, PA (P = 0.7622 ) or OA (P =0.4140 ) compared to 
vehicle (DMSO) (Figure 3.3b). However, GLO 1 expression was significantly down- regulated 
in the CHX treated cells (P = 0.0302). 
  
15 
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 Figure 3-3: GLO 1 expression unchanged after PA or OA treatment (low glucose) 
HepG2 cells cultured in low (5.5mM) glucose containing DMEM (n=3 independent 
experiments) were treated with either DMSO (vehicle), 400µM PA, 500µM OA or CHX for 24 
B 
A 
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hours.  Cells were then lysed with IP lysis buffer to get protein. 20µg denatured protein 
samples were subjected to western blot analysis (multiplexed) on a reducing gel using COX 
IV as a loading control. Primary antibody: COX IV (cell signalling, 1:5000) and Rat anti- GLO 
1 (sigma, 1:4000). Secondary antibody: Donkey anti- rabbit 800CW (1:10,000) and Goat anti- 
rat 680 RD (1:10,000). (a): coloured image of blot, (b): bar graph of GLO 1 expression 
normalised to untreated control.  Relative quantification performed using Image studio Lite 
software. Individual GLO 1 protein expressions were normalized to the expressions of loading 
control COX IV and value thereafter normalised to untreated control. 
 
3.4 Effects of Oleic acid and palmitic acid treatment on lipid accumulation, cell  
viability and GLO 1 protein expression in HepG2 cells (high glucose) 
High (25mM) glucose is a model for hyperglycaemia. In the initial experiments, HepG2 
cells cultured in high (25mM) glucose containing DMEM  were treated with either DMSO 
(vehicle) as a control, 400 µM palmitic acid (PA) or 500 µM oleic acid (OA) for 24 hours.  Cells 
were then assessed for viability and intracellular lipid accumulation using Trypan blue and Nile 
red staining respectively. In the repeat experiments, cells were treated with either DMSO 
(vehicle), 400 µM palmitic acid (PA), 500 µM oleic acid (OA) or 1 µL/ mL cycloheximide (CHX) 
for 24 hours. Untreated cells were also included as negative control. Photomicrographs of 
cells were taken after Nile red staining to assess intracellular lipid accumulation. Denatured 
protein samples were then analysed by western blotting. 
3.4.1  Palmitic acid and oleic acid induces significant lipid accumulation in HepG2 
cells (high glucose). 
HepG2 cells cultured in 25mM glucose (n= 3 independent experiments) revealed a 
significantly higher intracellular lipid accumulation after treatment with 400 µM PA (P = 0.0084) 
and 500 µM OA (P = 0.0002) compared to vehicle. 500 µM OA treatment had a higher fold 
change in lipid accumulation than 400 µM PA treatment (Figure 3.4). In the repeat 
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experiments, cells were treated with DMSO (vehicle), 400 µM palmitic acid (PA), 500 µM oleic 
acid (OA) or 1 µL/ mL cycloheximide (CHX) for 24 hours, followed by Nile red staining 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4: Palmitic acid and oleic acid induce significant lipid accumulation in HepG2 cells 
 
HepG2 cells cultured in high glucose containing DMEM were treated with either DMSO 
(vehicle) as control, 400µM PA or 500 µM OA for 24 hours. Intracellular lipid accumulation  
was quantified by Nile red staining. Values are expressed relative to vehicle as mean ± SD,: 
n=3 independent experiments, PA (P = 0.0084), OA (P = 0.0002). Statistical Analysis was 
carried out using one-way ANOVA with Dunnett’s test post hoc. *P < 0.05, **P < 0.01, ***P < 
0.001, ****P < 0.0001. 
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3.4.2 Effects of PA and OA on HepG2 cell viability  
Viability of HepG2 cells cultured in 25mM (high) glucose (n = 3 independent experiments) was 
assessed by Trypan blue staining. Findings showed a reduction in cell viability after treatment 
with 400µM PA and 500 µM OA  (Figure 3.5). Cell viability was reduced by 28.3 % with 400µM 
PA treatment (P = 0.0121) while cell viability reduction was induced by 24 % with 500 µM OA 
treatment (P = 0.0329).  
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Figure 3-5 Effects of PA and OA on HepG2 cell viability (high glucose) 
HepG2 cells cultured in 25mM glucose containing DMEM were treated with either DMSO 
(vehicle), 400 µM PA or 500 µM OA for 24 hours. Cell viability was determined by Trypan blue 
staining. Values are expressed relative to vehicle as mean ± SD,  n = 3 independent 
experiments, PA (P = 0.0121), OA (P = 0.0329). Statistical Analysis was carried out using one-
way ANOVA with Dunnett’s test post hoc. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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3.4.3 PA and OA treatment of HepG2 cells does not affect GLO 1 expression (high 
glucose), GLO 1 expression in HepG2 cells unchanged after PA and OA 
treatment (high glucose). 
 
Following this, HepG2 cells maintained in high glucose were treated with either DMSO 
(vehicle), 400 µM palmitic acid (PA), 500 µM oleic acid (OA) or 1 µL/ mL cycloheximide ( CHX), 
for 24 hours, or  untreated cells (negative control). 20 µg protein of whole  Hep G2 cell lysates 
or 50ng protein of the pure recombinant human GLO 1 (Rh GLO 1) were also loaded on the 
same gel (n = 3 independent experiments). Protein samples were subjected to western 
blotting. Findings showed GLO 1 monomer protein bands around the 26 kDa region and GLO 
1 dimer bands around the 55 kDa region for both HepG2 and Rh GLO 1 (Figure 3.6A). The 
26 kDa band is close to the 21 kDa molecular weight band specified for GLO 1 monomer by 
the manufacturers and 25 kDa band specified for recombinant GLO 1 by the manufacturer. 
Total GLO 1 was computed as described in materials and methods and was normalised to the 
loading control, COX IV. 
Statistical analysis revealed no significant difference in GLO 1 protein expression in 
HepG2 cells treated with either fatty acid, PA (P = 0.4053) or OA (P = 0.1390 ) or CHX (0.1286) 
compared to vehicle (DMSO) (Figure 3.6B).  
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       Figure 3-6: GLO 1 expression unchanged after PA or OA treatment (high glucose) 
HepG2 cells cultured in high glucose (n = 3 independent experiments) were treated with either 
DMSO (vehicle), 400µM PA, 500µM OA or CHX for 24 hours.  Cells were then lysed with IP 
lysis buffer to get protein. 20µg denatured protein samples were subjected to western blot 
analysis (multiplexed) on a reducing gel using COX IV as a loading control. Primary antibody: 
COX IV (cell signalling, 1:5000) and Rat anti- GLO 1 (sigma, 1:4000). Secondary antibody: 
Donkey anti- rabbit 800CW (1:10,000) and Goat anti- rat 680 RD (1:10,000). (a): coloured 
image of blot, (b): bar graph of GLO 1 expression normalised to untreated control. Relative 
quantification performed using Image studio Lite software. Individual GLO 1 protein 
expressions were normalized to the expressions of loading control COX IV and value 
thereafter normalised to untreated. Relative GLO 1 expression shown as normalized means 
± SD. Statistical analysis by one way ANOVA with Dunnett’s test post hoc. P = 0.4053 (PA),  
P = 0.1390 (OA) and P = 0.1286 (CHX). 
 
3.5 Differences in expression of GLO 1 in normal and fatty human primary 
hepatocyte.  
 
3.5.1 GLO 1 expression unchanged in normal and fatty human primary hepatocyte 
samples (n=5 biological replicates).  
In the initial analysis, Western blotting of normal and fatty human primary hepatocyte 
samples (n = 5 biological replicates) revealed GLO 1 protein bands around the 24 kDa and 46 
kDa regions (Figure 3.7a). Also, the loading control, COX IV was detected around the 17kDa 
region. The 24 kDa band is close to the 21 kDa molecular weight band specified for GLO 1 
monomer by the manufacturer and the 46 kDa band has been specified for the active human 
GLO 1 dimer (Thornalley, 2003). However, statistical analysis by unpaired t- test showed that 
there was no significant difference between GLO 1 expression in normal and fatty hepatocytes 
(Figure not shown).  
 
Normal 
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 Figure 3-7: GLO 1 expression unchanged in normal and fatty primary hepatocyte 
(n=5) 
 
40µg of protein were analysed by Western blot (multiplexed) using COX IV as a loading 
control. Primary antibody: COX IV (cell signalling, 1:5000) and Rat anti- GLO 1 (sigma, 
1:4000). Secondary antibody: Donkey anti- rabbit 800CW (1:10,000) and Goat anti- rat 680 
RD (1:10,000). Proteins were separated by running in 1X TGS for 2 hours after which the gel 
was stained with Coomassie dye for 1 hour and de - stained overnight. Quantification of band 
intensity performed and imaging done by Image Lite software. Individual protein expressions 
were normalized to the expression of COX IV. Relative protein expressions are shown as 
normalized means ± SEM. Analysis by unpaired t-test. (A): greyscale image of blot, (B) image 
of coomassie stained gel. 
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3.6 Testing of GLO 1 Dimer using different reducing agents  
 
3.6.1  GLO 1 dimer expressions in primary hepatocyte samples unchanged with 
different reducing agents in buffers. 
In the initial experiments, in order to confirm GLO 1 dimer expression, 3 normal primary 
hepatocyte samples were subjected to western blotting analysis using three reducing agents 
in 3 buffers. This include an old sample of dithiothreitol (DTT) in 5X Non-reducing buffer, a 
freshly prepared DTT in 5X Non-reducing buffer and β- Mercaptoethanol  in LICOR buffer. 
COX IV was used as a loading control. GLO 1 monomer and dimer protein expression were 
detected around the 24 kDa and 46 kDa regions respectively (Figure 3.8) as with previous 
experiments.  
 Statistical analysis using one-way ANOVA followed by Turkey’s test post hoc showed 
no significant difference in GLO 1 expression in the three buffers used. 
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(a)       
 
                                                            
 
 
 
 
 
 Figure 3-8: GLO 1 dimer expression unchanged with different reducing agents 
 
20ug protein of primary hepatocyte samples (n=3 normal) were prepared using 3 reducing 
agents in buffer. These include old DTT in 5x Non-reducing buffer, BME in LICOR buffer and 
freshly prepared DTT in 5x Non-reducing buffer. Samples were then heated at 95 degree 
Celsius for 10 minutes and subjected to western blotting with COX IV as a loading control. 
Primary antibody: COX IV (1:5000) Rat anti- GLO 1 (1:4000). Secondary antibody: Donkey 
anti-rabbit 680 RD, Goat anti- rat 800CW. Quantification performed by Image Lite software. 
Individual protein expressions were normalized to the expressions of corresponding loading 
control and relative protein expression are shown as normalized means ± SEM (a): greyscale 
image of blot, (b): scatter dot presentation of normalised GLO 1 (dimer) expression, one-way 
ANOVA with Turkey’s test post hoc , oDTT  VS BME (P=0.5346), oDTT  VS n DTT (P=0.8978), 
nDTT  VS BME (P= 0.3267).*P < 0.05.  
oDTT: old Dithiothreitol, nDTT: new Dithiothreitol, BME: β-Mercaptoethanol. 
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3.7 Testing of GLO 1 Dimer using different reducing agents in recombinant GLO 1 
 
 50ng of pure Recombinant Human Glo 1 protein was treated with different reducing agents 
and heat in order to see the effect on the dimer formation. The reducing agents used included 
DDT, Mercaptoethanol, and glutathione, Western blotting findings showed the presence of 
both monomer and dimer on the reducing gel (Figure 3.9). 
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Figure 3-9  GLO 1 dimer expression unchanged with different reducing agents 
 
50 ng of Recombinant human Glo 1 protein was treated with different reducing agents and at 
different conditions and (n=3 independent experiments) were prepared using 3 reducing 
agents in buffer. These include DTT in 5x Non-reducing buffer, BME in LICOR buffer and 
freshly prepared Glutathione. Samples were further denatured by heating at 95 degree Celsius 
for 5 minutes or not and subjected to western blotting with COX IV as a loading control. Primary 
antibody: COX IV (1:5000) Rat anti- GLO 1 (1:4000). Secondary antibody: Donkey anti-rabbit 
680 RD, Goat anti- rat 800CW. Presence of both monomer and dimer remained. 
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Figure 3.9.4: 40ug protein of primary hepatocyte samples (n=3 biological replicates) 
subjected to western blotting on a 15% reducing gel with COX IV as a loading control.  50 ng 
of Rh GLO 1 was also loaded on the same gel. Primary antibody: COX IV (1:5000) Rat anti- 
GLO 1 (1:4000). Secondary antibody: Donkey anti-rabbit 800 CW, Goat anti- rat 680RD. 
Presence of  monomer and dimer on the Rh GLO 1 sample lane but no band corresponding 
to Rh GLO 1 monomer band was found in the primary hepatocyte samples. 
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3.8       Discussion 
 
The present study objectives were to characterise glyoxalase 1 expression to hepatic lipid 
loading and nutrient perturbation. GLO 1 expression to hepatic lipid loading. GLO 1 expression 
to low and high glucose perturbation was done initially at different time periods and later the 
experiment was repeated with low and high glucose treatment done concurrently. 
Lipid accumulation was quantified using Nile Red assay and findings revealed a greater 
level of lipid accumulation in fatty acid- treated cells compared with vehicle- treated cells. 
Overall, the study found that exposure of HepG2 cells to the monounsaturated fatty acid, 
oleate and the saturated fatty acid, palmitate, resulted in a significant increase in intracellular 
lipid accumulation compared to control. In HepG2 cells cultured in low glucose, up to 3 fold 
increase in lipid accumulation was shown in OA- treated cells while up to 2 fold increase was 
shown in PA- treated cells. Similar increases were found in HepG2 cells cultured in high 
glucose, with up to 5 fold increase in lipid accumulation shown in OA- treated cells and up to 
3 fold increase found in PA- treated cells. Such higher levels of hepatic lipid accumulation as 
a result of exposure to unsaturated fatty acid has been reported in NAFLD patients compared 
to control  (van Werven et al., 2010).  
Furthermore, findings from this study revealed that PA treatment induced significant 
cytotoxic effects on the cells cultured in low glucose, reducing cell viability by up to 32% while 
OA treatment did not exert such significant cytotoxic effect on the cells. Study findings showing 
similar magnitude of lipid accumulation of OA and cytotoxic effect of PA have been 
documented previously (Ricchi et al., 2009, Mei et al., 2011). Although certain parameters 
such as fatty acid concentration and time of treatment different to this study were utilized in 
the studies mentioned. For instance, Mei et al., (2011), also using HepG2 cells, employed Nile 
red assay to quantify lipid accumulation in addition to Oil red O staining of cells and showed a 
greater lipid accumulation in OA- treated cells compared to PA- treated cells. 
 Also, Ricchi et al., (2009), investigated the effects of fatty acids (PA and OA), alone and 
in combination on steatosis, apoptosis and insulin signalling. Although employing the same 
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24 hour treatment period as  in this study, assessed three different hepatic cell lines (HepG2, 
HUH 7, and WRL 68) and different concentrations of the fatty acids PA (0.33mM and 0.66mM) 
and OA (0.66mM and 1.32mM) including combining the two fatty acids in a 2:1 ratio of OA: 
PA treatments  (Ricchi et al., 2009). Findings from a previous study also showed that saturated 
FA interrupts lipid accumulation in liver cells by inducing mitochondrial apoptosis  and 
induction of endoplasmic reticulum (ER) stress which further leads to lower levels of 
intracellular lipid accumulation (Mantzaris et al., 2011). However, with the addition of OA, the 
capacity of cells to accumulate lipid was restored (Gomez-Lechon et al., 2007, Mantzaris et 
al., 2011)  
Contrary to the findings on viability of cells cultured in low glucose, cell viability of 
HepG2 cells cultured in high glucose was reduced by almost the same magnitude by OA and 
PA treatment. A possible explanation for this is that high glucose consumption by cells would 
result to elevation of MG generation which will in turn result to increasing oxidative stress 
which is damaging to cells. MG has been reported to be cytotoxic previously (Antognelli et al., 
2013). 
  Lipid accumulation was confirmed by photographic imaging of cells using fluorescent 
microscope following the application of Nile red stain to treated cells. In the same manner, 
findings revealed a higher level of lipid accumulation in fatty acid- treated cells compared with 
vehicle- treated cells and untreated cells. Increase in hepatic lipid accumulation in fatty acid- 
treated cells suggests an elevation in uptake of free fatty acids by hepatocytes which is a 
significant risk factor for the development of NAFLD (Bradbury, 2006). Increased levels of FFA 
has been suggested to be contributory to the induction of insulin resistance and diabetes, the 
mechanism of which is thought to be due in part to the modification of glucose and lipid 
metabolism as well as  inflammation occurring in the muscle, adipose tissue and liver (de Luca 
and Olefsky, 2006). 
Although the mechanism by which fatty acids exhibit cytotoxic effects on cells are 
unknown, it has been suggested that cytotoxicity of fatty acid may be reduced through its 
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conversion to Triglyceride, TG (Mei et al., 2011). It has been documented that the ready 
conversion of OA to TG may be responsible for its less toxic nature while the enhanced 
cytotoxic effect of PA may be due to its poor conversion to TG (Listenberger et al., 2003). 
Experiment on GLO 1 expression in HepG2 cells: The present study hypothesizes that 
when hepatocytes are exposed to fatty acids, a downregulation of GLO1 will occur.  Findings 
in HepG2 cells grown in both low and high glucose and treated with fatty acids or translation 
inhibitor cycloheximide showed no significant difference in GLO 1 protein levels in fatty- acid 
treated cells compared with vehicle- treated cells. It appears that GLO 1 protein expression 
remained stable in the cells despite treatment with fatty acids. However, a significant reduction 
was observed in HepG2 cells cultured in low glucose and treated with cycloheximide. A similar 
result showing no significant difference in GLO 1 protein expression was reported in the initial 
experiment. Result from both experiments negates the hypothesis of this study.   
One possible explanation for the unchanged expression of GLO 1 in fatty acid – treated 
HepG2 cells compared to control is the reported fact that GLO 1 gene is upregulated by 
transcription factors in situations of oxidative stress (Xue et al., 2012). Treatment of cells with 
fatty acids will generate ROS in addition to MG generated from glucose breakdown. These 
will together increase generation of reactive oxygen species. Indeed, studies have identified 
and confirmed the control of GLO 1 gene by Nuclear factor erythroid 2-related factor 2 (Nrf2) 
(Xue et al., 2012). Nrf2 has been shown to play an important role in the expression of heme 
oxygenase – 1 and GLO1, being an essential component of antioxidant response element 
(ARE) - directed induction (Kobayashi and Yamamoto, 2005). This would further protects 
against MG- induced oxidative stress, and may prevent a reduction in GLO 1 expression.  
Presence of GLO 1 monomer and dimer in HepG2 cells and recombinant GLO1: 
Western blotting of 20 µg protein of HepG2 whole cell lysate and 50ng of pure recombinant 
human GLO 1 protein revealed the presence of  GLO 1 monomer  and a smaller amount of 
GLO 1  dimer on the SDS / PAGE  gel  which is a reducing gel. This implies that GLO 1 protein 
is not completely reduced/ denatured by the reducing agents in the gel or buffer or the heating 
procedure during sample preparation. A possible explanation for the observed resistance is 
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the reported partly-covalent crosslinking observed in the GLO 1 subunits (Thornalley, 2003a)  
The reducing agents are effective for breaking disulphide bonds while the covalent bonds are 
resistant.  
In terms of GLO 1 protein expression in normal and fatty human primary hepatocytes, 
GLO 1 protein bands were initially detected in the regions of approximately 24 kDa and 46 
kDa. The 24 kDa band is close to the 21 kDa molecular weight band specified for GLO 1 
monomer by the manufacturer and the 46 kDa band has been specified for the human GLO 1 
dimer (Thornalley, 2003b). In the repeat experiment in which the recombinant human GLO 1 
was loaded on the same gel with the primary hepatocyte samples, GLO 1 monomer and dimer 
protein bands were missing in the primary hepatocyte samples. It is not clear why this is so. 
These findings suggest the need for the understanding of factors regulating the glyoxalase 
system. 
3.9 Conclusion 
 
As it is well known that NAFLD is the most common liver disease in the western world 
today, in vitro studies of hepatic lipid loading are important to provide more understanding of 
the molecular mechanism of NAFLD. Findings in this chapter have shown the differential role 
of saturated and monounsaturated FA in the induction of lipid accumulation which typifies 
NAFLD.  Experimental findings in this chapter did not support the hypothesis of a down-
regulation of GLO 1 protein in the hepatocytes following fatty acid treatment. This shows that 
further investigation confirming the role of GLO 1 in NAFLD is warranted. 
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4  
CHAPTER 4 
 
INVESTIGATING THE EFFECTS OF VITAMIN D SUPPLEMENTATION ON THE 
SECRETION OF IL-8 AND IL-6 CYTOKINES FROM FATTY ACID TREATED 
HEPATOCYTES 
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4.1 Introduction 
 
Non-alcoholic fatty liver disease (NAFLD) has been referred to as the hepatic 
manifestation of metabolic syndrome (Neuschwander-Tetri, 2005). While hepatic steatosis is 
recognised as benign, it can progress to non - alcoholic steatohepatitis (NASH), a severe form 
of NAFLD which may eventually result to cirrhosis and hepatocellular carcinoma (McCullough, 
2006) . The mechanism of progression from steatosis to NASH is not clear but it has been 
suggested that oxidative stress, inflammation and proinflammatory cytokines play key roles. 
The CXC chemokine, interleukin-8 (IL-8) is one of the major pro-inflammatory cytokines which 
modulates the inflammatory response and it functions as a potent chemoattractant which 
induces and activates neutrophils, T cells and basophils (Andoh et al., 2000, Zeng et al., 
2005). 
 Elevated levels of IL-8 have been shown to be associated with liver injury as well as 
other diseases including diabetes, obesity and atherosclerosis suggesting that IL-8 may 
contribute to inflammatory responses thereby promoting the progression of these diseases 
(Kim et al., 2006, Jaeschke, 2002). Furthermore, studies have shown that hepatocytes can 
secrete significant levels of IL-8 and as a result, can initiate and / or promote hepatic injury  
(Thornton et al., 1990, Joshi‐Barve et al., 2003). Moreover, elevated levels of proinflammatory 
cytokines (IL-8) have been reported in patients with NASH, supporting the role of cytokines in 
NAFLD (Kugelmas et al., 2003, Bahcecioglu et al., 2005) .  
Experimental findings in the previous chapter revealed that exposure of HepG2 cells to 
400µM PA and 500µM OA led to significant lipid accumulation in the hepatocytes with PA 
treatment resulting to reduction in cell viability compared to OA treatment.  Furthermore, 
previous studies have shown that exposure of cells to fatty acids led to the induction of 
cytokine secretion. For example, PA was shown to induce the secretion of IL-8 from 
hepatocytes (Joshi‐Barve et al., 2007). It was also found to induce the production of IL-6 and 
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TNFα from 3T3-LI adipocytes (Ajuwon and Spurlock, 2005). In the same vein, exposure of 
skeletal muscle C2C12 cells to palmitic acid also led to the induction of TNFα (Jové et al., 
2006). These studies support that long chain fatty acids such as palmitate can induce 
expression and secretion of pro-inflammatory cytokines. 
Previous studies by (Haussler et al., 2008, Cohen-Lahav et al., 2006) have documented 
the anti-inflammatory effects of vitamin D suggesting an association between vitamin D and 
NAFLD. Studies in murine macrophages have shown that vitamin D3 upregulates 1KBα, the 
inhibitor of NFKB by causing an increased mRNA stability and decreasing the phosphorylation 
of 1KB-α. As a result, it can reduce inflammation in macrophages (Haussler et al., 2008, 
Cohen-Lahav et al., 2006).   
Experimental studies in animals have also shown similar results. Findings from the study 
by Kong et al., (2014) suggested that vitamin D deficiency up-regulate synthesis of 
endogenous fatty acid in NASH through the impairment of enterohepatic circulation. Findings 
from the same study revealed that the administration of vitamin D3 suppresses hepatic 
lipogenesis and inflammation which altogether resulted in correction of NASH phenotypes 
(Kong et al., 2014). Studies on the effects of vitamin D on fatty acid treated hepatocytes is 
scarce in the literature hence this study aims and objectives are to: 
1. Investigate the induction of the inflammatory cytokine, IL-8 and IL-6 by fatty acids 
in hepatocytes. 
2.  Determine the effect of vitamin D supplementation on the secretion of IL-8 and IL-
6 cytokines in the fatty acid - treated hepatocytes. 
 
4.2 Method 
 
In order to test the effect of vitamin D3 it was necessary to establish a model system in 
which fatty acids stimulated the production of cytokines, as have been found previously (Joshi‐
Barve et al., 2007).  25mM oleic acid or 25mM palmitic acid prepared in DMSO also referred 
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to as vehicle (VEH) were complexed with fatty acid free (FAF) bovine serum albumin (BSA)  
at a molar ratio of 3.3:1 as described fully in section 2.6. Investigating the effects of fatty acids 
(with or without vitamin D supplementation) on the secretion of pro-inflammatory cytokines 
from HepG2 cells was carried out using 3 different methods. In the first method, HepG2 cells 
were treated with fatty acids complexed with FAF BSA and co- incubated with 100nM vitamin 
D3 for 24 hours. Treatments were applied in serum –free media.  
The second method was divided into 2 parts, 2a and 2b.  In method 2a, Vitamin D3 was 
supplemented into growth media 48hrs before treatment with the fatty acids which were 
complexed with FAF BSA and applied in serum free media.  In method 2b, vitamin D3 was 
supplemented into growth media 48hrs before treatment with the fatty acids which were 
complexed with FAF BSA or standard BSA and applied in complete media. Lastly, in the third 
method, vitamin D3 was added into growth media 48hrs before fatty acids. The fatty acids 
were complexed with FAF or standard BSA and vitamin D3 was also included in the fatty acid 
treatment for the 24 hour period hence referred to as continuous. This is again illustrated in 
table 2.4 below. 
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 Time and method of 
vitamin D supplementation 
Fatty acids complexed 
with § 
Media state #  
Method 1 24 hours (co- incubation*) Fatty acid free BSA 
 
Serum-free 
Method 2a 48hours (supplementation**) FAF or standard BSA Serum- free  
Method 2b 48hours (supplementation**) FAF or standard BSA Complete 
Method 3 48 hours supplementation 
+24 hours continuous*** 
FAF or standard BSA Complete 
* Co-incubation: Vitamin D3 and Fatty acids were added together for 24hrs. 
 ** Supplementation: Vitamin D3 was added 48hrs before fatty acids. During the fatty acid 
treatment, no vitamin D3 was present. 
 *** Continuous: Vitamin D3 was added 48hrs before fatty acids and was also included in the 
fatty acid treatment.  
§:  BSA is used as a carrier for the fatty acids, and different preparations were tested. FAF 
BSA (Sigma A7030)): Prepared using heat shock fractionation but free from fatty acid, 
essentially globulin free. Standard BSA (Sigma A3059): Prepared using heat shock 
fractionation from. FAF and standard BSA were compared in the same experiments. Serum- 
free media (prepared without FBS) or complete media (prepared with FBS) were used.  
Method 2 developed as complete media was tried. 
 
4.3 Results 
 
4.3.1 Palmitic acid treatment of HepG2 cells resulted to elevated but non-significant 
levels of cytokines (IL-8) secretion. 
Firstly, HepG2 cells were treated with fatty acids (400µM palmitic and 500 µM oleic 
acid) complexed with FAF BSA and added together with 100nM vitamin D3 for 24 hours. 
Treatments were applied in serum - free media and the untreated cells served as the control.  
In the absence of vitamin D3 supplementation, the level of IL-8 cytokines secreted (mean) 
from cells exposed to the treatments were: PA: 80.93 pg/mL, OA: 40.83 pg/mL, VEH: 39.88 
pg/mL. On the other hand, the amount of secreted cytokines from untreated cells were 
141.2pg/mL, which was unexpectedly higher than the levels secreted from cells exposed to 
vehicle control (P = 0.0005), and fatty acids treatments. As a result, in the statistical analysis, 
the levels of cytokines secreted by fatty acid - treated cells were compared to the levels 
secreted from vehicle - treated cells (since the palmitic acid and oleic acid were prepared in 
vehicle). 
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The levels of IL-8 secreted  in HepG2 cells exposed to palmitic acid was not 
significantly greater than the amount secreted by the vehicle - treated cells (P = 0.2120, figure 
4.1). This finding was contrary to already published literature which found a significant 
induction of IL-8 secretion with palmitic acid treatment (Joshi‐Barve et al., 2007). The effect of 
vitamin D supplementation was also not seen after comparing the cells with and without 100 
nM vitamin D3. 
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Figure 4.1: Palmitic acid induced elevated but not significant IL-8 levels from 
HepG2 cells compared to vehicle (method 1). 
HepG2 cells were seeded in 6-well plates until 70% confluent and treated with either 
vehicle (VEH), palmitic acid (PA) or oleic acid (OA) complexed with FAF BSA and 
applied in serum - free media all in the presence or absence of vitamin D (100 nM) for 
24 hours. Untreated cells served as control. Culture supernatants were collected and 
secretion of IL-8 measured by ELISA. Data expressed as mean +/- SEM. N = 3 
independent experiments. One – way ANOVA followed by Dunnett’s post hoc. 
UNTREATED vs VEH P= 0.0005, VEH VS PA (P= 0.2120). 
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4.4   Palmitic acid treatment resulted to induction of IL-8 secretion from HepG2 cells 
 
In the second method, method 2a, the initial method of adding vitamin D together with 
the fatty acid complex was changed to supplementing vitamin D3 into growth media of cells 
48hrs before treatment with the fatty acids which were complexed with FAF BSA and applied 
in serum - free media. In addition, TNFα, a known inducer of IL-8 was used as positive control 
and this was also applied in serum free media. However, contrary to expectation, the levels of 
IL-8 induction measured in the cells exposed to TNFα was not significantly different from the 
amount of IL-8 secreted by untreated cells, P = 0.3538 (figure 4.2A), raising a question of 
whether the use of serum free media is appropriate for this method. 
 Furthermore, a significant induction of IL-8 cytokines by palmitic acid compared to 
vehicle control was shown (P < 0.0001), while oleic acid treated cells did not induce a 
significant level of IL-8 secretion compared to vehicle (P = 0.7704). However, no significant 
effect of vitamin D3 supplementation on the palmitate- induced IL-8 cytokine secretion was 
observed; PA vs PA+100nMD3: P = 0.9978 (Figure 4.2B). 
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Figure 4.2: Palmitic acid, but not oleic acid, induced significant IL-8secretion from 
HepG2 cells compared to vehicle. Vitamin D3 (supplemented into growth media 48hrs 
before treatment with the FA in serum-free media) shows no significant reduction in 
Palmitate induced IL-8 in HepG2 cells (method 2a).  
 
HepG2 cells were seeded in 6-well plates until 70% confluent and then treated with either 
vehicle (VEH), 400µMpalmitic acid (PA), 500µM oleic acid (OA) or TNF α (20µg/ml) in serum 
free media. Fatty acids were applied in the presence or absence of vitamin D3 (100nM) for 24 
hours. A. Controls, B. fatty acids. Data expressed as mean=+/- SEM. N = 3 independent 
experiments, one – way ANOVA followed by Tukey’s post hoc **** P <0.0001. 
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4.4.1  Application of TNFα to HepG2 cells in complete medium results to significant 
IL-8 induction 
Following the previous findings, It was investigated whether complete, rather than, 
serum - free medium would give the expected result for TNFα. Cells were treated with TNFα  
(20ug/ml) which was applied in complete media, and this resulted in a significant induction of 
IL-8 cytokines in cells exposed to TNFα compared to untreated cells, P = 0.0009 (figure 4.3).  
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Figure 4.3: TNFα  induced significant IL-8 secretion in HepG2 cells when applied in 
complete media 
 
HepG2 cells were grown in 6 well plates until 70% confluency then treated with TNFα 
(20ug/ml) for 24 hrs. Culture supernatants were collected and secretion of IL-8 
measured by ELISA. Data expressed as mean=+/- SEM. N = 3 independent 
experiments. Unpaired t- test ***P < 0.001. 
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4.5  No effect of vitamin D3 supplementation on Palmitate induced IL-8 in HepG2 
cells when palmitate was complexed with FAF BSA. 
 
Next, vitamin D3 was supplemented into growth media 48hrs before treatment with the 
fatty acids which were complexed with FAF BSA and applied in complete media. Findings 
showed a significant induction of IL-8 cytokines in cells exposed to TNFα compared to 
untreated cells (P < 0.0001; figure 4.4A). In addition, the results showed a significant induction 
of IL-8 cytokines by palmitic acid, P < 0.0001 but not with oleic acid (P >0.9999), compared 
with vehicle. However, no effect of vitamin D3 supplementation on the palmitate- induced IL-
8 cytokine secretion was shown: PA vs PA + 50nM vit D3 = 0.8058; PA vs PA + 100nM vit D3 
= 0.8797 (figure 4.4B).  
4.6 Effect of Palmitic and oleic acid on secretion of IL-6 cytokines 
 
Now after the model seemed established, secretion of IL-6 cytokines in the cells treated 
with either vehicle, fatty acids or TNFα was carried out. Findings revealed that neither palmitic 
acid nor oleic acid induced secretion of IL-6 protein above the detection limit of the ELISA. 
Even after ten-fold concentration of culture supernatant, only a minimal induction of IL-6 
secretion was shown by TNF- treated cells (data not shown). 
 
 
 
 
101 
 
 
 
Figure 4.4: Vitamin D3 (supplemented into growth media 48hrs before 
treatment with the FA in complete media) shows no significant reduction in 
Palmitate induced IL-8 in HepG2 cells when palmitate was complexed with FAF 
BSA (method 2b). 
 
 HepG2 cells supplemented with 0nM, 50 nM or 100 nM vit.D3 for 48hrs, were 
treated with either vehicle (DMSO), 400uM Palmitic acid (PA) or 500uM Oleic acid 
(OA) complexed with FAF BSA and applied in serum containing media for 24 hrs.  
Untreated cells and TNFα (20ug/ml) - treated cells served as negative and positive 
controls respectively. Culture supernatants were collected and secretion of IL-8 
measured by ELISA. Data expressed as mean=+/- SEM. N = 3 independent 
experiments. A. Controls (unpaired t-test), B FAF BSA (One-way ANOVA, Tukey’s 
post hoc). ****P <0.0001, 
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 4.5 Vitamin D3 effected a significant reduction in Palmitate induced IL-8 in HEPG2 
cells when palmitate was complexed with STD BSA. 
 
 Until now, all experiments had been performed using a vehicle prepared with fatty 
acid-free BSA. In order to investigate whether this had an impact on the assay, standard BSA 
was also tested as the complexing agent for the fatty acids as this would more closely 
resemble the physiological state. Findings in control cells showed a significant induction of IL-
8 cytokines in cells exposed to TNFα compared to untreated cells (P <0.0001; figure 4.5A). In 
addition, a significant induction of IL-8 cytokines by palmitic acid P <0.0001, and a significant 
effect of 50nM vitamin D3 Supplementation on the palmitate- induced IL-8 cytokine secretion 
was found, P = 0.0124 (Figure 4.5B). 
 
 
 
 
103 
 
 
  
Figure 4.5: Vitamin D3 (supplemented into growth media 48hrs before 
treatment with the FA in complete media) shows a significant reduction in 
Palmitate induced IL-8 in HepG2 cells when palmitate was complexed with 
standard BSA (method 2b). 
 
 HepG2 cells supplemented with 0nM, 50nM or 100nM vitamin D3 for 48hrs, were 
treated with either vehicle (DMSO), 400uM Palmitic acid (PA) or 500uM Oleic acid 
(OA) complexed with STD BSA and applied in serum containing media for 24 hrs. 
Untreated cells and TNFα (20ug/ml) - treated cells served as negative and positive 
controls respectively. Culture supernatants were collected and secretion of IL-8 
measured by ELISA. Data expressed as mean=+/- SEM. N = 4 independent 
experiments. A. Controls (unpaired t-test), B FAF BSA (One-way ANOVA, Tukey’s post 
hoc). ****P<0.0001, *P<0.05. 
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4.6.1 Vitamin D3 supplementation shows no significant reduction in Palmitate 
induced IL-8 in HepG2 cells when Palmitate was complexed with FAF BSA  
However, while the previous result was encouraging, the approach where vitamin D3 
was present in the 48 hrs prior to fatty acid addition, but not present in the fatty acid treatment 
media was queried. Therefore, the next step was to include vitamin D3 throughout the entire 
72 hr period, to more closely resemble the physiological state. Hence, in the third method, 
vitamin D3 was added into growth media 48hrs before adding fatty acids and was also 
included in the fatty acid treatment for the 24hour period. Once again, the fatty acids were 
complexed with either FAF or standard BSA before applying to cells. The untreated cells and 
TNFα- treated cells were also supplemented with 50nM and 100nM vitamin D3 for the same 
period.  
For the FAF BSA vehicle, findings in controls showed a significant induction of IL-8 
cytokines in cells exposed to TNFα compared to untreated cells (P <0.0001 figure 4.6A) and 
a significant reduction in IL-8 secreted by cells treated with TNFα containing 100nM vitamin 
D3 compared to cells treated with TNFα  without supplementation (P = 0.0026). In addition, a 
significant induction of IL-8 secretions in palmitate- treated cells compared to vehicle control 
was found, P = 0.0212; Fig 4.6B). 
However, supplementation with vitamin D3 did not lead to a significant reduction in 
Palmitate induced IL-8 in HepG2 cells PA vs PA + 50nM D3; P = 0.9822 (figure 4.6B), PA vs 
PA +100Nm D3; P = 0.9718.  
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Figure 4.6: Vitamin D3 supplementation shows no significant reduction in 
Palmitate induced IL-8 in HepG2 cells when Palmitate was complexed with 
FAF BSA (method 3). 
HepG2 cells supplemented with 0nM, 50nM or 100nM vitamin D3 for 
48hrs, were either untreated or treated with vehicle (DMSO), 400uM 
Palmitic acid (PA) or 500uM Oleic acid (OA) complexed with BSA and 
applied in serum containing media plus vitamin D3 for 24 hrs. Untreated 
cells and TNF-α (20ng/ml) - treated cells served as negative and positive 
controls respectively Culture supernatants were collected and secretion 
of IL-8 measured by ELISA. Data expressed as mean +/- SEM. N = 3 
independent experiments. One- way ANOVA, Tukey’s post hoc. A. 
Controls, B. FAF BSA. ***P< 0.001, ****P<0.0001. 
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 Findings were comparable when the vehicle was prepared with standard BSA. 
Findings in controls showed a significant induction of IL-8 cytokines in cells exposed to TNFα 
compared to untreated cells (P <0.0001; figure 4.6C) and this could be suppressed by 100nM 
vitamin D3. In addition, a significant induction of IL-8 secretion in palmitate- treated cells 
compared to vehicle control was found (P <0.0001; figure 4.6D). However, supplementation 
with vitamin D3 did not lead to a significant reduction in Palmitate induced IL-8 (PA vs PA + 
50 nM vit D3; P = 0.4674 and PA vs PA +100Nm vit D3, P = 0.7126 Figure 4.7B).  
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Figure 4.7: Vitamin D3 supplementation shows no significant reduction in 
Palmitate induced IL-8 in HepG2 cells when Palmitate was complexed with 
standard BSA 
HepG2 cells supplemented with 0nM, 50nM or 100nM vitamin D3 for 48hrs, were 
either untreated or treated with vehicle (DMSO), 400uM Palmitic acid (PA) or 500uM 
Oleic acid (OA) complexed with REG BSA and applied in serum containing media 
plus vitamin D3 for 24 hrs. Untreated cells and TNFα (20ng/ml) - treated cells served 
as negative and positive controls respectively Culture supernatants were collected 
and secretion of IL-8 measured by ELISA. Data expressed as mean +/- SEM. N = 
3-4 independent experiments. One- way ANOVA, Dunnets’ post hoc C: 
CONTROLS, D: STD BSA 
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4.6.2  TNFα induced IL-8 secretion in HepG2 cells was reduced by Vitamin D3 
supplementation in a dose-dependent manner 
While it was impossible to show a convincing effect of vitamin D on fatty acid –induced 
IL-8 secretion, it did significantly suppress TNF induced IL-8. In order to understand this better 
a longer dose response curve was performed. HepG2 cells were supplemented with 0nM, 
50nM, 75nM or 100nM vitamin D3 for 48hrs and then exposed to treatment with TNFα 
(20ng/ml) continuous with vitamin D3 for 24 hrs. Untreated cells served as control. Findings 
revealed a significant and dose dependent reduction effect of vitamin D3 supplementation on 
IL-8 cytokines secretion in the HepG2 cells. Supplementation with 75 or 100nM vitamin D3 
resulted to a significant reduction in levels of IL-8 cytokines secreted compared to TNF alone. 
TNF vs TNF +75nM vit D3, P = 0.0355, TNF vs TNF +100 nM vit D3, P = 0.0018 (figure 4.8). 
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Figure 4.8: Vitamin D3 supplementation shows a dose dependent reduction in 
TNF-induced IL-8 secretion in HepG2 cells 
HepG2 cells supplemented with 0 nM, 50 nM, 75 nM or 100 nM vit D3 for 48hrs, were 
treated with TNF alpha (20ng/ml) plus vit D3 for 24 hrs. Untreated cells served as 
control. Culture supernatants were collected and secretion of IL-8 measured by 
ELISA. Data expressed as mean+/- SEM. N = 3 independent experiments, One- way 
ANOVA, Dunnets’ post hoc. **P<0.01 
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4.7 Discussion 
 
The study aims were two faceted, the first aim was to investigate the induction of IL-8 
secretion in fatty acid treated HepG2 cells, using the vehicle (DMSO), palmitic and oleic acid. 
The second aim was to investigate the effect of vitamin D supplementation on the induction of 
IL-8, by the same fatty acids in the cells. Overall, the study findings showed that the long chain 
saturated fatty acid, palmitic acid, induced significant cytokine secretion in HepG2 cells as 
opposed to the unsaturated fatty acid, oleic acid. The levels of IL-8 secreted by cells exposed 
to oleic acid were very similar to the amounts secreted by the cells exposed to DMSO which 
is the vehicle.  
Similar effects of palmitic acid on IL-8 secretion in HepG2 cells, primary human and rat 
hepatocytes have been documented previously (Joshi‐Barve et al., 2007). In the study, HepG2 
cells were treated with a range of concentration (0.3-0.4mM) palmitate up to 48 hrs in a time 
dependent manner. Also, a similar effect of palmitate on cytokine mRNA expression has been 
documented in human macrophage - like cells, where palmitate induced TNFα, IL-1β and IL-
8 mRNA expression in differentiated THP-1 after  4, 6 and 9 hours (Håversen et al., 2009). 
However, the present study found that IL-8 secretion in untreated cells were higher than the 
secretion in cells treated with vehicle.  
In the same HepG2 cells, neither palmitate nor oleate - treated cells showed any 
appreciable secretion of IL-6 protein. Furthermore, aliquots of cell culture supernatants from 
palmitate and TNFα treated cells were concentrated fivefold and then measured for IL-6 
secretion. This revealed only minimal levels of IL-8 in cells treated with TNFα. 
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In terms of the effects of vitamin D supplementation on the secretion of IL-8 from the 
fatty acid treated cells, the only effect seen was with 50nM vitamin D3 supplementation in cells 
preceding fatty acid exposure. This was not the case when vitamin D was applied in a 
continuous manner.  On the other hand, findings in TNFα- treated cells showed that vitamin 
D3 supplementation suppresses TNF induced IL-8. These findings in the TNF-treated cells 
could be extrapolated to the effects of vitamin D3 on TNF gene / protein expression.  
Similar effects of vitamin D3 supplementation on IL-8 secretion have been reported in 
other cells including THP-1 cells and human primary monocytes where vitamin D3 reduced 
the expression of LPS- induced IL-8 cytokines (Kuo et al., 2010). One animal study on 
inflammatory bowel disease have shown that vitamin D3   resulted in a reduced expression of 
TNFα gene expression (Zhu et al., 2005).  Furthermore, findings showed that supplementation 
with vitamin D3 led to a reduction in the secretion of TNFα from THP-1 cells treated with 
Interferon gamma. 
Mechanism for PA induced IL-8 and Vitamin D signalling 
The findings in palmitate-treated HepG2 cells agree with the findings from other studies 
that suggested a linkage between IL-8 and diseases such as obesity (Straczkowski et al., 
2003, Kim et al., 2006) and NAFLD (Jarrar et al., 2008). Evidences from human studies 
(Bahcecioglu et al., 2005, Torer et al., 2007)  have shown an independent association between 
elevated levels of IL-8 and NASH suggesting that the proinflammatory cytokine, IL-8 may also 
have a role in NASH development. The mechanism of palmitate-induced IL-8 has been 
suggested to be through the activation of NFKB, a major regulator of inflammation (Feldstein 
et al., 2004). In addition to NFKB, another transcription factor: activator protein 1 (AP-1) has 
been known to be a major player in IL-8 expression (Hoffman, 2002).  
Previous studies have documented that NFKB dependent (Wang et al., 2001) and 
NFKB independent (Kim et al., 2000) mechanisms are responsible for IL-8 expression in cells. 
Studies have reported the role of another regulatory mechanism involved in PA induced IL-8 
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expression, such as MEK as its inhibitor U0126 was found to down regulate PA induced IL-8 
expression (Joshi‐Barve et al., 2007). These results suggest that complex regulatory 
mechanisms drive PA-induced IL-8 secretion in cells. 
In terms of vitamin D signalling, studies have shown that the activity of NFKB in human 
fibroblasts is inhibited by vitamin D3 (Harant et al., 1998). As mentioned earlier, It has been 
shown that vitamin D3 upregulates 1KB-α, the inhibitor of NFKB by causing an increased 
mRNA stability and decreasing the phosphorylation of 1KB-α. As a result, preventing 
inflammation in macrophages (Cohen-Lahav et al., 2006, Haussler et al., 2008). Other studies 
have suggested that vitamin D effects may be through the activation of mitogen-activated 
protein kinase (MAPK) pathways and this may inhibit the transcription of pro-inflammatory 
genes (Zhang et al., 2012, Suzuki and Abdelmalek, 2009). 
TNFα induced IL-8 production has been  documented to be mediated via the NFKB 
pathway (Osawa et al., 2002) hence the significant suppressant effect of vitamin D3 
supplementation on  IL-8 production in the HepG2 cells could be explained based on the 
inhibition of NFKB by vitamin D3. However, considering the different mechanisms documented 
for PA-induced IL-8 secretion, the inability of vitamin D to effect a significant reduction in IL-8 
levels in Hep G2 cells may be explained. 
4.8 Conclusion 
 
  Findings from this chapter demonstrate that exposure of hepatic cells to palmitic acid 
results to the induction of significant levels of the neutrophil chemoattractant proinflammatory 
cytokines, IL-8. Such production of cytokines may play a key role in inflammation- dependent 
liver injury thus the development of steatohepatitis which is an important stage in NAFLD 
progression. This is the first study to report the effect of vitamin D3 supplementation on 
Palmitate induced IL-8 in HepG2 cells. The experimental findings did not show a major effect 
of vitamin D3 supplementation in palmitate induced IL-8 secretion from HepG2 cells. However, 
a significant effect was shown on TNFα induced IL-8. This could be explained based on the 
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fact that PA- induced IL-8 secretion occurs through several mechanisms which are different 
from the single NFKB- dependent mechanism driving the production of TNF induced IL-8 
secretion in HepG2 cells.  
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5 CHAPTER 5 
INVESTIGATING THE EFFECTS OF VITAMIN D3 SUPPLEMENTATION ON THE 
SECRETION OF IL-6 CYTOKINES IN SOUTH ASIANS AND CAUCASIAN WOMEN: 
FURTHER ANALYSIS OF THE D2-D3 STUDY. 
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5.1 INTRODUCTION 
 
Vitamin D is well known for its vital role in maintaining bone health as evidenced by its 
promotion of calcium and phosphate absorption which helps in bone mineralisation and 
turnover. However, many evidences have recently emerged as to the effect of vitamin D on 
immune function regulation as well as inflammation. 1.25 (OH) 2 D3 has been shown to 
function in many different ways including exhibiting different immune responses in the 
body(DeLuca, 2004a, Lang and Aspinall, 2015)  As mentioned in chapter 1, 1,25(OH) 2 D3 
exhibits its activities by binding to the VDR. The VDR has been found to be expressed in 
various immune cells such as monocytes/macrophages, B and T cells (BHALLA et al., 1983). 
Hence1, 25(OH) 2 D3 have been found to repress the proliferation of B and T cell (Bhalla et 
al., 1984, Lemire et al., 1984). 
 Furthermore, studies have shown that 1, 25(OH)2 D3 can inhibit the differentiation and 
maturation of dendritic cells which play a key function in the development of immunological 
memory and tolerance (Penna and Adorini, 2000). This demonstrates the immune regulation 
properties of vitamin D. 
Cytokines such as IL-6, TNF, IL-8 have also been implicated in NAFLD, although 
minimal or absent in in the liver in physiological situations, however, in pathological situations 
such as NAFLD, hepatic cells are induced to produce inflammatory cytokines.  Studies have 
shown elevated levels of IL-6 in patients with NAFLD  (Kugelmas et al., 2003) and NASH 
(Wieckowska et al., 2008). However, although cytokines play active roles in NAFLD 
development and progression, they are also essential in the regeneration of hepatocytes after 
an injury (Tilg and Diehl, 2000).  
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5.1.1 Vitamin D and IL-6 cytokines 
 It has been suggested that Vitamin D may be involved in the regulation of cytokine 
production. Studies in human monocytes have shown that 1, 25 (OH)2 D  can inhibit the 
production of pro-inflammatory cytokines including tumour necrosis factor α (TNF-α), 
Interleukin-1β (IL-1β) and Interleukin-6 (IL-6) (Zhang et al., 2012, Almerighi et al., 2009). A 
major role of IL-6 is the mediation of acute inflammatory response, but it also functions in 
chronic inflammation for example as reported in arthritis (Gabay, 2006). Study findings have 
documented the inhibition of IL-6 by 25OHD and 1, 25 (OH)2 D3 in vitro (Zhang et al., 2012). 
The mechanism for the inhibition of IL-6 by vitamin D has been suggested to be due to 
the up-regulation of MAPK phosphatase-1 which blocks the signalling cascade for cytokine 
production (Zhang et al., 2012). Furthermore, 1,25(OH)2D have been found to inhibit pro-
inflammatory Th1 and Th17 responses (Cantorna and Waddell, 2014) which are implicated in 
the development of autoimmune condition (Cantorna et al., 2015).  
5.2 Aims and Objectives 
 
The overall aim: was to determine the effect of vitamin D3 supplementation on IL-6 levels 
in South Asian and Caucasian women in the D2-D3 intervention study. The study objectives 
were to: 
1.  Determine ethnic differences in serum Interleukin-6 (IL-6) levels between South Asian 
and Caucasian women from the D2-D3 study at baseline and Visit 2 (6 weeks). 
2.   Determine any changes in IL-6 measurements across the intervention period in 
women taking either placebo or vitamin D3 supplements and identify any ethnic 
differences. 
5.3 Research questions 
 
The study aimed to answer some research questions including: 
1. What is the effect of vitamin D3 supplementation on IL-6 levels as serum 25OHD 
increases? 
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2. Is there a difference between IL-6 levels in placebo and intervention group?  
5.4 Methods 
 
5.4.1 Study population 
The data and blood samples used for this further analysis were collected for the D2-D3 
main study. As described in section 2.11.1, a total of 335 participants were included in the 
study consisting of healthy South Asian or Caucasian women, aged 20 - 65 years with a BMI 
of 18 - 30kg/m2. Participants were randomised to receive either placebo or vitamin D 
intervention product (an orange juice and a biscuit), daily, alongside their normal diet, thereby 
receiving 15µg/day of vitamin D2, 15ug/day vitamin D3 or placebo for 12 weeks across two 
consecutive winter periods.  
There were five intervention products including: placebo, vitamin D2 juice, vitamin D2 
biscuit, vitamin D3 juice and vitamin D3 biscuit. Subjects received an orange juice and a biscuit 
to consume daily, only one of these would be fortified while the other would be a placebo. 
However, both products were placebo in the placebo group. Participants made three visits 
over the 12- week study period: at baseline, visit 1 (V1), week 6, visit 2 (V2) and week 12, visit 
3 (V3). 
5.4.2 Ethical Considerations  
  Ethical approval for the D2D3 study was obtained from the South-East Coast (Surrey) 
NHS Research Ethics Committee (NHS REC No.11/LO/0708) and the University of Surrey 
Ethics Committee (Fast-Track EC/2011/97/FHMS). 
5.4.3 Blood sample collection and serum vitamin D measurements 
 Blood samples were collected from fasted participants at each visit by a trained 
individual using a vacutainer system (Beckton Dickinson Diagnostics, USA) and stored at -
80°C. A total of 80 participants (South Asian n = 34, Caucasian n = 46) were selected for this 
sub-study. For each of these participants plasma samples were collected at baseline and visit 
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2 and levels of IL-6 cytokines were measured by ELISA. Serum 25 OH D levels had been 
determined previously and were available for use in this study. Details of sample collection 
and measurements have been published previously (Tripkovic et al., 2017). 
5.5 Results 
 
5.5.1 Anthropometric characteristics of respondents at baseline 
The characteristics of respondents at baseline were compared to measure if there 
were any significant difference between the South Asian women and the Caucasian women. 
The findings are described in table below. There was no statistically significant difference 
between the groups in following parameters including age, weight, BMI, Hip circumference 
diastolic blood pressure and heart rate. However, the Caucasians women were significantly 
taller than the South Asian women (median height of 1.65m compared to 1.59m, P < 0.01).   
  Furthermore, the two groups of women were significantly different in terms of their 
waist circumference, waist to hip ratio body fat and systolic blood pressure, with the South 
Asian women having a larger waist circumference (P = 0.022), waist to hip ratio (P  < 0.001) 
and percentage body fat (P = 0.047). However, the systolic blood pressure of South Asian 
women was significantly lower than that of Caucasian women (P = 0.018). These information 
are illustrated in the table 5.1 below.  
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Table 5-1: Anthropometric characteristics of South Asian and Caucasian 
women at baseline 
 
  Age 
(years) 
Height 
(m) 
Weight 
(kg) 
BMI 
(Kg/m2) 
Waist 
Circ 
(cm) 
Hip 
Circ 
(cm) 
WHR 
Ratio 
Body 
fat 
(%) 
Systolic 
BP 
(mmHg) 
Diastolic 
BP 
(mmHg) 
HR 
(bpm) 
 Mean 40.7 1.6 63.3 24.9 87.8 101.8 0.86 32.8 114.4 77.5 68.7 
South 
Asian 
(n=34) 
SD 9.8 0.05 9.4 4.0 12.5 7.0 0.09 6.4 14.6 9.5 6.8 
 Median 39.0 1.59 63.5 24.5 89.3 102.5 0.85 34.3 112.7 77.0 69.0 
 IQR 17.0 0.07 13.3 4.8 12.5 9.3 0.10 6.2 13.8 9.8 10.3 
 Mean 43.7 1.67 67.7 24.5 81.3 104.1 0.78 29.6 121.0 79.1 67.2 
Caucasian 
(n=46) 
SD 13.1 0.07 11.7 4.2 12.2 8.5 0.07 7.2 14.8 9.7 9.1 
 Median 42.0 1.65 65.5 23.7 80.0 104.0 0.77 30.5 120.5 78.0 67.5 
 IQR 22.0 0.11 14.1 6.5 13.9 10.5 0.08 9.6 20.0 12.5 15.4 
 P value 0.263 <0.001a 0.072 0.696 0.022a 0.197 <0.001a 0.047 0.018b 0.471 0.427 
SD = standard deviation; Circ = circumference; IQR = Interquartile range; BMI = body mass index; WHR = waist-to-hip ratio;  
BP = blood pressure; HR = heart rate. a Significant difference (P<0.05) determined by Independent samples T-test; 
 b Significant difference (P<0.05) determined by Mann Whitney U test. 
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5.5.2 Measurements of serum 25 (OH) D and Interleukin-6 levels at baseline 
Baseline measurements of serum 25 OHD and IL-6 cytokines from South Asian and 
Caucasian women were compared. It was found that Caucasian women had significantly 
higher 25 OHD levels than the South Asian women (P< 0.001). Furthermore, South Asian 
women were vitamin D deficient having serum 25 OHD levels of less than 25 nmol/L. However, 
although with a significant higher level of serum 25 (OH) D compared to the South Asian, the 
Caucasian women had insufficient 25 (OH) D level (< 50nmol/L).  
Baseline IL-6 levels for South Asian women (0.76pg/mL) was significantly different to 
that of Caucasian women (0.35pg/mL) (P= 0.002). These are illustrated in the table 5.2 below: 
 
Table 5-2: Measurements of serum 25 (OH) D and Interleukin-6 levels at baseline 
 
South Asian (n = 34) Caucasian (n = 46) 
 
 Mean SD Median IQR Mean SD Median IQR P value 
25OHD 
(nmol/L) 
23.92 15.29 17.2 25.05 50.47 23.94 44.0 34.50 <0.001a 
IL-6 
(pg/mL) 
1.34 2.03 0.76 0.95 0.55 0.68 0.35 0.84 0.002a 
 SD = standard deviation; IQR= interquartile range 
a (P< 0.05) as determined by Mann Whitney U test. 
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5.5.3 Correcting for possible confounder effect at baseline 
In order to account / correct for the baseline differences observed between the South 
Asian and Caucasian women in terms of their height, waist circumference, waist-to-hip ratio, 
body fat and systolic blood pressure measurements, an ANCOVA was performed to determine 
if the statistical difference in IL-6 measurements would remain between the two ethnic groups. 
The statistical difference remained significant after controlling for these possible confounders 
(P = 0.007) (Table 5.3). 
 
Table 5-3: Analysis of covariance (ANCOVA) for Interleukin-6 levels in South Asian and 
Caucasian women, at baseline, controlling for height, body fat, waist-to-hip ratio and systolic 
blood pressure. 
 
IL-6 IL-6 Observed 
(mean pg/mL) 
IL-6 Adjusted 
(mean pg/mL) 
n P value 
South Asian  1.39 1.58 32 0.007a 
 
Caucasian  0.54 0.24 45  
     
 F value P value 
Height 0.643 0.425 
WHR 1.654 0.203 
Body fat 3.159 0.080 
SBP 1.026 0.315 
WHR = waist hip ratio; SBP= systolic blood pressure; a (P< 0.05) as determined by Mann 
Whitney U test 
 
 
 
 
 
 
 
 
 
122 
 
 
5.5.4 Serum 25 (OH) D and Interleukin-6 levels at visit 2 in Placebo and D3 
intervention group 
After 6 weeks of vitamin D supplementation, measurements of serum 25 (OH) D levels 
were found to be decreased for the South Asian and Caucasian women in the placebo group. 
However, significant difference was observed in the levels of serum 25 (OH) D between the 
south Asian and Caucasian women. IL-6 levels were also significantly different in the South 
Asian (1.47pg/mL) compared to the Caucasian (0.47pg/mL) women (P = 0.009). 
In addition, in the vitamin D3 intervention group, serum 25(OH) D levels were 
increased in both South Asian and Caucasian women compared to baseline levels. However, 
serum 25 (OH) D levels in Caucasian women remained significantly higher than the South 
Asian women (P=<0.001). Although IL-6 levels in South Asian (1.56pg/mL) appears to be 
higher than in the Caucasian (0.52pg/mL). No statistically significant difference was observed 
in IL-6 levels between the two groups. These findings are described in table 5.4 below. 
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Table 5-4 Serum 25 (OH) D and Interleukin-6 levels at visit 2 in Placebo and D3 
intervention group 
 
Placebo 
Group 
South Asian (n = 13)                                       Caucasian (n = 26) 
 Mean  SD Median IQR Mean SD Median IQR P value 
25OHD 
(nmol/L) 
 
17.36 
 
7.02 
 
15.50 
 
13.30 
49.48 20.92 42.15 30.38 <0.001a 
IL-6 (pg/mL) 2.28 2.67 1.47 2.30 0.67 0.72 0.47 0.85 0.009a 
D3 Group South Asian (n=18 )                                       Caucasian (n=18) 
 Mean  SD Median IQR Mean SD Median IQR P value 
25OHD 
(nmol/L) 
56.17 11.75 56.55 19.35 81.82 21.86 78.30 32.40 <0.001 
IL-6 (pg/mL) 2.21 1.06 2.08 1.53 1.84 1.40 1.26 1.66 0.088 
SD = standard deviation; IQR= interquartile range 
a (P< 0.05) as determined by Mann Whitney U test. 
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Figure 5-1: Differences in median Interleukin-6 (IL-6) levels from Visit 1 (baseline) to Visit 2 
(6 weeks) within placebo and D3 intervention groups. 
 
5.6 Discussion 
 
This study aimed to determine the effect of vitamin D supplementation on IL-6 cytokines 
levels among healthy women of South Asian and Caucasian ethnic groups and to identify if 
ethnicity had any effect on their vitamin D status and or IL-6 levels. Findings from this study 
revealed that South Asian women had higher levels of IL-6 than the Caucasian women, both 
at baseline and at the second visit after supplementation with vitamin D. In addition, statistical 
analysis of the baseline data from this study showed significant differences in the height, waist 
circumference, waist-hip-ratio, body fat and systolic blood pressure between the two ethnic 
groups. The significant difference in IL-6 at baseline was still seen after correcting for the 
potential confounders. This finding indicates significant difference in baseline characteristics 
between the two ethnic groups. 
Furthermore, comparison of serum 25 (OH) D levels between the two ethnic origins 
revealed a significant difference with the Caucasian women having a significantly higher levels 
of serum 25 (OH) D. The South Asian women were found to be vitamin D deficient. Low levels 
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of serum 25 (OH) D is prevalent in South Asian populations and have been documented by 
previous studies. One longitudinal study assessing the vitamin D status in young Asian women 
residing in the UK reported serum 25 (OH) D measurement of  < 25 nmol/L which persisted 
throughout the year (Darling et al., 2013).  
The finding of higher levels of IL-6 cytokines in South Asian women compared to the 
Caucasian women is also similar to other studies. For example, findings from a cross sectional 
study involving South Asian and Caucasian male and female found that IL-6 levels in South 
Asian women were higher than in European women (Peters et al., 2013). The observed 
differences in IL-6 levels in females between the ethnic groups was absent in their male 
counterpart hence, the explanation for the elevated IL-6 was attributed to higher levels of 
viscera fat in the south Asian women which was also significantly greater than in the European 
women. However, the IL-6 levels reported in our study was within the normal physiological 
range (< 1.0- 3.5pg/mL) (Yamamura et al., 1998) . 
 Serum 25 (OH) levels did not show significant correlation with IL-6 levels in the groups 
of women studied, either at baseline or after supplementation with vitamin D. Few studies 
have examined the effect of vitamin D supplementation in healthy South Asian or Caucasian 
women. However, comparing with similar studies in other healthy ethnic origins, the study 
findings are also similar to one randomised control trial carried out on healthy African 
Americans (Chandler et al., 2013). In this study, healthy black population comprising of 54 
female and 27 male subjects received either placebo, 1000IU, 2000IU or 4000 IU vitamin D 
supplementation for 3 months. The authors reported no significant reduction in markers of 
inflammation including IL-6, CRP and soluble TNF ratio (sTNF-R2) following the intervention 
period (Chandler et al., 2013). In addition, the intervention did not produce a rise in the levels 
of IL-10, which is an anti-inflammatory marker.   
Another study in healthy postmenopausal women who received calcium and vitamin D3 
supplementation for 3 months also failed to show any significant difference in IL-6 and TNFα 
cytokines (Gannage-Yared et al., 2003). Furthermore, a systematic review and meta-analysis 
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of 13 RCTs involving a total of 1955 subjects did not find any significant effect of vitamin D 
supplementation on IL-6 concentrations. (Jamka et al., 2016). Although the participants 
studied were mostly overweight or obese, and from white populations from America and 
Europe. 
Although findings from experimental studies have shown a beneficial inhibitory effect of 
vitamin D supplementation on IL-6 cytokines, randomised controlled studies in human that 
have reported similar positive findings were carried out in certain groups of patients such as 
those having diabetes (Shab‐Bidar et al., 2012) or congestive heart failures (Hopkins et al., 
2011).  
It is worthy of note that circulating plasma IL-6 concentrations could vary depending on 
various factors including ethnicity as found in this study and discussed above. In addition, 
fluctuations in IL-6 levels have been documented in certain conditions such as in irritable 
bowel syndrome (IBS) (Bashashati et al., 2017). Also, it has been documented that menstrual 
cycle could cause fluctuations in IL-6 levels (Angstwurm et al., 1997) while increase in IL-6 
could occur with age (Puzianowska-Kuźnicka et al., 2016)  and smoking (Tappia et al., 1995). 
Furthermore, consuming diets rich in cruciferous vegetable could result to a reduction in the 
levels of circulating IL-6 (Jiang et al., 2014). Moreover, a high level of complex interactions 
exist with cytokines; and IL-6 could exhibit anti-inflammatory properties when regulating levels 
of pro-inflammatory cytokines. 
5.7 Conclusion 
 
In conclusion, the study found that serum vitamin D levels were significantly higher after 
vitamin D supplementation in both groups of Caucasian and South Asian women. In addition, 
the study found a significant difference in serum IL-6 levels between the two ethnic groups 
suggesting that ethnic differences exist. However, no significant change was observed in the 
circulating IL-6 levels following intervention with vitamin D3 in the groups of healthy women 
population studied.  
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6 CHAPTER 6 
 
META ANALYSIS OF VITAMIN D AND NAFLD 
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META ANALYSIS OF VITAMIN D AND NAFLD 
 
6.1 Introduction 
 
Non-Alcoholic Fatty Liver Disease (NAFLD) describes a wide range of hepatic 
pathological conditions beginning with accumulation of lipids especially triglycerides, (termed 
‘steatosis’) in hepatocytes in the absence of significant alcohol intake (Kleiner and Brunt, 
2012, Angulo et al., 2007).  NAFLD prevalence has been estimated to be between 20 – 30% 
in Europe (Bedogni et al., 2005, Zelber-Sagi et al., 2012, Zelber‐Sagi et al., 2006) and up to 
15% in Asia  (Fan et al., 2005). Furthermore, NAFLD shows a strong association with obesity, 
type 2 diabetes (T2D), insulin resistance (IR), hyper triglyceridaemia and arterial hypertension 
(Sanyal et al., 2010, Loomba et al., 2012). Hence it is referred to as the hepatic manifestation 
of the metabolic syndrome. Although the multiple hit hypothesis has been accepted as the 
pathogenesis of NAFLD, a conclusion on the mechanism of NAFLD development and 
progression is yet to be reached.   
Vitamin D is a fat soluble vitamin which exists in multiple forms of which, vitamin D2 
(Ergocalciferol) and vitamin D3 (Cholecalciferol) are the main forms. Vitamin D2 is not 
constitutively produced by vertebrates but is produced by phytoplankton, yeast and 
invertebrate organisms following exposure to ultraviolet irradiation; on the other hand, vitamin 
D3 is produced in the skin of humans and most vertebrate animals following exposure of 7-
dehydrocholesterol to ultraviolet light (Eliades and Spyrou, 2015). Although vitamin D is 
majorly involved in the regulation of bone metabolism (Kucukazman et al., 2014), 
mineralisation (Zhai et al., 2016), recent studies have shown significant association between 
vitamin D levels and other diseases including diabetes, hyperlipidemia, hypertension and 
peripheral vascular disease (Anderson et al., 2010), as well as  obesity, inflammation and 
insulin resistance (Chagas et al., 2012). 
  Although optimal vitamin D level is yet to be established worldwide, vitamin D 
deficiency is defined as serum 25 (OH) D concentrations below 20ng/mL (50nmol/L) (Thomas 
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et al., 1998, Malabanan et al., 1998, Bischoff-Ferrari et al., 2006), although the cut off for 
insufficiency and sufficiency vary among nations. According to the Institute of Medicine (IOM), 
a serum 25 OH D level of 50 nmol/L is sufficient to meet a daily vitamin D requirement 
(Thacher and Clarke, 2011). Vitamin D deficiency is an important public health problem which 
may occur due to inadequate diet, poor exposure to sunlight, vitamin D malabsorption, kidney 
or liver disease and genetic disorder (Zhai et al., 2016). Such deficiency has been attributed 
to bad bone mineralisation resulting progressively to diseases such as bone softening, 
Osteomalacia, rickets and osteoporosis (Zhai et al., 2016).  
The reducing trend in serum 25 hydroxy vitamin D levels has been associated with 
decreasing rate of milk consumption, avoidance of sunlight exposure and increasing rate of 
body mass index (Yetley, 2008). Previous cross sectional studies have investigated the 
relationship between vitamin D deficiency and NAFLD. Many of these studies showed an 
inverse relationship between serum 25(OH) D levels and NAFLD and its associated 
syndromes including IR, diabetes risk and metabolic syndrome (Li et al., 2013a, Bozkurt et 
al., 2012), suggesting a possible role for vitamin D in the pathogenesis of NAFLD. Few 
randomised controlled trials have investigated the relationship between vitamin D and 
NAFLD. Therefore, the aim of this chapter is to systematically review the association between 
NAFLD and vitamin D levels using both randomised control trials (RCT) and continuous data 
from cross-sectional and case-control studies. This is in order to quantify the effect size for 
the effect of vitamin D supplementation on NAFLD development and or severity.  
The objectives are to: 
1. Assess whether vitamin D deficiency increases the risk for developing NAFLD. 
2. Assess whether vitamin D supplementation decreases the risk for NAFLD 
development and or severity. 
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6.2 Methods 
 
 
6.2.1 Literature search 
Using PUBMED database, all studies that evaluated the association between NAFLD 
and vitamin D in from inception up until April 2017 without language restrictions were identified. 
The database searches were carried out using the following search keywords: Vitamin d, 
Vitamin D, 25- hydroxylvitamin d, 25- hydroxyvitamin D, 25(OH)D, 25(OH) d AND NAFLD, 
non- alcoholic fatty liver disease. Reference lists on articles extracted were checked for 
relevant papers to add.  In addition, no ethical approval was required for this review as it used 
the analysis of already published data.  
6.2.2 Eligibility criteria for inclusion and data extraction 
All human studies including cross-sectional, case- control or intervention design up to 
April 2017 without language restriction were assessed. Studies published in English language 
were considered for inclusion, studies reporting data from adolescents and adults were also 
considered for inclusion. Studies reporting data without a control group and studies reporting 
data from children were however excluded. Unpublished reports or studies published only in 
abstract formats were also excluded from the analysis. Articles obtained from searches were 
exported to endnote and managed on Microsoft excel. Titles and abstracts were checked 
against the inclusion criteria and eligible articles were read in full.  
For each eligible publication, data were extracted on key study characteristics such as 
author details, year of publication, study location, study design, characteristics of participants 
(age, gender, ethnicity), season of collection of data, method of diagnosing NAFLD and 
controls, assay method for measuring serum vitamin D as well as the cut off level for defining 
vitamin D deficiency. For all included studies (cross sectional, cohort or retrospective case-
control and intervention), mean and standard deviation for 25 (OH) D concentration in NAFLD 
and control groups were extracted, For cohort or retrospective case-control studies, the 
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relative risk or odds of having NAFLD or developing its severity were also extracted when 
available.  
6.2.3 Primary and secondary outcomes 
The primary outcomes were serum 25 (OH) D levels, vitamin D deficiency, Presence 
of NAFLD or severity (steatosis, fibrosis, hepatocyte ballooning), odds or risk of NAFLD. 
Secondary outcomes include insulin resistance (HOMA-IR), fasting blood glucose, fatty liver 
index and other measurements including BMI, TAG, HDL, and LDL if available.   
6.3 Statistical Analysis 
 
Mean ± standard deviation (SD) and correlation coefficients (r) were obtained for cross-
sectional studies and intervention studies where available. Odds ratios (OR) or hazard ratios 
(HR) were extracted for case-control studies. The number of participants (n), P values and 
95% confident intervals for effect estimates were extracted for all study types. Furthermore, 
multivariate adjusted analysis were used where available to reduce confounding effects. 
Meta- analysis was performed using Review manager (REVMan5.2). Heterogeneity test 
was performed using I2 to decide between random and fixed effects. For the systematic review, 
the Jadad scale (Jadad et al., 1996)  was used to assess the quality of the design and conduct 
of the randomised control trial (RCT). 
6.4 Results 
 
One hundred and twenty nine (129) publication records were identified from database 
searches from which 24 studies were included in the systematic review. The process of 
screening and selection of publications as well as the results generated is based on the 
PRISMA statement (www.prisma-statement.org) / as illustrated in Figure 6.1 below. 
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Figure 6-1: Flow chart illustrating the results from database searches, methods of screening 
and selection of studies for inclusion in systematic review 
 
Records identified through 
database searches  
(n = 129) 
Records for full article 
assessment  
(n = 50) 
Full-text articles assessed for 
eligibility  
(n = 35) 
Studies included in systematic review  
(n = 24) 
Cross sectional (n= 10) 
Cohort (prospective or case control) (n =10) 
Intervention study (n = 4) 
 In vitro or animal (n = 2)  
Meta-analysis    (n = 2) 
Review articles   (n = 2) 
Study in children (n = 5) 
Letters/comments (n = 2) 
Conference abstract (n =1) 
Pilot study   (n = 1) 
Full-text articles excluded, 
with reasons  
(n = 11) 
Studies included in qualitative 
synthesis (meta-analysis of 
categorical vitamin D)  
(n = 4) 
Records excluded based 
on title and abstract  
(n = 77) 
Duplicate articles excluded 
(n = 2) 
Studies included in quantitative 
synthesis (meta-analysis of 
continuous vitamin D)  
(n = 18) 
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6.5 Systematic review  
 
Twenty-four studies were included in this systematic review. Out of the included studies, 
most findings reported a significant association between serum 25 (OH) D and NAFLD. 
Significant lower serum 25 (OH) D levels were shown to be associated with NAFLD suggesting 
that serum 25 (OH) D levels may play a significant role in NAFLD pathogenesis and or 
progression. 
6.5.1 Systematic review of continuous studies (Cross sectional, cohort and case – 
control studies) 
A total of 9 cross- sectional studies (table 6.1) were included in this review. Out of 
these, 7 showed significant association between lower serum 25 (OH) D levels and NAFLD 
(Zhai et al., 2016, Chung et al., 2016, Katz et al., 2010, Kucukazman et al., 2014, Eraslan et 
al., 2013, Rhee et al., 2013, Barchetta et al., 2011),  while findings from only one study 
revealed no association (Li et al., 2013b). One study however, found significant association 
between lower serum 25 (OH) D levels and NAFLD among male subjects and no association 
among female subjects (Park et al., 2017).  
Findings from all the 5 case control studies showed significant association between 
lower serum 25 (OH) D levels and NAFLD (Nseir et al., 2011, Jablonski et al., 2013, Bhatt et 
al., 2013, Pirgon et al., 2013, Targher et al., 2007)  and findings in the 4 out of the cohort 
studies showed significant association between lower serum 25 (OH) D levels and NAFLD  
(Dasarathy et al., 2014, Hao et al., 2014, Kasapoglu et al., 2013, Black et al., 2014) while one 
study did not show a significant association between vitamin D levels and severity in NAFLD 
(Patel et al., 2016)  (table 6.2).  
6.5.2 NAFLD diagnosis and vitamin D measurement 
 NAFLD was diagnosed by ultrasound in most studies and by the gold standard, liver 
biopsy in 4 studies (Dasarathy et al., 2014, Patel et al., 2016, Eraslan et al., 2013, Targher et 
al., 2007). One study did not report the method of NAFLD diagnosis (Nseir et al., 2011). Serum 
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vitamin D measurements were carried out mostly by radioimmunoassay or 
chemiluminescence immunoassay. One study reported using standard colorimetric method 
for vitamin D measurement (Dasarathy et al., 2014).  Findings in one study showed that low 
plasma 25(OH)D levels were associated with NAFLD activity score measured by steatosis, 
hepatocyte ballooning and fibrosis (Dasarathy et al., 2014). Others showed association 
between low serum 25(OH)D levels and presence of NAFLD (Jablonski et al., 2013, 
Kasapoglu et al., 2013), in adolescents (Black et al., 2014) and in addition to high PTH 
hormone levels (Bhatt et al., 2013). However, one study did not find an association between 
low vitamin D levels and NAFLD severity (Patel et al., 2016). 
6.6 Systematic review of RCT 
 
Six clinical trials were identified but five out of these were included in this systematic 
review. This was because the subjects in one study served as both intervention and control, 
Out of the  included publications in this systematic review, 3 were described as double-blind, 
randomized and placebo - controlled (Barchetta et al., 2016, Agah, 2016, Amiri et al., 2017), 
while one study was described as parallel, double-blind, placebo- controlled (Sharifi et al., 
2014). The last study was described as Randomized placebo-controlled (Foroughi et al., 
2014). The Characteristics of included studies are shown in the table 6.4 below.
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Table 6-1: Characteristics of cross-sectional studies (n = 9) 
Study and 
location 
NAFLD 
N/Total 
Diagnosis Vit.D NAFLD 
(mean ± S.D) 
Vit.  D 
Control 
(mean ± S.D) 
Assay 
method for vit. 
D 
measurement 
P value Notes Association 
between 
low vit. D 
levels and 
NAFLD 
Park et al., 
2017 (Korea) 
3, 104/ 
7,514 
Ultrasound  53.75 ±  
20.25 nmol/L 
54.5 ± 21.75 
nmol/L 
Radioimmuno
assay 
P = 0.151 Participants in a 
health screening 
program were 
also subdivided 
according to vit D 
levels 
Significant 
association 
found in 
men but not 
in women 
Zhai et al., 
2016 (East 
China) 
2193/5066  
 
Ultrasound 40.05 ± 9.83 
nmol/L 
40.98 ± 10.8 
nmol/L 
Chemilumine
scence 
immunoassay 
P < 0.01 Population based 
study in male and 
female 
Yes 
Chung et al., 
2015 (Korea) 
1,660/5,409 
 
Ultrasound 54.38 ± 
18.85 nmol/L 
55.05 ± 
21.075 
nmol/L 
Chemilumine
scence 
immunoassay 
P < 0.001 Study involving 
health check –up 
subjects 
Yes 
Kucukazman 
et al., 2014 
(Turkey) 
154/211 
 
Ultrasound 0.31 ± 0.22 
nmol/L 
0.05 ± 0.34 
nmol/L 
Radioimmuno
assay 
P < 
0.0001 
Subjects referred 
to endocrinology 
& gastrology 
outpatient clinic 
Yes 
Eraslan et 
al., 2013 
 
63 /109 
 
Biopsy 90.15 ± 
32.68 nmol/L 
127.975 ± 
58.625 
nmol/L 
Radioimmuno
assay 
P < 0.01  Yes 
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ALT = alanine aminotransferase. 
 
 
 
 
 
 
Li et al., 2013 
(China) 
378/ 
1248 
Ultrasound 55.25 ± 
20.25 nmol/L 
57 ± 21 
nmol/L 
Radioimmuno
assay 
P = 0.21 Study of 
comprehensive 
health exam for 
employees of a 
factory 
No 
Rhee et al., 
2013 (Korea) 
2863/6567  Ultrasound 38.75 ± 9.0 
nmol/L 
39.7 ± 9.7 
nmol/L 
Electro-
chemilumines
cence 
immunoassay 
P < 0.001 Healthy subjects 
were in a medical 
check - up  
program 
Yes 
Barchetta et 
al., 2011 
(Rome) 
162/262 Ultrasound 51.25 ± 
24.25 nmol/L 
37 ± 23 
nmol/L 
Validated 
colorimetric 
mtd (LAISON, 
Diasorin) 
P < 0.001 Adults with normal 
serum liver 
enzymes referred 
to metabolic clinic 
Yes 
Katz, 2010 
(USA). 
143/1630  ALT ≥ 30, or 
40  
57.5 ± 3.475 
nmol/L 
64 ± 2 
nmol/L 
Radioimmuno
assay 
P = 0.03 Subjects are 
adolescents 
Yes 
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 Table 6-2: Characteristics of n = 10 cohort and case-control studies 
Study and 
location 
NAFLD N 
/Total 
Diagnosis Vit D. NAFLD 
(mean ± S.D) 
Vit D. Control 
(mean ± S.D) 
Assay method for vit. 
D measurement 
P value Study type Notes Association 
between 
low vit. D 
levels and 
NAFLD 
Patel et al., 
2016 
(USA) 
244 /283 Biopsy 69.25 ± 29.75 
nmol/L 
 
69.75 ± 32 nmol/L Chemiluminescence 
immunoassay 
P=0.88 Cohort  No 
Black et al., 
2014 
(Australia) 
156/994 Ultrasound 67 ± 22 nmol/L 77 ± 24  nmol/L 
 
Radioimmunoassay 
(14yr) 
LC-MS/MS (17 yr) 
P<0.001 Cohort Adolescent 14 
yr, 17yr 
(values at 17 
yrs recorded) 
Yes 
Dasarathy et 
al., 2014 
(USA) 
148/187 Biopsy 53 ±  26 nmol/L 89.25 ± 15 nmol/L Standard colorimetric 
method 
P < 
0.001 
Cohort  NAFLD 
outpatients 
being 
followed  up 
in metabolic 
liver clinic * 
Yes 
Hao et al., 
2014 China 
(Shanghai) 
76/514 
 
Ultrasound 
 
33.65±11.63nmol/L 39.13±14.73nmol/L Chemiluminescence 
immunoassay 
P = 
0.002 
Cohort Male subjects 
with normal 
BMI but with 
IR. 
Yes 
Bhatt et al., 
2013 (India) 
162/335 Ultrasound 48.5 ± 21.25 
nmol/L 
69.5 ± 23.5 nmol/L Radioimmunoassay P = 
0.00001 
Case – 
control  
Subjects were 
study, sex 
and age 
matched 
Yes 
Jablonski et 
al., 2013 
(USA) 
607 /1214  Ultrasound 75 ± 17 nmol/L 85 ± 20 nmol/L Radioimmunoassay P < 
0.001 
Retrospective 
case- control.  
Subjects 
matched with 
controls for 
Yes 
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age, sex, 
race, season  
Kasapoglu et 
al., 2013 
(Turkey) 
338/613 Ultrasound 
 
36.5±23nmol/L 66±24.5nmol/L NR NR Cohort  Yes 
Pirgon et al., 
2013 
(Turkey) 
45/87 
 
Ultrasound 73.75±46nmol/L 102.5±44.75nmol/L Chemiluminescence 
immunoassay 
P < 
0.001 
Case-control Obese 
adolescents 
admitted to 
Endocrinology 
Yes 
Nseir et al., 
2011 
(Nazareth, 
Israel) 
247/347 NR 57.25+/- 
24.5nmol/L 
77.5 +/-15nmol/L Radioimmunoassay 
(Enzyme-
immunoassay) 
P < 
0.001 
Retrospective 
case-control  
Study on 
hospitalised 
NAFLD 
patients 
Yes 
Targher et 
al., 2007 
(USA) 
60/120 
 
Biopsy 
 
51.0 ± 22nmol/L 
 
74.5± 15nmol/L 
 
Chemiluminescence 
immunoassay 
P < 
0.001 
Case-control NAFLD 
patients and 
healthy 
controls 
Yes 
LC-MS/MS = Liquid chromatography - mass spectrometry; NR = Not reported; 
 *Plasma D3 and insulin concentrations were predictors of NAFLD activity score in Dasarathy et al., (2014):  
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 Table 6-3: Characteristics of n=5 randomised control trial 
Study and 
location 
Study setting 
/duration 
Intervention Study design Primary 
outcome 
Secondary 
outcome 
Statistical 
analysis 
intervention 
Statistical 
analysis 
placebo 
Jadad 
scale/commen
t 
 Amiri et al., 
2017 (Iran) 
12 wks 
37 calcitriol, 37 
calcitriol + 
calcium 
carbonate, 36 
placebo 
Total = 120 
1000 IU 
(25µg) /day or 
plus 500mg 
calcium 
carbonate + 
caloric 
restriction 
Randomized 
controlled 
double blind 
Improvement 
in grade of 
fatty liver 
disease. 
Changes in 
serum 
aminotransfera
se levels, 
antropometric 
measures 
Baseline: 9.9 ± 
0.64 nmol/L 
12wks: :27.1 ± 
1.1 nmol/L 
Baseline:10± 
0.63 nmol/L 
12 wk:11 ± 
0.78 nmol/L 
 Significant 
decrease in 
ALT and FPG 
and increase 
in HDL.C seen 
with calcium 
+calcitriol vs 
calcitriol alone/  
Barchetta et 
al., 2016 
(Rome) 
24 wks 
26 
Cholecalciferol
, 29 Placebo, 
Total = 55 
Diagnosis: 
Ultrasound 
followed by 
MRI 
2000 IU/day Randomized, 
double blind, 
placebo- 
controlled.  in 
T2D +NAFLD 
Reduction in 
Hepatic fat 
fraction, CK-
18-M30,P3NP 
levels, FLI 
Improvement 
in metabolic 
and 
cardiovascular 
parameter 
HbA1c, Lipids, 
HOMA –IR, 
HOMA -B 
Baseline: 
48.15 ± 23.7 
nmol/L 
 24 wk: 89.80 
± 23.6 nmol/L 
Baseline:37.1 
± 6.08 nmol/L 
24 wk: 40 ± 
9.93 nmol/L 
4/ significant 
increase in in 
25 OHD 
P<0.001. No 
sig effect on 
metabolic 
profile or 
cardiovascular 
parameters. 
Sharifi et al., 
2014 
(Iran) 
 24 wks, 
 27 vitamin D, 
26 placebo 
Total = 53 
50,000 IU D3 
every 2 weeks 
for 16 wks 
Parallel, 
double blind, 
placebo-
controlled 
study  
Changes in 
serum ALT 
levels and 
HOMA -IR 
 Baseline: 
11.50 
 
 
24 wks: 75 ± 
13 nmol/L 
Placebo 
Baseline: 16.5 
24 wks: 48 ± 
7.5 nmol/L 
4/ Significant 
increase in vit 
D levels in 
intervention vs 
control. Also 
sig decrease 
in serum MDA, 
near sig 
change in hs-
CRP. 
P<0.001,P=0.0
3, P= 0.06 
respectively. 
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Foroughi et 
al.,2016 (Iran) 
10 wks 
30 
intervention, 
30 control 
Total = 60 
 
50,000IU 
weekly for 
6wks 
Randomized 
placebo-
controlled 
Blood sugar 
and indices of 
IR 
FBS, HOMA –
IR, HOMA -B 
Baseline: 49 
±1 nmol/L 
10 wks:117 
±13 nmol/L 
 
Baseline 4:47 
± 2 nmol/L 
10 wks: 45.8 ± 
0.44 nmol/L 
3/ marginally 
significant 
reduction in 
FBS and 
HOMA IR: IV 
vs control, 
P=0.055, 
P=0.066. 
Significant 
increase in 
serum 25 OH d 
P< 0.001. 
Serum calcium 
increase vs 
control 
Agah et al., 
2016 (Iran) 
12 wks 
37 calcitriol, 36 
placebo group 
Total = 72 
1000 IU vit D 
plus low 
calorie diet 
Randomised, 
double blind, 
placebo-
controlled 
Grade of fatty 
liver disease 
Changes in 
serum 
aminotransfera
se levels, 
anthropometric 
measures, 
insulin 
resistance, 
lipid profile 
Baseline: 
9.9 ± 3.9 
nmol/L 
12 wks: 67.75 
± 18 nmol/L 
Baseline: 0.39 
± 0.37 
12 wks: 
27.5±11.75 
nmol/L 
3/ significant 
reduction in 
ALT in cases 
vs controls grp. 
P =0.006 
Increase in 
HDL cases vs 
control=0.04 
Significant 
change in vit D 
levels in cases 
vs control 
P<0.001 
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6.6.1 Vitamin D measurement 
In the included intervention studies, serum 25 OH D was the form of vitamin D 
measured. Different assay methods were utilised in the measurements including ELISA, direct 
competitive immune assay, chemiluminescence and colorimetric assay. The 25 OH D level < 
20ng/mL was regarded as cut off for deficiency in most of the studies while <15ng/ML was set 
as the cut off only in one study (Amiri et al., 2017). The duration of vitamin D 
intervention/supplementation was between 10 and 24 weeks in the included studies and only 
one study investigated the effect of vitamin D supplementation with or without calcium in 
weight loss (Amiri et al., 2017). 
6.6.2 Outcome measurements: Liver steatosis, fibrosis and liver enzymes 
All the five included intervention studies assessed the effects of vitamin D 
supplementation on liver steatosis in NAFLD patients. Three studies utilised ultrasound 
imaging in measuring hepatic fat (Foroughi et al., 2014, Amiri et al., 2017, Sharifi et al., 2014). 
In the studies by Barcheta et al., (2016) and Sharifi et al., (2016), measurements of cytokeratin 
18 and transforming growth factor TGF-β1 were utilised respectively in addition to ultrasound 
to determine non-invasive biomarkers of NAFLD (Barchetta et al., 2016, Sharifi et al., 2014).  
A significant decrease in hepatic steatosis following vitamin D supplementation was observed 
only in one study (P= 0.002) (Agah, 2016) but not in other studies. 
Serum levels of ALT and AST were determined in all the included studies. Vitamin D 
supplementation resulted in a significant decrease in serum levels of AST and ALT in cases 
versus control groups in one study (Amiri et al., 2017). In the same study, vitamin D 
supplementation was carried out with or without calcium co-supplementation, and both 
intervention resulted in a significant reduction in serum aminotransferase level in NAFLD 
patients with vitamin D deficiency. 
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6.6.3 Oxidative stress, inflammatory markers and insulin resistance 
All intervention studies included measured the effects of vitamin D on parameters 
measuring glucose metabolism. A significant change in glucose metabolism markers were 
observed in two out of the studies (Amiri et al., 2017, Agah, 2016). In the study by Amiri et al., 
2017, 1000 IU vitamin D supplementation was done with or without calcium resulted in a 
significant reduction in serum FBG and HOMA –IR. A pronounced decrease was observed in 
the group that received calcium with vitamin D supplements. 
Most of the included studies evaluated high-sensitive C-reactive protein (hs-CRP) and 
tumor necrosis factor a (TNFα) as inflammatory biomarkers as secondary outcomes although 
only one of them showed a near statistically significant decrease following vitamin D 
supplementation (Sharifi et al., 2014). 
6.7 Meta- analysis  
 
For the cross- sectional and case-control studies, 18 studies including Barchetta et al., 
(2011), Bhatt et al., (2013), Black et al., (2014), Chung et al., (2013), Dasarathy et al., (2014), 
Eraslan Eraslan et al., (2013), Hao et al., (2014), Jablonski et al., (2013), Kasapoglu et al., 
(2013), Katz., (2010), Kucukazman et al., (2014), Li et al., (2013),  Nseir et al., (2011), Park et 
al., (2017), Pirgon, (2013), Rhee et al., (2013) Targher et al., (2007), Zhai et al., (2016) were 
suitable for inclusion in the meta-analysis, while for the  RCTs, 4 studies (Agah, 2016, 
Barchetta et al., 2016, Foroughi et al., 2014, Sharifi et al., 2014) were included in the meta- 
analysis. 
 
Figures 6.2 to 6.6 summarise the meta-analysis of the included studies including the 
95% confidence intervals indicating the statistical significance at both individual study levels 
and for the overall effect estimate of the mean difference for serum 25 (OH) D levels in NAFLD 
and control groups for continuous studies and in NAFLD vitamin D supplemented versus 
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NAFLD placebo groups for RCTs. Significant heterogeneity was observed with I2 values 
ranging between 90-99%. 
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Figure 6-2: Meta-analysis of studies reporting mean difference for serum 25 (OH) D levels (nmol/L) in NAFLD vs control group, chronologically 
ordered (random effects model). 
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Figure 6-3: Meta-analysis of studies reporting ORs with 95% confidence interval to compare outcomes of serum 25 (OH) D levels in NAFLD vs 
controls, chronologically ordered (random effects model). 
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Figure 6-4: Meta-analysis of RCT reporting mean difference for serum 25 (OH) D levels (nmol/L) in NAFLD vitamin D supplemented vs  NAFLD 
placebo group, chronologically ordered (random effects model). 
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Figure 6-5: Meta-analysis of RCT reporting mean difference for HOMA- IR levels in NAFLD vitamin D supplemented vs NAFLD placebo group, 
chronologically ordered (random effects model). 
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Figure 6-6: Meta-analysis of RCT reporting mean difference for fasting blood glucose levels in NAFLD vitamin D supplemented vs NAFLD 
placebo group, chronologically ordered (random effects model).
 
 
 
 
 
6.8 Discussion 
 
In this systematic review and meta-analysis, approximately 13500 NAFLD cases and 
19970 controls were included. Overall, findings revealed that patients with NAFLD have 
significant lower 25 (OH) D concentrations than subjects without NAFLD. These findings 
suggest that lower serum 25 (OH) D is an important factor to consider in NAFLD risk or 
development. The findings are similar to other meta-analysis (Eliades et al., 2013, Wang et 
al., 2015). The systematic review and meta-analysis by Eliades et al., 2013 was carried out 
on 5000 cases of NAFLD and 8000 cases of control. Findings from the study revealed that 
subjects with NAFLD had a significant lower  serum vitamin D level compared with control 
(Eliades et al., 2013). Furthermore, subjects with NAFLD were predicted to be 26% times more 
likely to be vitamin D deficient than subjects without NAFLD.  
In the systematic review and meta-analysis of vitamin D and NAFLD/NASH by Wang et 
al., (2015), 15 cross-sectional and 14 case control studies were included, comprising of 5896 
NAFLD patients and 7628 controls (Wang et al., 2015). Findings showed significant lower 
levels of 25 (OH) in NAFLD and NASH patients compared to control. In addition, NAFLD cases 
were reported to be 1.26 times more vitamin D deficient than control. All these demonstrate 
that lower 25 (OH) D levels play a role in the development and progression of NAFLD. 
In terms of the odds for NAFLD development and severity of NAFLD based on the serum 
25 (OH) D levels in this research, results from meta-analysis of studies reporting odds ratio 
revealed no significant effect of 25 (OH) D levels when studies from different geographical 
regions were pooled together in the analysis. However, a statistically significant difference was 
seen when the studies were stratified based on geographical location. This showed that 
heterogeneity may affect the interpretation of results in meta-analysis. Based on the significant 
 
 
 
difference observed, our findings suggest that serum 25OH D may be a predictor of NAFLD 
risk or may be a predictor for development of NAFLD severity.  
Result from the pooled data of RCT showed that serum 25 (OH) D levels were lower in 
NAFLD subjects compared with control (P< 0.00001). This finding is consistent with the result 
from the cross sectional and case –control studies. Experimental studies using animal models 
have also shown similar results. The study by Kong et al., (2014) proposed that vitamin D 
deficiency probably up-regulate synthesis of endogenous fatty acid in NASH through the 
impairment of enterohepatic circulation (Kong et al., 2014). 
 Findings from the same study revealed that the administration of 1, 25- dihydroxy 
vitamin D3 suppresses hepatic lipogenesis and inflammation which altogether resulted in 
correction of NASH phenotypes (Kong et al., 2014).  Another study by Nakano et al., (2011) 
studied the effect of sunlight therapy and vitamin D supplementation on NAFLD progression 
in rats. Authors found that both treatments additionally decreased IR and hepatic steatosis. 
Result from the meta-analysis of RCT reporting mean difference for fasting blood 
glucose levels in NAFLD subjects supplemented with vitamin D compared with NAFLD 
subjects who received placebo showed a statistically significant effect of vitamin D 
supplementation in improving fasting blood glucose levels. Furthermore, results from the 
meta-analysis of RCT on the mean difference of HOMA-IR as a result of supplementation with 
vitamin D  did not show a  statistically significant difference between intervention and control 
group (P = 0.78) when the random effect model was used. However, the fixed effect model 
showed a significant difference (P< 0.000001) (figure not shown).  
 Due to high level of heterogeneity, interpretations were made based on random effect 
model. The random effect model is the acceptable model in conditions of high heterogeneity 
as was the case in this study. Therefore, the result suggests that intervention with vitamin D 
may not improve insulin resistance. The fact that Heterogeneity is high in our study implies 
that the findings need to be interpreted with caution. The differences in study design including 
 
 
 
the length of intervention period, the dosage of vitamin D supplementation also differ across 
the RCT studies so this may account for the high heterogeneity and the loss of significant 
difference seen in some of the measurements. 
6.8.1 Strengths and limitations of study. 
 
This study employed a robust technique of meta-analysis by combining both systematic 
review and meta-analysis in one study and also carried out separate meta-analysis for 
randomised control trials and continuous studies in order to measure definite effects of vitamin 
D on NAFLD risk, development or progression. 
A number of limitations were observed in this study including the fact that NAFLD was 
diagnosed by ultrasound in most studies.  NAFLD was diagnosed by biopsy only in 3 studies 
(Patel et al., (2016), Dasarathy et al., (2014) and Targher et al., 2007). It is well known that 
the gold standard for NAFLD diagnosis is the use of liver biopsy.  However, it is practically 
impossible to screen a healthy population for NAFLD by liver biopsy. The use of different 
study parameters could contribute to the heterogeneity of the results.  
6.9 Conclusions 
 
 The present study has shown that vitamin D deficiency is significant in NAFLD subjects 
as the 25(OH)D status was lower in individuals with NAFLD than in those without NAFLD. This 
suggests that serum vitamin D levels may be a factor in the development of NAFLD. However, 
this may be as a result of NAFLD patients having a higher level of adiposity than those without 
NAFLD, as increased adiposity is associated with reduced 25(OH)D concentration. In addition, 
this is the first study to carry out the meta-analysis of randomised control trials in determining 
NAFLD development or progression. Although results from this study did not show a beneficial 
effect of vitamin D supplementation for NAFLD patients, an effect was seen in the 
improvement of fasting blood glucose levels and it could also have other health benefits such 
as for musculoskeletal and immune health hence vitamin D supplementation is supported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 General Discussion / Concluding Remarks 
 
The overall aim of the study was to investigate the effect of vitamin D3 supplementation 
on the progression of NAFLD typified by elevated lipid accumulation in hepatocytes using 
HepG2 cells as a model. Initial data in chapter 3 confirmed NAFLD as a spectrum which begins 
with accumulation of lipid in hepatocyte cell line (HepG2) following exposure of the cells to 
saturated fatty acid (palmitate) and the monounsaturated fatty acid (oleate).  Furthermore, 
oleic acid treatment induced a higher level of lipid accumulation in the HepG2 cells than 
treatment with palmitic acid. However, palmitic acid treatment resulted to a greater reduction 
in cell viability, confirming the cytotoxic effects of palmitic acid on the hepatocytes.  
These findings on accumulation of lipid following exposure of cells to fatty acids agree 
with other published literatures (Ricchi et al., 2009, Mei et al., 2011) and is indicative of 
increased free fatty acid levels in hepatocytes as seen and documented in NAFLD.  Such 
increase in levels of free fatty acid has been linked with insulin resistance, obesity and 
diabetes which are also strongly associated with NAFLD. Further data generated in chapter 3 
demonstrated that GLO 1 protein expression levels in cells exposed to fatty acids was not 
significantly different from the protein expression in cells exposed to DMSO which is the 
vehicle in which the fatty acids were prepared.  
These findings obtained from western blotting procedures suggested that GLO 1 protein 
is stable in the hepatocyte cell line (HepG2) following treatment with palmitic or oleic acid. This 
observation could be explained since fatty acid treatment results to oxidative stress and the 
production of reactive oxygen species in cells. It has been documented that such generation 
of reactive oxygen species activates the upregulation of GLO 1 gene by transcription factors 
such as NRF2 and this may prevent a reduction in the gene level (Xue et al., 2012).  
Following on these findings, an approach of moving the research forward was to 
investigate other genes that may be beneficial in improving NAFLD outcome. Therefore, in 
chapter 4, NAFLD progression from steatosis to NASH was investigated and confirmed in the 
 
 
 
hepatocyte cell line (HepG2) by assessing the induction of proinflammatory cytokines (IL-8 
and IL-6) following exposure of cells to fatty acids (PA and OA). The effects of vitamin D 
supplementation on the induction of the proinflammatory cytokines (IL-8 and IL-6) was also 
investigated. A background of IL-8 induction in HepG2 cells after exposure to palmitic acid 
has been documented previously (Joshi‐Barve et al., 2007). Moreover, elevated IL-8 levels 
have been reported in NASH patients indicating that IL-8 chemokines may play a role in 
NAFLD progression.  
HepG2 cells were exposed to the same concentration of palmitic and oleic acid utilised in 
previous experiments for 24 hours and TNFα, a known inducer of IL-8 and IL-6 cytokines was 
utilised as positive control. Culture supernatants were assayed for IL-8 and IL-6 using ELISA. 
Data revealed that palmitic acid, but not oleic acid, induced significant IL-8 cytokines in fatty 
acid - treated hepatocytes, compared to vehicle treated cells. These findings suggest that diets 
rich in palmitic acid may play significant role in NAFLD/ NASH development. Vitamin D 
supplementation of the HepG2 cells using 50 or 100nM D3 showed some reduction in 
palmitate induced IL-8 levels when standard BSA was used, this however failed to reach a 
statistically significant level of reduction in palmitate induced IL-8 levels.  
Furthermore, vitamin D supplementation showed a statistically significant and dose- 
dependent reduction of TNF- induced IL-8 in the same hepatocytes. This suggests that vitamin 
D supplementation suppresses inflammation due to TNFα, the potent IL-8 inducer, which 
mediates its effect through NFKB pathway, but not PA which has been documented to mediate 
its effect through a combination of pathways.  
The study in chapter 5 investigated the effects of vitamin D supplementation on IL-6 levels 
in healthy South Asian and Caucasian women in the D2D3 RCT. Subjects were randomised 
to receive either vitamin D intervention products or placebo, alongside their normal diet. Data 
from chapter 5 describes significant differences in baseline measurements of IL-6 and serum 
25 (OH) D levels between two ethnic origins, with the South Asian women having higher IL-6 
level and lower 25 (OH)D level than the Caucasian women. Similar findings of higher levels of 
 
 
 
IL-6 cytokines in the SA women compared to the Caucasian women living in Europe have also 
been documented previously (Peters et al., 2013). Moreover, vitamin D deficiency is a 
prevalent problem in the South Asian population. After the intervention period, serum 25 (OH) 
D levels were increased in both groups of women but this did not show a significant reductive 
effect on the IL-6 levels.  A similar RCT of vitamin D supplementation in healthy males and 
females of African American origin also found that the intervention failed to produce a 
statistical significant reduction in levels of IL-6 and CRP. 
In chapter 6, data from the extensive systematic review and meta-analysis on vitamin D 
and NAFLD were presented. The study included approximately 13500 NAFLD cases and 
19970 controls. Overall, data obtained showed that patients with NAFLD have significant lower 
25 (OH) D concentrations than subjects without NAFLD suggesting that lower serum 25 (OH) 
D may be an important factor to consider in NAFLD risk or development. These findings are 
similar to other meta-analysis (Eliades et al., 2013, Wang et al., 2015). The systematic review 
and meta-analysis by Eliades et al., (2013) revealed that subjects with NAFLD had a 
significant lower serum vitamin D level compared with control (Eliades et al., 2013).  
Findings from another systematic review and meta-analysis of vitamin D and 
NAFLD/NASH included 15 cross-sectional and 14 case control studies comprising of 5896 
NAFLD patients and 7628 controls (Wang et al., 2015). Significant lower levels of 25 (OH) in 
NAFLD and NASH patients compared to control were also shown. All these demonstrate that 
lower 25 (OH) D levels play a role in the development and progression of NAFLD. 
Further data in chapter 6 describes the odds for NAFLD development and severity based 
on the serum 25 (OH) D levels, results from our meta-analysis of studies reporting odds ratio 
revealed no significant effect of 25 (OH) D levels when studies from different geographical 
regions were pooled together in the analysis. However, a statistically significant difference was 
seen when the studies were stratified based on geographical location. Based on the significant 
difference observed, our findings suggest that serum 25OH D may be a predictor of NAFLD 
risk or may be a predictor for development of NAFLD severity.  
 
 
 
Furthermore, data obtained from the meta-analysis of RCT reporting mean difference 
for fasting blood glucose levels in NAFLD subjects supplemented with vitamin D compared 
with NAFLD subjects who received placebo showed a statistically significant effect of the 
vitamin D supplementation on lowering fasting blood glucose. However, data from the meta-
analysis of RCT on the mean difference of HOMA-IR as a result of supplementation with 
vitamin D did not show a statistically significant difference between intervention and control 
group, suggesting that intervention with vitamin D may not improve insulin resistance. The 
differences in study design including the length of intervention period, the dosage of vitamin 
D supplementation also differ across the RCT studies so this may account for the high 
heterogeneity and the loss of significant difference seen in some of the measurements.        
Therefore, a meta- analysis of RCTs with similar study parameters would provide a more 
robust data.  
The implications of the findings on the significant association between low serum 25 
(OH) D levels and NAFLD risk may include the need to monitor vitamin D levels in NAFLD 
patients as they may be more prone to other diseases associated with vitamin D deficiency 
such as osteomalacia and rickets. Future work will also benefit from the investigation of vitamin 
D supplementation on the induction of cytokine secretion utilising cells of adipose tissue origin. 
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Vitamin D and non-alcoholic fatty liver disease: a systematic review and meta-analysis. 
By O.A. Akinyemi1, A.L. Darling1 and S.A. Lanham-New1 1Department of Nutritional 
Sciences, School of Biosciences and Medicine, Faculty of Health and Medical Sciences, 
University of Surrey, Guildford, GU2 7XH. 
 
Non-Alcoholic Fatty Liver Disease (NAFLD) describes a wide range of hepatic pathological 
conditions beginning with accumulation of lipids, especially triglycerides, in the hepatocytes 
in the absence of significant alcohol intake1. NAFLD shows a strong association with obesity, 
type 2 diabetes (T2D), insulin resistance (IR), hyperlipidaemia and arterial hypertension. 
Hence it is referred to as the hepatic manifestation of the metabolic syndrome2. Studies have 
shown significant inverse associations between 25-hydroxyvitamin D (25(OH)D concentration 
and other diseases including diabetes, hyperlipidaemia, hypertension and peripheral vascular 
disease, suggesting a possible role for vitamin D in the pathogenesis of NAFLD3, 4.The aim of 
this study was to systematically review the association between NAFLD and vitamin D using 
data from both randomised control trials (RCT), cross-sectional and case-control studies. This 
was to quantify differences in 25(OH)D status between individuals with and without NAFLD, 
as well as the effect of vitamin D supplementation in NAFLD patients on metabolic function. 
The PUBMED database was electronically searched for relevant studies in adolescents 
and adults from inception up until April 2017. A total of 129 relevant studies were identified 
and 24 of these were suitable for inclusion in the systematic review. 
Meta-analysis of cross-sectional, cohort and case control studies suggested a 
statistically significantly lower serum 25 (OH) in those with NAFLD, compared with those 
without NAFLD (Mean Difference (random)= -16.80 nmol/L [-24.38, -9.21] I
2=96% P <0.0001). 
In addition, meta-analysis of 4 randomised control trials (RCTs) suggested a statistically 
significant effect of vitamin D supplementation on serum 25 (OH) D levels  (Mean Difference 
(random)= 53.08nmol/L [28.22,77.93] I
2=96% P < 0.0001), Furthermore, meta-analysis of 
HOMA-IR suggested no statistically significant effect of vitamin D supplementation (Mean 
Difference (random) = -0.26  [-2.02, 1.51]  I
2= 99% P = 0.78).  
In conclusion, 25(OH)D status was lower in individuals with NAFLD than in those 
without NAFLD, suggesting that serum 25(OH)D levels may be a factor in the development of 
NAFLD. However, it may also simply be a result of persons with NAFLD having higher 
adiposity than those without NAFLD, as increased adiposity is associated with reduced 
25(OH)D concentration. This is the first study to report a meta-analysis of vitamin D 
supplementation in NAFLD patients. No effect was found of vitamin D supplementation on 
HOMA-IR. Therefore this review does not support the use of vitamin D supplementation for 
NAFLD patients in terms of improving metabolic function, although it could have other health 
benefits, such as for immune and musculoskeletal health. 
1. Sanyal et al., 2010. N Eng J Med, 362,1675-85. 
2. Loomba et al., 2012. Hepatol, 56,943-51. 
3. Anderson et al., 2010. Am J cardiol, 106,963-68. 
4. Li et al., 2013. Endocrine, 44,465-72. 
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